

Financial news for BMY dated on 2020-06-09: UbiVac Reports Trial Collaboration With Bristol Myers To Evaluate Safety, Tolerability, Prelim. Efficacy Of Co.'s DPV-001 Cancer Vaccine

Financial news for BMY dated on 2020-06-04: Jounce Therapeutics Regains Worldwide Rights To JTX-8064 From Bristol Myers Squibb

Financial news for BMY dated on 2020-06-03: Traders Share Their Health Care Picks

Financial news for BMY dated on 2020-06-03: The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study

Financial news for BMY dated on 2020-06-03: Bristol Myers Squibb Highlights New Data Reinforcing 'Improved and Durable Clinical Responses of Orencia in Moderate-to-Severe Early Rheumatoid Arthritis Patients with Autoantibodies Linked to More Severe Disease'

Financial news for BMY dated on 2020-06-02: l Myers Squibb Announces Topline Results From Pivotal Phase 3 True North Trial Evaluating Zeposia In Moderate to Severe Ulcerative Colitis; Study Met Primary Endpoint

Financial news for BMY dated on 2020-06-01: Compugen Announces FDA Clearance Of IND Application For Phase 1/2 Triple Combination Study Of COM701 With Bristol Myers Squibb's Opdivo (Nivolumab) And TIGIT Inhibitor

Financial news for BMY dated on 2020-06-01: Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA, an Oral Treatment for Relapsing Forms of Multiple Sclerosis

Financial news for BMY dated on 2020-05-30: Benzinga's Bulls And Bears Of The Week: Amazon, Disney, Netflix And More

Financial news for BMY dated on 2020-05-30: The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight

Financial news for BMY dated on 2020-05-29: Bristol Myers CEO To Appear On CNBC's 'Squawk On The Street' At 9:45 a.m. EDT

Financial news for BMY dated on 2020-05-29: Cramer Shares His Thoughts On Teva, Oxford Industries And More

Financial news for BMY dated on 2020-05-27: 'metformin recalls are expected as early as this week. The carcinogen found in the diabetes drug is NDMA, the same one that forced recalls of millions of blood pressure pills and Zantac' -Tweet From Bloomberg Health Policy Reporter

Financial news for BMY dated on 2020-05-27: Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold \$15B In Peak Sales Potential

Financial news for BMY dated on 2020-05-27: The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Financial news for BMY dated on 2020-05-27: Bristol Myers Squibb Receives European Commission Approval For Zeposia (ozanimod) For Treatment Of Adult Patients With Relapsing Remitting Multiple Sclerosis With Active Disease

Financial news for BMY dated on 2020-05-26: Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb; BMS Will Make \$65M Upfront Payment Including \$15M In Equity Investment

Financial news for BMY dated on 2020-05-22: European Medicines Agency Validates Bristol Myers Squibb's Applications For Idecabtagene Vicleucel (Ide-cel, bb2121) And CC-486

Financial news for BMY dated on 2020-05-20: Checkpoint Therapeutics CEO On Tapping Into A \$25 Billion Cancer Treatment Market

Financial news for BMY dated on 2020-05-19: Telemedicine A COVID-19 Winner

Financial news for BMY dated on 2020-05-15: Bristol Myers Squibb Press Release Confirms FDA Approval Of Opdivo+ Yervoy

Financial news for BMY dated on 2020-05-15: Bristol Myers Shares At Session High, Up 2.5%; Hearing FDA Okayed Opdivo, Yervoy Combo For Metastatic Non Small Cell Lung Cancer

Financial news for BMY dated on 2020-05-15: FDA Approves Bristol Myers Squibb's Pomalyst (pomalidomide) For AIDS-Related And HIV-Negative Kaposi Sarcoma

Financial news for BMY dated on 2020-05-13: Bristol Myers Reports 3-Year Data From CheckMate -277 Confirm Durable, Long-Term Survival Benefits For Opdivo Plus Yervoy vs Chemo

Financial news for BMY dated on 2020-05-13: Bristol Myers, bluebird bio Will Present Updated Results From Pivotal KarMMa Study Of Ide-cel In Relapsed and Refractory Multiple Myeloma Patients at ASCO On May 29

Financial news for BMY dated on 2020-05-13: Bristol Myers Reports Opdivo Plus Yervoy With Limited Chemo Significantly Improves Overall Survival vs Chemo Alone

Financial news for BMY dated on 2020-05-13: AbbVie's Potential Is 'Underappreciated,' Says Morgan Stanley Analyst

Financial news for BMY dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for BMY dated on 2020-05-13: Bristol Myers Squibb And bluebird bio Say Upon Preliminary Review, FDA Determined That The Chemistry, Manufacturing And Control Module Of The BLA For Idecabtagene Vicleucel Requires Further Detail To Complete The Review

Financial news for BMY dated on 2020-05-11: Bluebird Bio Announces Amended BCMA CAR-T Collaboration Agreement; Bristol Myers Squibb To Buy Out Its Ex-US Milestone And Royalty Obligations To Bluebird Bio For \$200 Million

Financial news for BMY dated on 2020-05-08: 5 Biopharmas Where BofA Would Put Its Money To Work

Financial news for BMY dated on 2020-05-07: Mid-Afternoon Market Update: Dow Jumps 270 Points; Twilio Shares Rise On Upbeat Results

Financial news for BMY dated on 2020-05-07: CFRA Maintains Buy on Bristol-Myers Squibb, Raises Price Target to \$70

Financial news for BMY dated on 2020-05-07: Mid-Day Market Update: Crude Oil Rises 8%; Vista Outdoor Shares Plunge

Financial news for BMY dated on 2020-05-07: Mid-Morning Market Update: Markets Open Higher; Bristol-Myers Squibb Tops Q1 Estimates

Financial news for BMY dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for BMY dated on 2020-05-07: Bristol-Myers Squibb shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.

Financial news for BMY dated on 2020-05-07: Bristol Myers Reaffirms FY20, FY21 Adj. EPS Guidance

Financial news for BMY dated on 2020-05-07: Bristol-Myers Squibb Q1 Adj. EPS \$1.720 Beats \$1.490 Estimate, Sales \$10.800B Beat \$10.020B Estimate

Financial news for BMY dated on 2020-05-07: A Peek Into The Markets: US Stock Futures Climb Ahead Of Earnings, Initial Jobless Claims Data

Financial news for BMY dated on 2020-05-07: 8 Stocks To Watch For May 7, 2020

Financial news for BMY dated on 2020-05-07: Earnings Scheduled For May 7, 2020

Financial news for BMY dated on 2020-05-06: Bristol Myers Squibb Reports FDA Extended Action Date By 3 Months For Biologics License Application for Lisocabtagene Maraleucel; New PDUFA Date Set as Nov. 16, 2020

Financial news for BMY dated on 2020-05-05: Why Shares Of Gene Therapy Company Genprex Are Surging Higher

Financial news for BMY dated on 2020-05-05: What You Should Know About Alexion's \$1.4B Proposed Buyout Of Portola Pharma

Financial news for BMY dated on 2020-05-04: 3 Keros Analysts On Why Biopharma Is A Compelling Investment Opportunity

Financial news for BMY dated on 2020-05-04: Benzinga Pro's Top 5 Stocks To Watch For Mon., May 4, 2020: DIS, BMY, PTON, QTNT, TBIO

Financial news for BMY dated on 2020-05-03: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

Financial news for BMY dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for BMY dated on 2020-05-01: Shares of several healthcare companies are trading lower as markets dip following recent strength. Markets have sold off as investors weigh recent earnings and amid concerns of renewed US-China trade frictions.

Financial news for BMY dated on 2020-05-01: UPDATE: Bristol Myers Sets FDA PDUFA Date As Sep. 3, 2020

Financial news for BMY dated on 2020-05-01: Bristol Myers Reports FDA Accepted For Priority Review Co.'s Application For CC-486 For Maintenance Treatment of Adult Patients in Remission with Acute Myeloid Leukemia

Financial news for BMY dated on 2020-04-30: Bristol Myers Squibb And Acceleron Receive Positive CHMP Opinion For The Treatment Of Adults With Anemia In Beta Thalassemia And Myelodysplastic Syndromes

Financial news for BMY dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for BMY dated on 2020-04-25: Fast Money Picks For April 27

Financial news for BMY dated on 2020-04-21: WindMIL Therapeutics Opens Combination Therapy Portion Of Its Phase 2a Clinical Trial Of Marrow-Infiltrating Lymphocytes (MILs) For Treatment Of Patients With Non-Small Cell Lung Cancer

Financial news for BMY dated on 2020-04-20: Bristol-Myers Squibb shares are trading higher after the company announced the results from its Phase 3 CheckMate -9ER Trial met the primary endpoint.

Financial news for BMY dated on 2020-04-20: Bristol Myers Squibb And Exelixis Announce Topline Results From Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo In Combination With CABOMETYX In Previously Untreated Advanced Renal Cell Carcinoma; Study Met Primary Endpoint

Financial news for BMY dated on 2020-04-14: Intensity Therapeutics Signs Clinical Collaboration Agreement With Bristol Myers Squibb For Advanced Solid Tumors

Financial news for BMY dated on 2020-04-09: Cramer Weighs In On Uber, Yelp And More

Financial news for BMY dated on 2020-04-08: The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO

Financial news for BMY dated on 2020-04-08: Bristol Myers Squibb Announces Acceptance Of US And EU Regulatory Filings For Opdivo Plus Yervoy Combined With Limited Chemotherapy In First-Line Lung Cancer

Financial news for BMY dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for BMY dated on 2020-04-02: Credit Suisse Compiles List Of Corporations With Most And Least Cash

Financial news for BMY dated on 2020-04-01: CLARIFICATION: B of A Securities Yesterday Maintained Buy on Bristol-Myers Squibb, Announced \$75 Price Target

Financial news for BMY dated on 2020-04-01: Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.

Financial news for BMY dated on 2020-03-31: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for BMY dated on 2020-03-31: Shares of several healthcare companies are trading higher amid market strength. NOTE: The coronavirus pandemic has potentially benefited the sector due to demand for medical supplies, testing and treatment candidates

Financial news for BMY dated on 2020-03-31: The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions

Financial news for BMY dated on 2020-03-31: Bristol Myers Squibb And Bluebird Bio Announce Submission Of Biologics License Application For Anti-BCMA CAR T Cell Therapy

Idecabtagene Vicleucel To FDA

Financial news for BMY dated on 2020-03-30: Shares of several healthcare companies are trading higher as the market rebounds on extended measures to help curb the coronavirus. NOTE: The sector could also be trading higher due to increased demand for medical products amid the coronavirus outbreak.

Financial news for BMY dated on 2020-03-29: The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty

Financial news for BMY dated on 2020-03-27: Bristol Myers Reports Receives Positive CHMP Opinion Recommending Approval Of ZEPOSIA For Treatment Of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease

Financial news for BMY dated on 2020-03-26: Why Bristol-Myers Squibb's Stock is Trading Higher Today

Financial news for BMY dated on 2020-03-26: Shares of several healthcare companies are trading higher following Senate passage of a \$2 trillion economic stimulus package, which has lifted stocks across sectors.

Financial news for BMY dated on 2020-03-26: Bristol-Myers Squibb shares are trading higher after the company announced the FDA has approved ZEPOSIA, its new oral treatment for relapsing forms of multiple sclerosis.

Financial news for BMY dated on 2020-03-26: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger

Financial news for BMY dated on 2020-03-26: Bristol-Myers Reports FDA Approval For ZEPOSIA 0.92 mg For Treatment Of Adults With Relapsing Forms Of Multiple Sclerosis

Financial news for BMY dated on 2020-03-26: 'Bristol-Myers Zeposia appears to be approved. Drug is listed on Bristol's website. Here is the label: https://packageinserts.bms.com/pi/pi_zeposia.pdf' -Tweet From STAT News' Adam Feuerstein

Financial news for BMY dated on 2020-03-25: Bristol-Myers Says No Sites For New Studies Will Be Initiated Or Activated Until Apr. 13

Financial news for BMY dated on 2020-03-25: UPDATE: BeiGene Sees Disruption In ABRAXANE Supply In China, Is Working With Partner Bristol Myers To Restore Supply As Soon As Possible

Financial news for BMY dated on 2020-03-25: BeiGene Reports China National Medical Products Admin. Suspended Import, Sale, Use Of ABRAXANE Supply In China, Suspension Based On 'inspection findings at Bristol Myers contract manufacturing facility in the United States'

Financial news for BMY dated on 2020-03-25: Infinity Receives Fast Track Designation For IPI-549 In Combination With The Checkpoint Inhibitor Opdivo For The Treatment Of Advanced Urothelial Cancer

Financial news for BMY dated on 2020-03-25: The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down

Financial news for BMY dated on 2020-03-24: Shares of several healthcare companies are trading higher as equities gain amid hopes of a US stimulus agreement. Additionally, the coronavirus outbreak has increased demand for certain medical supplies.

Financial news for BMY dated on 2020-03-23: Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.

Financial news for BMY dated on 2020-03-23: Bristol-Myers Reports Will Not Initiate New Clinical Trial Studies Until Apr. 13, 2020

Financial news for BMY dated on 2020-03-23: Societe Generale Downgrades Bristol-Myers Squibb to Hold, Announces \$50 Price Target

Financial news for BMY dated on 2020-03-22: The Week Ahead In Biotech: Bristol-Myers, Rockwell Medical Await FDA Decisions, COVID-19 Updates In Focus

Financial news for BMY dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for BMY dated on 2020-03-15: The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review

Financial news for BMY dated on 2020-03-14: Barron's Picks And Pans: Roundtable Picks, Airline And Oil Stocks, And More

Financial news for BMY dated on 2020-03-12: Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.

Financial news for BMY dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for BMY dated on 2020-03-11: FDA Approves Opdivo + Yervoy For Patients With Hepatocellular Carcinoma Previously Treated With Sorafenib

Financial news for BMY dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for BMY dated on 2020-03-09: 52 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for BMY dated on 2020-03-09: Bristol Myers' Phase 3 Trial of Empliciti in Untreated Multiple Myeloma Did Not Meet its Primary Endpoint

Financial news for BMY dated on 2020-03-08: The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

Financial news for BMY dated on 2020-03-04: Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.

Financial news for BMY dated on 2020-03-03: Voluntis, Bristol-Myers Report Will Co-Develop Digital Therapeutics For Oncology

Financial news for BMY dated on 2020-03-02: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Financial news for BMY dated on 2020-03-02: Heat Biologics Rallies On Provisional Coronavirus Patent Application

Financial news for BMY dated on 2020-02-28: EMA Says Bristol-Myer's Application For Use Of Opdivo, Yervoy To Treat Metastatic Non-Small Cell Lung Cancer Was Withdrawn

Financial news for BMY dated on 2020-02-27: Benzinga's Top Upgrades, Downgrades For February 27, 2020

Financial news for BMY dated on 2020-02-27: Barclays Initiates Coverage On Bristol-Myers Squibb with Equal-Weight Rating, Announces \$69 Price Target

Financial news for BMY dated on 2020-02-24: Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.

Financial news for BMY dated on 2020-02-24: Bristol-Myers Squibb Advances CytomX Therapeutics' Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion of Ongoing Clinical Trial

Financial news for BMY dated on 2020-02-21: Bristol-Myers Squibb Option Alert: Mar 20 \$70 Calls Sweep (37) near the Ask: 704 @ \$0.31 vs 8146 OI; Ref=\$65.53

Financial news for BMY dated on 2020-02-21: Bristol-Myers Squibb Reports Japan's Ministry Of Health, Labor And Welfare Approves Opdivo For Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer

Financial news for BMY dated on 2020-02-15: Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced or Metastatic Renal Cell Carcinoma

Financial news for BMY dated on 2020-02-13: FDA Accepts For Priority Review Bristol-Myers Squibb's Biologics License Application For Lisocabtagene Maraleucel For Adult Patients With Relapsed Or Refractory Large B-Cell Lymphoma

Financial news for BMY dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines

IPO

Financial news for BMY dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for BMY dated on 2020-02-06: Bristol-Myers Sees FY20 Adj. EPS \$6-\$6.20; FY21 Adj. EPS \$7.15-\$7.45

Financial news for BMY dated on 2020-02-06: Bristol-Myers Q4 Sales \$7.9B; Adds \$5B To Buyback

Financial news for BMY dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for BMY dated on 2020-02-06: 44 Stocks Moving in Thursday's Pre-Market Session

Financial news for BMY dated on 2020-02-06: Bristol-Myers Squibb shares are trading higher after the company reported better-than-expected Q4 EPS results.

Financial news for BMY dated on 2020-02-06: Bristol-Myers Squibb Q4 EPS \$1.22 Beats \$0.94 Estimate

Financial news for BMY dated on 2020-02-06: Earnings Scheduled For February 6, 2020

Financial news for BMY dated on 2020-02-05: 13 Key NASH Drug Candidates To Watch For In A Potential \$30-Billion Market

Financial news for BMY dated on 2020-02-03: Catalent To Buy Cell Therapy CDMO MasTherCell For \$315M

Financial news for BMY dated on 2020-02-03: Surprise, Surprise: Stocks Wearing Their Rally Hats Despite China Market Tanking

Financial news for BMY dated on 2020-02-02: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Financial news for BMY dated on 2020-01-31: Bristol-Myers Squibb Withdraws European Application of Opdivo Plus Yervoy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Financial news for BMY dated on 2020-01-31: Position Scrimmage: Coronavirus, End-Of-Month Profit Taking Influencing Markets

Financial news for BMY dated on 2020-01-29: February Market Outlook: Coronavirus, D.C. Proceedings, Earnings Season Could Mean Volatility

Financial news for BMY dated on 2020-01-28: Turnaround Tuesday? Stocks Look To Bounce Back As Apple Earnings Loom Later

Financial news for BMY dated on 2020-01-24: Shares of several companies in the healthcare and pharmaceutical space are trading lower, not currently seeing sector-specific news. NOTE: The global spread of the Wuhan coronavirus has caused equities across to sell off.

Financial news for BMY dated on 2020-01-23: The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment

Financial news for BMY dated on 2020-01-22: Stocks That Hit 52-Week Highs On Wednesday

Financial news for BMY dated on 2020-01-22: The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

Financial news for BMY dated on 2020-01-20: 7 Blockbuster Drugs Expected To Be Launched In 2020

Financial news for BMY dated on 2020-01-17: 9 Takeaways From The JPMorgan Healthcare Conference

Financial news for BMY dated on 2020-01-17: Stocks That Hit 52-Week Highs On Friday

Financial news for BMY dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for BMY dated on 2020-01-15: FDA Accepts For Priority Review Bristol-Myers Squibb's Application For Opdivo Plus Yervoy In First-Line Non-Small Cell Lung Cancer

Financial news for BMY dated on 2020-01-14: The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

Financial news for BMY dated on 2020-01-11: Barron's Picks And Pans: Apple, Bank of America, Lockheed Martin And More

Financial news for BMY dated on 2020-01-10: Stocks That Hit 52-Week Highs On Friday

Financial news for BMY dated on 2020-01-10: A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations

Financial news for BMY dated on 2020-01-10: The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

Financial news for BMY dated on 2020-01-10: UPDATE: Nektar, Bristol Amendment Includes ' new joint development plan under which Nektar and Bristol-Myers Squibb will expand the active clinical development program for bempeg plus nivolumab from three ongoing registrational trials'

Financial news for BMY dated on 2020-01-10: Nektar Therapeutics, Bristol-Myers Amend Strategic Collaboration For Bempegaldesleukin Plus Opdivo

Financial news for BMY dated on 2020-01-09: Stocks That Hit 52-Week Highs On Thursday

Financial news for BMY dated on 2020-01-09: Bristol-Myers Squibb Company shares are trading higher after the company reported results for its pivotal Phase 3 Reblozyl MEDALIST trial in the New England Journal of Medicine.

Financial news for BMY dated on 2020-01-09: Bristol-Myers CMO Says Company Confident On Track To Receive US Approvals For Drugs Tied To Celgene CVR

Financial news for BMY dated on 2020-01-09: Bristol-Myers Squibb Highlights Publishing Of Results For Pivotal Phase 3 Reblozyl MEDALIST Trial In New England Journal Of Medicine

Financial news for BMY dated on 2020-01-07: December's Investor Movement Index Ends 2019 On A High Note

Financial news for BMY dated on 2020-01-07: Investor Movement Index Summary: December 2019

Financial news for BMY dated on 2020-01-06: Citigroup Reinstates Buy on Bristol-Myers Squibb, Announces \$73 Price Target

Financial news for BMY dated on 2020-01-03: 34 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for BMY dated on 2020-01-02: Drugmakers Kick Off 2020 With Margin-Expanding Price Hikes

Financial news for BMY dated on 2020-01-01: Bristol-Myers Squibb, Gilead Sciences, Biogen Raised U.S. List Prices on 50+ Drugs on Wednesday an Average of 5%

Financial news for BMY dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for BMY dated on 2019-12-24: 10 Biotech M&A Targets Under The Scanner For 2020

Financial news for BMY dated on 2019-12-23: A Perspective On Biopharma's Record M&A Run In 2019

Financial news for BMY dated on 2019-12-20: Bristol-Myers Squibb Reports EC Approved Revlimid In Combo With Rituximab For Treatment of Adult Patients with Previously Treated Follicular Lymphoma

Financial news for BMY dated on 2019-12-18: Bristol-Myers Squibb Reports Submission Of Biologics License Application For CAR T-Cell Therapy Liso-Cel

Financial news for BMY dated on 2019-12-16: iRhythm Announces Participation In GUARD-AF Study Focused On Undiagnosed Atrial Fibrillation, Sponsored By Bristol-Myers Squibb-Pfizer Alliance

Financial news for BMY dated on 2019-12-13: Bristol-Myers Squibb Wins Patent Royalty Fight Against Gilead; Co. Awarded \$585M In Damages Plus Royalty

Financial news for BMY dated on 2019-12-13: Stocks That Hit 52-Week Highs On Friday

Financial news for BMY dated on 2019-12-13: The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer

Financial news for BMY dated on 2019-12-13: Argus Research Upgrades Bristol-Myers Squibb to Buy, Announces \$80 Price Target

Financial news for BMY dated on 2019-12-12: Stocks That Hit 52-Week Highs On Thursday

Financial news for BMY dated on 2019-12-12: The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win

Financial news for BMY dated on 2019-12-11: Stocks That Hit 52-Week Highs On Wednesday

Financial news for BMY dated on 2019-12-11: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for BMY dated on 2019-12-10: Stocks That Hit 52-Week Highs On Tuesday

Financial news for BMY dated on 2019-12-10: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy \$3M In ContraFect Shares

Financial news for BMY dated on 2019-12-10: Bristol-Myers Squibb Presents Overall Survival And Safety Data From Pivotal CC-486 Study QUAZAR AML-001

Financial news for BMY dated on 2019-12-09: Bristol-Myers Reports Reblozyl Studies Evaluating Treatment Of Anemia In Rare Blood Diseases Presented At ASH

Financial news for BMY dated on 2019-12-09: 5 Stocks Moving On ASH Presentations

Financial news for BMY dated on 2019-12-09: Bristol-Myers Squibb Company shares are trading higher after the company announced the Lisocabtagene Maraleucel (Liso-Cel) met its primary and secondary endpoints in the TRANSCEND NHL 001 study at the ASH 2019.

Financial news for BMY dated on 2019-12-08: Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at ASH 2019

Financial news for BMY dated on 2019-12-07: Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study at ASH 2019

Financial news for BMY dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for BMY dated on 2019-12-06: Bristol-Myers, bluebird bio Report Top-Line Results From Phase 2 KarMMa Study Of Ide-cel: Met Primary, Key Secondary Endpoints

Financial news for BMY dated on 2019-12-06: Bristol-Myers Squibb Option Alert: Dec 13 \$60 Calls Sweep (7) near the Ask: 849 @ \$0.686 vs 2653 OI; Earnings 1/23 Before Open [est] Ref=\$59.99

Financial news for BMY dated on 2019-12-06: Bristol-Myers Squibb Option Alert: Mar 20 \$70 Calls Sweep (29) near the Ask: 693 @ \$0.391 vs 2058 OI; Earnings 1/23 Before Open [est] Ref=\$60.11

Financial news for BMY dated on 2019-12-06: Bristol-Meyers Squibb And Acceleron Were Notified By FDA That Reblozyl Will Not Be Reviewed At Dec. 18 Oncologic Drugs Advisory Committee

Financial news for BMY dated on 2019-12-06: Stocks That Hit 52-Week Highs On Friday

Financial news for BMY dated on 2019-12-06: The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

Financial news for BMY dated on 2019-12-05: Bristol-Myers Raises Qtr. Dividend From \$0.41 To \$0.45/Share

Financial news for BMY dated on 2019-12-05: Bristol-Myers Squibb Raises Quarterly Dividend From \$0.41 To \$0.45/Share

Financial news for BMY dated on 2019-12-05: Stocks That Hit 52-Week Highs On Thursday

Financial news for BMY dated on 2019-12-04: The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

Financial news for BMY dated on 2019-12-04: Bristol-Myers Squibb Announces FDA

Breakthrough Therapy Designation For ORENCIA To Help Prevent Acute Graft-Versus-Host Disease

Financial news for BMJ dated on 2019-12-03: Bristol-Myers Squibb And Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl For Use In Patients With Myelodysplastic Syndromes

Financial news for BMJ dated on 2019-12-01: The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Financial news for BMJ dated on 2019-11-29: Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Financial news for BMJ dated on 2019-11-27: Benzinga's Top Upgrades, Downgrades For November 27, 2019

Financial news for BMJ dated on 2019-11-27: Gabelli & Co. Initiates Coverage On Bristol-Myers Squibb with Buy Rating

Financial news for BMJ dated on 2019-11-24: The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More

Financial news for BMJ dated on 2019-11-22: AstraZeneca CEO: Closing In On A Cancer Cure

Financial news for BMJ dated on 2019-11-22: UPDATE: Morgan Stanley Reinstates Bristol-Myers With Equal-Weight \$60 Tgt Sees 'potential for earnings upside in the near-term, driven by bigger/faster cost synergy realization, balanced by patent erosion in mid-late 2020s and uncertainty about pipeline'

Financial news for BMJ dated on 2019-11-22: Morgan Stanley Reinstates Equal-Weight on Bristol-Myers Squibb, Announces \$60 Price Target

Financial news for BMJ dated on 2019-11-21: The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

Financial news for BMJ dated on 2019-11-20: Bristol-Myers Squibb Completes Acquisition Of Celgene

Financial news for BMJ dated on 2019-11-20: Bristol-Myers Squibb Announces CheckMate -915 Study Of Opdivo Did Not Show Statistically Significant Benefit In Co-Primary Endpoint Of Recurrence-Free Survival In

Financial news for BMJ dated on 2019-11-19: The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

Financial news for BMJ dated on 2019-11-15: Bristol-Myers Squibb Receives FTC Clearance For Celgene Acquisition

Financial news for BMJ dated on 2019-11-15: Bristol-Myers, Pfizer Report Randomized, Controlled Trial To Evaluate Effect Of Atrial Fibrillation Screening

Financial news for BMJ dated on 2019-11-15: Bristol-Myers Reports Extension Of Expiration Date For Celgene Exchange Offer From Nov. 15, 2019 To Nov. 20, 2019

Financial news for BMJ dated on 2019-11-14: The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

Financial news for BMJ dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvecra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for BMJ dated on 2019-11-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for BMJ dated on 2019-11-11: Bristol-Myers Squibb's Opdivo Plus Yervoy for Patients with Previously Treated Advanced Hepatocellular Carcinoma Accepted for Priority Review by the FDA

Financial news for BMJ dated on 2019-11-08: The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

Financial news for BMJ dated on 2019-11-07: 'Fast Money Halftime Report' Traders Give Their View On Ford, Starbucks And More

Financial news for BMJ dated on 2019-11-07: Bristol-Myers Squibb Company Announces Extension Of The Expiration Date For Exchange Offers For Celgene Corporation Notes

Financial news for BMJ dated on 2019-11-06: AstraZeneca Named The Most Innovative Global Pharma Company

Financial news for BMY dated on 2019-11-03: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Financial news for BMY dated on 2019-11-01: Stocks That Hit 52-Week Highs On Friday

Financial news for BMY dated on 2019-11-01: The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

Financial news for BMY dated on 2019-10-31: Mid-Afternoon Market Update: US Markets Down, Dow Loses More Than 200 Points

Financial news for BMY dated on 2019-10-31: Mid-Day Market Update: Markets Dip After Morning Rise; Oil Plunges

Financial news for BMY dated on 2019-10-31: Mid-Morning Market Update: Markets Inch Up; Bristol-Myers Squibb Reports Q3 Beat

Financial news for BMY dated on 2019-10-31: Bristol-Myers Squibb Posts Q3 Earnings Beat, Raises Full-Year Guidance

Financial news for BMY dated on 2019-10-31: A Peek Into The Markets: US Stock Futures Trade Lower; European Markets Decline

Financial news for BMY dated on 2019-10-31: The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut

Financial news for BMY dated on 2019-10-31: Bristol-Myers Raises FY19 Adj. EPS Guidance From \$4.20-\$4.30 To \$4.25-\$4.35 vs \$4.28 Estimate

Financial news for BMY dated on 2019-10-31: Bristol Myers Highlights CheckMate -9LA Met Primary Endpoint

Financial news for BMY dated on 2019-10-31: Bristol-Myers Squibb Q3 Adj. EPS \$1.17 Beats \$1.07 Estimate, Sales \$6.007B Beat \$5.9B Estimate

Financial news for BMY dated on 2019-10-31: 9 Stocks To Watch For October 31, 2019

Financial news for BMY dated on 2019-10-31: Earnings Scheduled For October 31, 2019

Financial news for BMY dated on 2019-10-30: 13 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for BMY dated on 2019-10-27: The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

Financial news for BMY dated on 2019-10-25: 'Fast Money Halftime Report' Give Their View On Bristol-Myers, Adobe And More

Financial news for BMY dated on 2019-10-24: European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) Four-Week Dosing Schedule For Adjuvant Treatment Of Adult Patients With Melanoma With Involvement Of Lymph Nodes Or Metastatic Disease Who Have Undergone Complete Resection

Financial news for BMY dated on 2019-10-23: UBS Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to \$53

Financial news for BMY dated on 2019-10-23: The Daily Biotech Pulse: Eli Lilly Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data

Financial news for BMY dated on 2019-10-22: 8 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for BMY dated on 2019-10-22: Bristol-Myers Squibb shares are trading higher after the company announced that CheckMate -9LA, a pivotal Phase 3 trial evaluating Opdivo plus low-dose Yervoy combined with chemotherapy met its primary endpoint.

Financial news for BMY dated on 2019-10-22: Bristol-Myers Squibb Phase 3 Trial Of Opdivo Plus Low-Dose Yervoy Combined With Chemotherapy Meets Primary Endpoint

Financial news for BMY dated on 2019-10-17: Bristol-Myers Squibb-Pfizer Alliance Announces They Are Collaborating With Fitbit To Develop Educational Content Around Atrial Fibrillation

Financial news for BMY dated on 2019-10-17: Bank of America Reinstates Buy on Bristol-Myers Squibb, Announces \$60 Price Target

Financial news for BMY dated on 2019-10-16: Biotech Stock On The Radar: Assessing Mirati's Oncology Franchise With An Eye On Multiple Readouts

Financial news for BMY dated on 2019-10-11: Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.

Financial news for BMY dated on 2019-10-10: Bank of America Reiterates Neutral on Bristol-Myers Squibb, Raises Price Target to \$50

Financial news for BMY dated on 2019-10-08: 'Fast Money Halftime Report' Picks For October 8

Financial news for BMY dated on 2019-10-08: Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on \$250 billion worth of goods from 25% to 30% on Oct 15.

Financial news for BMY dated on 2019-10-04: Cramer Weighs In On Yeti, Square And More

Financial news for BMY dated on 2019-10-02: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.

Financial news for BMY dated on 2019-10-01: Apple, Biogen And More 'Fast Money' Picks For October 1

Financial news for BMY dated on 2019-10-01: Najarian Brothers See Unusual Options Activity In Bristol-Myers, AMD And More

Financial news for BMY dated on 2019-09-30: 8 Latest Short Seller Targets

Financial news for BMY dated on 2019-09-30: Bristol-Myers Reports Opdivo Showed Statistically Significant Overall Survival Benefit Vs. Chemo In Patients With Advanced Esophageal Cancer

Financial news for BMY dated on 2019-09-29: The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear

Financial news for BMY dated on 2019-09-28: Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo Plus Low-Dose Yervoy vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer at EMSO 2019

Financial news for BMY dated on 2019-09-28: Bristol-Myers Squibb Says Adjuvant Treatment with Opdivo Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients

Financial news for BMY dated on 2019-09-28: Bristol-Myers Squibb Announces Five-Year Outcomes for Opdivo in Combination with Yervoy Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma at ESMO 2019

Financial news for BMY dated on 2019-09-26: The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J

Financial news for BMY dated on 2019-09-24: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo

Financial news for BMY dated on 2019-09-23: Carter Worth And Mike Khouw's Bristol-Myers Squibb Options Trade

Financial news for BMY dated on 2019-09-20: Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.

Financial news for BMY dated on 2019-09-19: 11 Most Aggressively Shorted Stocks

Financial news for BMY dated on 2019-09-12: Bristol-Myers To Report Q3 Results Thurs., Oct. 31, Before Market Open

Financial news for BMY dated on 2019-09-10: Bristol-Myers Squibb Earlier Announced Pooled Five-Year Results Showed Patients Treated With Opdivo (Nivolumab) Continued To Experience Long-Term Overall Survival (OS) Benefit Versus Docetaxel

Financial news for BMY dated on 2019-09-05: The Daily Biotech Pulse: Cheery Results

For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug

Financial news for BMY dated on 2019-09-05: UPDATE: Bristol-Myers Says Opdivo Trial Did Not Meet 1 Of Primary Endpoints; Data Monitoring Committee Recommended Trial Continue As Planned

Financial news for BMY dated on 2019-09-05: Bristol-Myers Squibb Offers Update On Phase 3 Opdivo CheckMate -548 Trial In Patients With Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme

Financial news for BMY dated on 2019-09-04: Bristol-Myers Squibb And BioMotiv Announce Partnership; Bristol-Myers Squibb To Become Limited Partner Of BioMotiv With Option To Invest Additional Funding In Selected Projects Of Mutual Interest

Financial news for BMY dated on 2019-09-03: Bank of America Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to \$49

Financial news for BMY dated on 2019-08-28: Celgene Strikes Cancer Immunotherapy Deal With Immatics For Up To \$1.59B

Financial news for BMY dated on 2019-08-28: The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved

Financial news for BMY dated on 2019-08-27: Bristol-Myers Squibb Announces European Commission Approval Of Empliciti Plus Pomalidomide And Low-Dose Dexamethasone (EPd) For Treatment Of Patients With Relapsed And Refractory Multiple Myeloma

Financial news for BMY dated on 2019-08-26: Alexion Trades Lower Amid Amgen-Celgene News

Financial news for BMY dated on 2019-08-26: Amgen's Proposed \$13.4B Acquisition Of Celgene's Otezla: What You Need To Know

Financial news for BMY dated on 2019-08-26: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday., August 26, 2019

Financial news for BMY dated on 2019-08-26: Amgen Earlier Announced It Will Acquire Global Rights To OTEZLA From Celgene For \$13.4B

Financial news for BMY dated on 2019-08-26: 16 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for BMY dated on 2019-08-26: 26 Stocks Moving in Monday's Pre-Market Session

Financial news for BMY dated on 2019-08-26: Bristol-Myers Squibb shares are trading higher after the company announced Celgene would sell OTEZLA to Amgen for \$13.4B. The sale of OTEZLA is important for the pending merger between Bristol-Myers and Celgene.

Financial news for BMY dated on 2019-08-26: Bristol-Myers Squibb Says the Divestiture of OTEZLA is Important for its Pending Merger with Celgene

Financial news for BMY dated on 2019-08-26: Bristol-Myers Squibb Announces Agreement with Celgene to Divest OTEZLA to Amgen for \$13.4B

Financial news for BMY dated on 2019-08-19: Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.

Financial news for BMY dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for BMY dated on 2019-08-15: Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios

Financial news for BMY dated on 2019-08-14: Elliott Mgmt. 13F Shows New Stake In Marathon Petroleum, Liquidated Stakes In EQT, Bristol-Myers

Financial news for BMY dated on 2019-08-14: Benzinga's Top Upgrades, Downgrades For August 14, 2019

Financial news for BMY dated on 2019-08-14: A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street

Financial news for BMY dated on 2019-08-14: Atlantic Equities Upgrades Bristol-Myers Squibb to Overweight

Financial news for BMY dated on 2019-08-09: Large Option Trader Buying Nektar Calls

Following Stock Crash

Financial news for BMY dated on 2019-08-09: Nektar Therapeutics Tumbles To 2-Year Low On Q2 Revenue Miss, Manufacturing Issues With Cancer Drug

Financial news for BMY dated on 2019-08-09: The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2

Financial news for BMY dated on 2019-08-05: Investor Movement Index Summary: July 2019

Financial news for BMY dated on 2019-08-04: Notable Insider Buys: AbbVie, Bristol-Myers And More

Financial news for BMY dated on 2019-08-01: Nektar Therapeutics And Bristol-Myers Squibb Announce FDA Breakthrough Therapy Designation For NKTR-214 In Combination With Opdivo For The Treatment Of Patients With Untreated Advanced Melanoma

Financial news for BMY dated on 2019-07-29: Bristol-Myers Squibb Option Alert: Jan 17 \$47 Calls at the Ask: 1000 @ \$2.13 vs 9610 OI; Ref=\$45.43

Financial news for BMY dated on 2019-07-28: The Week In Cannabis: Tobacco And Retail Stray In The Weeds, Congress Holds SAFE Banking Hearings, New ETFs, And More

Financial news for BMY dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for BMY dated on 2019-07-26: Bristol-Myers Reports Received Positive CHMP Opinion Recommending Approval Of Empliciti Plus Pomalidomide, Low-Dose Dexamethasone For Treatment Of Patients With Relapse, Refractory Multiple Myeloma

Financial news for BMY dated on 2019-07-25: ECB Chimes In: Hints Of Rate Cut Could Support Ahead Of Amazon, Alphabet

Financial news for BMY dated on 2019-07-25: Bristol-Myers Squibb Company shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also issued FY19 EPS guidance above analyst estimates.

Financial news for BMY dated on 2019-07-25: The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug

Financial news for BMY dated on 2019-07-25: Bristol-Myers Squibb Raises FY2019 EPS Guidance from \$4.1-4.2 to \$4.2-4.3 vs \$4.16 Est

Financial news for BMY dated on 2019-07-25: Bristol-Myers Squibb Q2 EPS \$1.18 Beats \$1.06 Estimate, Sales \$6.273B Beat \$6.11B Estimate

Financial news for BMY dated on 2019-07-25: A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings

Financial news for BMY dated on 2019-07-25: 35 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for BMY dated on 2019-07-25: Earnings Scheduled For July 25, 2019

Financial news for BMY dated on 2019-07-25: 12 Stocks To Watch For July 25, 2019

Financial news for BMY dated on 2019-07-24: Bristol-Myers Squibb Company shares are trading lower after the company reported Part 2 of CheckMate - 227 did not meet the primary endpoint.

Financial news for BMY dated on 2019-07-24: Bristol-Myers Reports Part 2 Of CheckMate -227 Did Not Meet Primary Endpoint

Financial news for BMY dated on 2019-07-24: Bristol-Myers Reports CheckMat -227 Part 1a Meets Co-Primary Endpoint

Financial news for BMY dated on 2019-07-24: What To Know About Jounce's Amended Licensing Deal With Celgene

Financial news for BMY dated on 2019-07-24: Bristol-Myers Squibb Option Alert: Aug 30 \$50 Calls Sweep (2) near the Ask: 2500 @ \$0.111 vs 0 OI; Earnings 7/25 Before Open Ref=\$42.76

Financial news for BMY dated on 2019-07-24: Bristol-Myers Squibb Option Alert: Jan, 2021 \$38 Puts at the Bid: 1800 @ \$3.25 vs 6238 OI; Earnings 7/25 Before Open Ref=\$43.105

Financial news for BMY dated on 2019-07-24: Hearing Unconfirmed Chatter Indicating

Pfizer Has Made Takeover Offer For Bristol-Meyers

Financial news for BMY dated on 2019-07-23: List of Companies Reaching Yearly Lows Tuesday

Financial news for BMY dated on 2019-07-23: ICC International Cannabis, Biotii Technologie Sign Advisory Agreement With Dr. Alexandros Makriyannis

Financial news for BMY dated on 2019-07-23: The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

Financial news for BMY dated on 2019-07-20: The Week Ahead In Biotech: Pharma Earnings Pick Up Pace

Financial news for BMY dated on 2019-07-18: Bristol-Myers, Bayer, Ono Pharma Report Clinical Collaboration Deal To Evaluate Combo Of Bayer's Stivarga, Bristol/Ono's Opdivo In Patients With Micro-Satellite Stable Metastatic Colorectal Cancer

Financial news for BMY dated on 2019-07-16: Jim Cramer Weighs In On Marvell, General Motors And More

Financial news for BMY dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for BMY dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for BMY dated on 2019-07-01: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Financial news for BMY dated on 2019-06-29: Bulls & Bears Of The Week: AT&T, Carnival, McDonald's, Microsoft And More

Financial news for BMY dated on 2019-06-28: Meet The 3 Biggest Industries Investing In Cannabis

Financial news for BMY dated on 2019-06-27: Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus

Financial news for BMY dated on 2019-06-25: 60 Biggest Movers From Yesterday

Financial news for BMY dated on 2019-06-24: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for BMY dated on 2019-06-24: Bristol-Myers Slips As Regulatory Hiccups Delay Celgene Deal; Liver Cancer Study Faces Setback

Financial news for BMY dated on 2019-06-24: 34 Stocks Moving In Monday's Pre-Market Session

Financial news for BMY dated on 2019-06-24: Bristol-Myers Squibb shares are trading lower after the company announced its CheckMate -459 study evaluating Opdivo did not reach its primary endpoint and announced plans to sell OTEZLA to help ease FTC concerns regarding its acquisition of Celgene.

Financial news for BMY dated on 2019-06-24: Bristol-Myers Squibb to Sell OTEZLA to Help Ease Federal Trade Commission Concerns Regarding its Acquisition of Celgene

Financial news for BMY dated on 2019-06-19: Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Italy

Financial news for BMY dated on 2019-06-19: Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy, No Terms Disclosed

Financial news for BMY dated on 2019-06-14: Bristol-Myers Squibb Gives Updated Efficacy Data from its Phase 2 Trial Data of Empliciti

Financial news for BMY dated on 2019-06-13: UBS Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to \$51

Financial news for BMY dated on 2019-06-11: FDA Greenlights Merck's Blockbuster Drug Keytruda For First-Line Treatment Of Head, Neck Cancer

Financial news for BMY dated on 2019-06-05: Jim Cramer Shares His Thoughts On AMD,

CME Group, Microsoft And More

Financial news for BMY dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for BMY dated on 2019-06-04: 'China to Audit Sanofi, Bristol-Myers in Drugmaker Accounts Probe' -Bloomberg

Financial news for BMY dated on 2019-06-03: Bristol-Myers Squibb Announces Five-Year Survival Data In Phase 1 CA209-004 Study In Melanoma Patients Data Showed Evidence Of Long-Term Survival Following Discontinuation

Financial news for BMY dated on 2019-06-03: Bristol-Myers Squibb Announces First Presentation of Results for Opdivo Plus Yervoy Combination in Advanced Hepatocellular Carcinoma at ASCO 2019

Financial news for BMY dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for BMY dated on 2019-05-28: Goldman Downgrades Gilead Sciences: 'We Find It Difficult To See The Stock's Multiple Expanding'

Financial news for BMY dated on 2019-05-28: Benzinga's Top Upgrades, Downgrades For May 28, 2019

Financial news for BMY dated on 2019-05-28: Goldman Sachs Initiates Coverage On Bristol-Myers Squibb with Buy Rating, Announces \$54 Price Target

Financial news for BMY dated on 2019-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for BMY dated on 2019-05-22: Trader Idea Feed: 'We took a look at the late-stage brain cancer pipeline, after \$TOCA news and \$ABBV and \$BMY failures this month. And found only 5 active pivotal trials. Which includes \$NWBO, so arguably only 4. Is \$CELG the next big hope?' @ByAmyBrown

Financial news for BMY dated on 2019-05-22: Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond

Financial news for BMY dated on 2019-05-20: Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines

Financial news for BMY dated on 2019-05-20: Benzinga's Top Upgrades, Downgrades For May 20, 2019

Financial news for BMY dated on 2019-05-20: Argus Research Downgrades Bristol-Myers Squibb Company Common Stock to Hold

Financial news for BMY dated on 2019-05-16: 5 ASCO Abstracts That Moved Stocks

Financial news for BMY dated on 2019-05-15: The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGaA's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi

Financial news for BMY dated on 2019-05-10: Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%

Financial news for BMY dated on 2019-05-09: Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study

Financial news for BMY dated on 2019-05-09: Bristol-Myers Squibb Reports Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint

Financial news for BMY dated on 2019-05-03: JP Morgan Reinstates Overweight on Bristol-Myers Squibb Company Common Stock

Financial news for BMY dated on 2019-05-03: 10 Biggest Price Target Changes For Friday

Financial news for BMY dated on 2019-05-03: Benzinga's Top Upgrades, Downgrades For May 3, 2019

Financial news for BMY dated on 2019-05-03: A Peek Into The Markets: US Stock Futures Up; Jobs Data In Focus

Financial news for BMY dated on 2019-05-03: Barclays Upgrades Bristol-Myers Squibb Company Common Stock to Overweight, Raises Price Target to \$55

Financial news for BMY dated on 2019-04-25: Exelixis Says Checkmate 9ER Recently Completed Enrollment

Financial news for BMY dated on 2019-04-25: Replimune's Lead Asset Likely To Clear Regulatory Hurdle, Wedbush Says In Bullish Initiation

Financial news for BMY dated on 2019-04-25: From Bristol-Myers Q1 Earnings Conference Call: Co. To Focus On Smaller, Earlier Stage Deals In Near Term

Financial news for BMY dated on 2019-04-25: The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

Financial news for BMY dated on 2019-04-25: A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Economic Data

Financial news for BMY dated on 2019-04-25: Bristol-Myers Squibb Reaffirms FY19 Adj. EPS Guidance Of \$4.10-\$4.20 vs \$4.19 Est.

Financial news for BMY dated on 2019-04-25: Bristol-Myers Squibb Q1 EPS \$1.1 Beats \$1.07 Estimate, Sales \$5.92B Beat \$5.71B Estimate

Financial news for BMY dated on 2019-04-25: 13 Stocks To Watch For April 25, 2019

Financial news for BMY dated on 2019-04-25: Earnings Scheduled For April 25, 2019

Financial news for BMY dated on 2019-04-21: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for BMY dated on 2019-04-18: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for BMY dated on 2019-04-17: BMO Capital Maintains Outperform on Bristol-Myers Squibb, Raises Price Target to \$63

Financial news for BMY dated on 2019-04-17: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for BMY dated on 2019-04-16: Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.

Financial news for BMY dated on 2019-04-15: Shares of some companies in the healthcare sector are trading higher in a potential rebound. Shares of several healthcare companies dipped last week on concerns of laws curbing drug prices.

Financial news for BMY dated on 2019-04-12: Celgene Shareholders Approve Deal With Bristol-Myers

Financial news for BMY dated on 2019-04-12: Bristol-Myers Shareholders Approve Deal With Celgene

Financial news for BMY dated on 2019-04-12: FameWave Reports Signing Of Clinical Collaboration Deal With Bristol Myers Squibb For Evaluation Of CM-24, Opdivo Combo In Patients With Non-Small Cell Lung Cancer; BZ NOTE: FameWave Will Be Acquired By Kitov Pharma

Financial news for BMY dated on 2019-04-03: Egan-Jones Supports Bristol-Myers Deal With Celgene

Financial news for BMY dated on 2019-04-02: UPDATE: Bristol-Myers, On Opdivo Pooled Results, Says 'in patients with PD-L1 $\geq 1\%$ and $< 1\%$, four-year overall survival rates were 19% and 11%, respectively'

Financial news for BMY dated on 2019-04-02: Bristol-Myers Reports Long-Term Survival Results From Pooled Analyses Of Opdivo In Previously-Treated Non-Small Cell Lung Cancer Patients: '14% of all Opdivo-treated patients were alive at four years'

Financial news for BMY dated on 2019-04-02: The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

Financial news for BMY dated on 2019-03-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for BMY dated on 2019-03-29: Bristol-Myers Offers Statement Following Celgene Settlement With Alvogen On Revlimid Patent Litigation

Financial news for BMY dated on 2019-03-29: ISS Has Issued Recommendation Bristol-Myers Shareholders Vote For Deal With Celgene

Financial news for BMY dated on 2019-03-27: Yields In Focus Again As 10-Year Falls Below 2.4%; Homebuilder Earnings Digested

Financial news for BMY dated on 2019-03-26: Jim Cramer Gives His Opinion On Bristol-Myers Squibb, Moderna And More

Financial news for BMY dated on 2019-03-26: Bristol-Myers 8-K Shows Co., Celgene Received Request For Added Info, Documentary Materials From FTC Related To Merger

Financial news for BMY dated on 2019-03-25: Bristol-Myers Squibb Sends Letter to Shareholders Encouraging Celgene Merger

Financial news for BMY dated on 2019-03-19: Activist Fund Starboard Value Issues Investor Presentation Opposing Bristol-Myers Squibb's Proposed Acquisition Of Celgene

Financial news for BMY dated on 2019-03-18: Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'

Financial news for BMY dated on 2019-03-12: Bristol-Myers CEO Speaking At Cowen Annual Health Care Conference, When Asked About Celgene Talks, Said Mgmt. Had Informal, High-Level Deal Talks With Others In The Past

Financial news for BMY dated on 2019-03-12: CNBC Reporting Third Point And D.E. Shaw Not Involved With Celgene/Bristol-Myers Deal

Financial news for BMY dated on 2019-03-12: Starboard Said to be Investigating Whether Third Point, D.E. Shaw Purchased Bristol-Myers Shares to Vote in Favor of Celgene Deal

Financial news for BMY dated on 2019-03-11: Third Point Holds Small Celgene Stake in Bet Bristol-Myers Deal will Close

Financial news for BMY dated on 2019-03-06: Loncar Cancer Immunotherapy ETF Expresses opposition To Bristol-Myers/Celgene Deal

Financial news for BMY dated on 2019-03-06: Starboard Value Reiterates Belief That Proposed Merger With Celgene Is 'Ill-Advised And Not In Best Interests' Of Bristol-Myers Stockholders

Financial news for BMY dated on 2019-03-06: Bristol-Myers Squibb Files Investor Presentation And Board Of Directors Sends Letter To Shareholders Regarding Pending Transaction With Celgene

Financial news for BMY dated on 2019-03-01: 'Bristol-Myers' imperiled megamerger may depend on Wall Street's loudest whisperers' -STAT News

Financial news for BMY dated on 2019-03-01: 75 Biggest Movers From Yesterday

Financial news for BMY dated on 2019-02-28: Major Shareholders Team To Scuttle Bristol-Myers Squibb's \$74B Celgene Buyout: What's Next?

Financial news for BMY dated on 2019-02-28: 51 Stocks Moving In Thursday's Mid-Day Session

Financial news for BMY dated on 2019-02-28: Bristol-Myers Offers Response To Starboard Letter, Says Welcomes Opinions Of All Shareholders, Will Review Firm's Letter, Respond In Due Course

Financial news for BMY dated on 2019-02-28: Starboard Value Issues Letter To Bristol-Myers Shareholders, Sees Co./Stock As 'Deeply Underavlued'

Financial news for BMY dated on 2019-02-28: 34 Stocks Moving In Thursday's Pre-Market Session

Financial news for BMY dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for BMY dated on 2019-02-28: Bristol-Myers Squibb, In Letter To Employees On Feb 27, Says Very Disappointed By Position of Wellington Management with Regard to Celgene Acquisition

Financial news for BMY dated on 2019-02-27: Bristol-Myers 13D From Wellington Shields Shows Sharply Raised Stake From ~33K Shares To ~125.7M Shares, Or 7.7% Stake

Financial news for BMY dated on 2019-02-27: 10 Stocks Moving In Wednesday's After-Hours Session

Financial news for BMY dated on 2019-02-27: Wellington Mgmt. Issues Press Release Highlighting It Does Not Support Bristol-Myers Purchase Of Celgene

Financial news for BMY dated on 2019-02-26: Starboard Gets Clearance For Its Bristol-Myers Investment

Financial news for BMY dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for BMY dated on 2019-02-21: Bristol-Myers Squibb Option Alert: Mar 1 \$54 Calls Sweep (31) near the Ask: 753 @ \$1.055 vs 521 OI; Ref=\$52.51

Financial news for BMY dated on 2019-02-21: Bristol-Myers Shares Spike ~0.8% Higher As Traders Circulate Speculation From Dealreporter Sanofi Interested In Takeover Of Co.

Financial news for BMY dated on 2019-02-21: Merck To Buy Immune Design For \$300M

Financial news for BMY dated on 2019-02-20: Celgene Shares Fall 0.5% Over Last Min., Now Below \$90.50 Level; Hearing Starboard Is Unhappy With Bristol-Myers Deal To Buy Co.

Financial news for BMY dated on 2019-02-20: Bristol-Myers Reports Starboard Value Proposed John Leonard, Steven Shulman, Jeffrey Smith, James Tyree, Janet Vergis For Election To Co. Board

Financial news for BMY dated on 2019-02-20: UPDATE: Bristol-Myers Sees Refiling Premerger Notification, Report Form Under HSR Act Wed., Feb. 20, 2019, Which Will Restart 30-Day Time Frame For FTC's Initial Review; Says Deal Closing Remains On Track For Q3'19

Financial news for BMY dated on 2019-02-20: UPDATE: Bristol-Myers Determined To Voluntarily Withdraw, Refile Its Premerger Notification, Report Form Under Hart-Scott-Rodino Antitrust Improvement Act

Financial news for BMY dated on 2019-02-20: Bristol-Myers Says Continuing Its Engagement With Regulatory Authorities Related To Deal With Celgene

Financial news for BMY dated on 2019-02-20: Bristol-Myers Offers Update On Pending Deal With Celgene: Says Remains On Track To Hold Special Meeting For Shareholders Apr. 12, 2019

Financial news for BMY dated on 2019-02-20: The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering

Financial news for BMY dated on 2019-02-17: Starboard Undecided Regarding Support for Celgene Acquisition by Bristol-Myers

Financial news for BMY dated on 2019-02-15: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Financial news for BMY dated on 2019-02-15: The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal

Financial news for BMY dated on 2019-02-14: Bristol-Myers Reports Opdivo Plus Yervoy Showed Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer

Financial news for BMY dated on 2019-02-12: The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares

Financial news for BMY dated on 2019-02-11: Bristol-Myers Squibb Reports Opdivo Plus Low-Dose Yervoy Demonstrated Continued Survival Benefit At 30-Month Follow-up In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Financial news for BMY dated on 2019-02-11: Bristol-Myers' Sprycel Approved by the European Commission in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Financial news for BMY dated on 2019-02-05: January's Market Bounce Resulted In Some Unexpected Retail Trading Trends

Financial news for BMY dated on 2019-02-04: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for BMY dated on 2019-02-04: Bristol-Myers shares are trading higher after a media report that hedge fund Starboard Value acquired a stake in the company.

Financial news for BMY dated on 2019-02-01: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

Financial news for BMY dated on 2019-02-01: Pharma Catches Another Case Of M&A Fever

Financial news for BMY dated on 2019-01-30: Premarket Prep Opening NYSE Imbalance Update: Bristol-Myers 102k Shares To Buy; Square 215k To Buy

Financial news for BMY dated on 2019-01-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for BMY dated on 2019-01-26: Barron's Picks And Pans: Caterpillar, Dell, Intel And More

Financial news for BMY dated on 2019-01-25: Morning Earnings Recap: The Biggest Reports From Thursday's Session

Financial news for BMY dated on 2019-01-24: Market Seems Generally Pleased With Earnings Results, But Geopolitics Still Weigh

Financial news for BMY dated on 2019-01-24: Bristol-Myers Squibb Withdraws Regulatory Application For Lung Cancer Combo Drug

Financial news for BMY dated on 2019-01-24: Bristol Myers Says After Celgene Deal, Sees More Than \$50B In 2025 Revenue, More Than \$20 B In 2025 Earnings

Financial news for BMY dated on 2019-01-24: The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial

Financial news for BMY dated on 2019-01-24: Bristol-Myers Squibb Reaffirms FY19 Adj. EPS Guidance \$4.10-\$4.20 vs \$4.14 Estimate

Financial news for BMY dated on 2019-01-24: Bristol-Myers Squibb Q4 EPS \$0.94 Beats \$0.85 Estimate, Sales \$5.973B Miss \$5.99B Estimate

Financial news for BMY dated on 2019-01-24: 12 Stocks To Watch For January 24, 2019

Financial news for BMY dated on 2019-01-24: Earnings Scheduled For January 24, 2019

Financial news for BMY dated on 2019-01-23: Bristol-Myers Squibb Q4 Earnings Preview

Financial news for BMY dated on 2019-01-16: Ligand Pharmaceuticals Hit By Bearish Citron Report

Financial news for BMY dated on 2019-01-14: Bristol-Myers Squibb Reports European Commisison Approval Of Opdivo Plus Low-Dose Yervoy For Patients with Intermediate And Poor-Risk Advanced Renal Cell Carcinoma

Financial news for BMY dated on 2019-01-13: Barron's Picks And Pans: Amazon, Apple, Bristol-Myers, Starbucks And More

Financial news for BMY dated on 2019-01-11: 4 Biotech Pipeline Areas To Keep An Eye On In 2019

Financial news for BMY dated on 2019-01-07: 5 Top-Selling Drugs With Growth Potential In 2019

Financial news for BMY dated on 2019-01-07: Eli Lilly Agrees To Buy Loxo For \$8B In Bid To Expand Oncology Franchise

Financial news for BMY dated on 2019-01-06: The Week Ahead In Biotech: Conferences, Clinical Trials

Financial news for BMY dated on 2019-01-04: 'Celgene Boosted the Price of Its Top Cancer Drug on the Same Day of Mega-Deal' -Bloomberg

Financial news for BMY dated on 2019-01-04: Flex Pharma Finds A Lifeline In Merger With Oncology Biotech Salarius Pharma

Financial news for BMY dated on 2019-01-04: Bristol-Myers Squibb Option Alert: Jun 21 \$55 Calls Sweep (26) near the Ask: 678 @ \$1.9 vs 26494 OI; Earnings 1/24 Before Open Ref=\$46.3425

Financial news for BMY dated on 2019-01-04: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning Of Fri., Jan. 4, 2019

Financial news for BMY dated on 2019-01-04: The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO

Financial news for BMY dated on 2019-01-04: 58 Biggest Movers From Yesterday

Financial news for BMY dated on 2019-01-03: Moody's Is Reviewing Celgene Credit Rating For Upgrade Following Deal With Bristol-Myers

Financial news for BMY dated on 2019-01-03: Benzinga Pro's Top 10 Most-Searchd Tickers For Afternoon Of Thurs., Jan. 3, 2019

Financial news for BMY dated on 2019-01-03: Canaccord Downgrades Celgene From Buy To Hold

Financial news for BMY dated on 2019-01-03: Moody's Reviewing Bristol-Myers For Credit Rating Downgrade Following Deal For Celgene

Financial news for BMY dated on 2019-01-03: Mid-Afternoon Market Update: Dow Down 575 Points; OHR Pharmaceutical Shares Spike Higher

Financial news for BMY dated on 2019-01-03: 44 Stocks Moving In Thursday's Mid-Day Session

Financial news for BMY dated on 2019-01-03: Mid-Day Market Update: Apple Falls On Lowered Sales Guidance; Kitov Pharma Shares Jum

Financial news for BMY dated on 2019-01-03: Apple's Lowered Guidance Underscores Worries About Trade, Global Growth

Financial news for BMY dated on 2019-01-03: Mid-Morning Market Update: Markets Open Lower; Bristol-Myers Squibb To Buy Celgene

Financial news for BMY dated on 2019-01-03: Bristol-Myers shares are trading lower after the company announced a \$74 billion acquisition of Celgene in cash and stock.

Financial news for BMY dated on 2019-01-03: From Conference Call: Bristol-Meyers Squibb CEO Says Valuation Of Celgene's Revlimid Is 'Somewhat More Conservative Than What Is Reflected In Consensus'

Financial news for BMY dated on 2019-01-03: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for BMY dated on 2019-01-03: CORRECTION: Bristol-Myers Deal For Celgene At \$50/Share In Cash Plus 1 Share Of Bristol-Myers Stock

Financial news for BMY dated on 2019-01-03: Bristol-Myers Squibb Bets Big On Celgene In \$74B Cash And Stock Deal

Financial news for BMY dated on 2019-01-03: The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen

Financial news for BMY dated on 2019-01-03: A Peek Into The Markets: US Stock Futures Drop, Apple Cuts Q1 Sales Guidance

Financial news for BMY dated on 2019-01-03: Gilead shares are trading up on news that Bristol-Myers will acquire Celgene in a \$74 billion deal.

Financial news for BMY dated on 2019-01-03: Bristol-Myers To Purchase Celgene At \$50/Share In Cash And 1 Share Of Bristol-Myers For ~\$74B Deal

Financial news for BMY dated on 2019-01-03: Bristol-Myers Squibb Sees FY19 Adj. EPS \$4.10-\$4.20

Financial news for BMY dated on 2019-01-02: Bristol-Myers Reports Sprycel Tablets Approved In Combo With Chemo In Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Financial news for BMY dated on 2019-01-02: Stocks That Will Be Trading Ex Dividend Thurs., Jan. 3, 2019

Financial news for BMY dated on 2018-12-27: The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede

Financial news for BMY dated on 2018-12-26: 6 Valuable Pipeline Drugs With Upcoming Catalysts

Financial news for BMY dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts

To Year-End Clinical Trial Results

Financial news for BMY dated on 2018-12-19: Bristol-Myers Squibb Announces Offer from Taisho Pharmaceutical to Purchase UPSA for \$1.6B

Financial news for BMY dated on 2018-12-18: Eisai Announces Bristol-Myers Squibb and H3 Biomedicine Enter Research Collaboration to Advance Novel Therapeutics Leveraging H3's RNA Splicing Platform

Financial news for BMY dated on 2018-12-17: Bristol-Myers Reports Research Collaboration With Boston Medical Center For Investigation Of Markers Of Immuno-Oncology Response, Resistance

Financial news for BMY dated on 2018-12-17: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Financial news for BMY dated on 2018-12-17: Bristol-Myers Announces a Multi-Year Collaboration Agreement with Eisai

Financial news for BMY dated on 2018-12-17: Taisho Said to be Near \$1.6B Deal for Bristol-Myers's UPSA

Financial news for BMY dated on 2018-12-14: Bristol-Myers, Costco, JPMorgan And XLU: 'Fast Money' Picks For December 14

Financial news for BMY dated on 2018-12-13: Bristol-Myers Squibb Option Alert: Dec 21 \$55 Calls Sweep (2) near the Ask: 1000 @ \$0.401 vs 9213 OI; Earnings 2/4 Before Open [est] Ref=\$53.92

Financial news for BMY dated on 2018-12-11: Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate

Financial news for BMY dated on 2018-12-11: UPDATE: Gabelli On Clovis Says Continues 'to believe Bristol, Sanofi and Roche to be the most interested buyers'

Financial news for BMY dated on 2018-12-10: Bristol-Myers Squibb, Vedanta Biosciences Announce New Clinical Collaboration to Evaluate OPDIVO and VE800 in Patients with Advanced or Metastatic Cancers; BMY to Make Equity Investment in Vedanta

Financial news for BMY dated on 2018-12-07: The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut

Financial news for BMY dated on 2018-12-06: Bristol-Myers Raises Qtr. Dividend From \$0.40 To \$0.41/Share

Financial news for BMY dated on 2018-12-06: Benzinga's Top Upgrades, Downgrades For December 6, 2018

Financial news for BMY dated on 2018-12-06: BMO Capital Upgrades Bristol-Myers Squibb to Outperform, Announces \$60 Price Target

Financial news for BMY dated on 2018-12-03: Bristol-Myers Squibb To Transfer \$3.8B In U.S. Pension Liabilities Through Termination Of Its US Retirement Income Plan

Financial news for BMY dated on 2018-12-03: TARGET PharmaSolutions Reports Strategic Partnership For TARGET-IBD With Bristol Myers Squibb, No Terms Disclosed

Financial news for BMY dated on 2018-11-30: Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Financial news for BMY dated on 2018-11-27: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for BMY dated on 2018-11-27: 32 Stocks Moving In Tuesday's Pre-Market Session

Financial news for BMY dated on 2018-11-27: The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

Financial news for BMY dated on 2018-11-26: Bristol-Myers shares down 2.2% as company reported its CheckMate -451 study did not meet its primary endpoint

Financial news for BMY dated on 2018-11-26: Bristol-Myers Reports CheckMate -451 Study Did Not Meet Its Primary Endpoint

Financial news for BMY dated on 2018-11-16: Bristol-Myers Squibb Option Alert: Fri \$57.5 Puts Sweep (74) near the Bid: 960 @ \$2.793 vs 10442 OI; Ref=\$54.57

Financial news for BMY dated on 2018-11-16: BMO Capital Maintains Market Perform on Bristol-Myers Squibb, Raises Price Target to \$58

Financial news for BMY dated on 2018-11-16: The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal

Financial news for BMY dated on 2018-11-15: Bristol-Myers Reports CHMP Recommended Approval Of Opdivo Plus Low-Dose Yervoy As First-Line Treatment For Patients With Intermediate-, Poor-Risk Advance Renal Cell Carcinoma

Financial news for BMY dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for BMY dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for BMY dated on 2018-11-06: FDA Approves Bristol-Myers Squibb Company's Empliciti Plus Pomalidomide And Dexamethasone For Relapsed Or Refractory Multiple Myeloma

Financial news for BMY dated on 2018-11-06: Morgan Stanley Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to \$59

Financial news for BMY dated on 2018-11-05: Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo in Combination with IPI-549 in Urothelial Cancer

Financial news for BMY dated on 2018-11-05: Bristol-Myers, Infinity Pharma Report New Clinical Collaboration To Evaluate Opdivo In Combo With IPI-549 For Urothelial Cancer

Financial news for BMY dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for BMY dated on 2018-10-26: The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

Financial news for BMY dated on 2018-10-25: Bristol-Meyers Sees Continued Growth From Opdivo In 2019, Says Eliquis Has 'Significant' Headroom For Further Growth

Financial news for BMY dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for BMY dated on 2018-10-25: UPDATE: Bristol-Myers Raises FY18 Adj. EPS From \$3.55-\$3.65 To \$3.80-\$3.90 vs \$3.64 Estimate

Financial news for BMY dated on 2018-10-25: Bristol-Myers Raises Guidance

Financial news for BMY dated on 2018-10-25: Bristol-Myers Squibb Company Q3 EPS \$1.09 Beats \$0.91 Estimate, Sales \$5.691B Miss \$5.72B Estimate

Financial news for BMY dated on 2018-10-25: 15 Stocks To Watch For October 25, 2018

Financial news for BMY dated on 2018-10-25: Earnings Scheduled For October 25, 2018

Financial news for BMY dated on 2018-10-24: Bristol-Myers Squibb Q3 Earnings Outlook

Financial news for BMY dated on 2018-10-24: Stocks Which Set New 52-Week Low Yesterday, October 23rd

Financial news for BMY dated on 2018-10-24: Benzinga's Top Upgrades, Downgrades For October 24, 2018

Financial news for BMY dated on 2018-10-24: The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering

Financial news for BMY dated on 2018-10-24: Wolfe Research Initiates Coverage On Bristol-Myers Squibb with Outperform Rating, Announces \$66 Price Target

Financial news for BMY dated on 2018-10-23: '6 kids dead, 12 sick in viral outbreak at New Jersey rehabilitation center' -ABC 7 NY

Financial news for BMY dated on 2018-10-23: 58 Biggest Movers From Yesterday

Financial news for BMY dated on 2018-10-22: 11 Stocks That Moved From ESMO 2018

Financial news for BMY dated on 2018-10-22: 45 Stocks Moving In Monday's Mid-Day Session

Financial news for BMY dated on 2018-10-22: 8 Biggest Price Target Changes For Monday

Financial news for BMY dated on 2018-10-22: Benzinga's Top Upgrades, Downgrades For October 22, 2018

Financial news for BMY dated on 2018-10-22: Citigroup Downgrades Bristol-Myers Squibb to Neutral, Lowers Price Target to \$57

Financial news for BMY dated on 2018-10-22: Bristol-Myers Gives Results From an Analysis on its Phase 3 Checkmate Study, Says Opdivo in Combination with Yervoy Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Financial news for BMY dated on 2018-10-22: Bristol-Myers Squibb Announces Opdivo Plus Low-Dose Yervoy Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer at ESMO 2018

Financial news for BMY dated on 2018-10-22: Bristol-Myers Squibb Announces Opdivo in Combination with Yervoy Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma at ESMO 2018

Financial news for BMY dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for BMY dated on 2018-10-20: Bristol-Myers Squibb Announces Opdivo in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer at ESMO 2018

Financial news for BMY dated on 2018-10-19: UPDATE: Bristol Says Obtained Deal From CHMP For An Extension Of Clock-Stop For Type II Variation App To Address First Request For Supplementary Info

Financial news for BMY dated on 2018-10-19: Bristol-Myers Offers Update On Ongoing Regulatory Review Of Opdivo Plus Low-Dose Yervoy In First-Line Lung Cancer Patients With Tumor Mutational Burden: CHMP Requested Added Info From CheckMate -227

Financial news for BMY dated on 2018-10-12: Barclays Maintains Equal-Weight on Bristol-Myers Squibb, Raises Price Target to \$58

Financial news for BMY dated on 2018-10-12: A Peek Into The Markets: US Stock Futures Gain Ahead Of Citigroup, Wells Fargo Earnings

Financial news for BMY dated on 2018-10-12: Bristol-Myers Squibb Reports Phase 3 CheckMate -331 Study Did Not Meet Primary Endpoint

Financial news for BMY dated on 2018-10-11: Compugen Shares are trading higher after the announcement of a \$12M investment and collaboration with Bristol-Myers Squibb.

Financial news for BMY dated on 2018-10-11: Bristol-Myers Squibb Reports Collaboration With Compugen To Evaluate Therapeutic Regimen In Advanced Solid Tumors, Will Make \$12M Investment

Financial news for BMY dated on 2018-10-09: Bristol-Myers, Disney, ETP, Paypal: 'Fast Money' Picks For October 9

Financial news for BMY dated on 2018-10-03: Stocks That Will Trade Ex Dividend Thurs., Oct. 4, 2018

Financial news for BMY dated on 2018-09-18: European Medicines Agency Validates Bristol-Myers Squibb's Application For Empliciti Plus Pomalidomide And Low-Dose Dexamethasone In Patients With Multiple Myeloma

Financial news for BMY dated on 2018-09-13: Natera Signs Agreement with Bristol-Myers Squibb to Investigate Signatera ctDNA Assay as a Potential Biomarker for Opdivo In Phase 2 Clinical Trial

Financial news for BMY dated on 2018-09-12: Bristol-Myers Squibb Filing Shows Registration For Mixed Securities Shelf Offering

Financial news for BMY dated on 2018-09-12: Bristol-Myers Squibb Announces Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial

Financial news for BMY dated on 2018-09-07: Health Care Has Been On Fire. Will The Uptrend Continue?

Financial news for BMY dated on 2018-08-30: FDA Accepts Bristol-Myers Squibb's Application for Sprycel, Application Based On Results From Phase 2 CA180-372 Study

Financial news for BMY dated on 2018-08-23: UPDATE: Bristol-Myers Says FDA Granted

Application Priority Review With Action Date Of Dec. 27, 2018

Financial news for BMY dated on 2018-08-23: Bristol-Myers Reports FDA Accepted For Priority Review Co.'s Application For Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Financial news for BMY dated on 2018-08-17: Bristol-Myers Squibb Receives FDA Approval For Opdivo (nivolumab) For Certain Patients With Previously Treated Small Cell Lung Cancer

Financial news for BMY dated on 2018-08-16: The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

Financial news for BMY dated on 2018-08-16: REMINDER: Bristol-Myers Has FDA PDUFA Decision Date Today For CM-32 (Opdivo + Chemotherapy for Small Cell Lung Cancer)

Financial news for BMY dated on 2018-08-15: Q2 13F Roundup: How Buffett, Einhorn, Loeb And Others Adjusted Their Portfolio

Financial news for BMY dated on 2018-08-13: The Week Ahead: Nvidia, Retailer Earnings In Focus

Financial news for BMY dated on 2018-08-12: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for BMY dated on 2018-08-08: Benzinga's Top Upgrades, Downgrades For August 8, 2018

Financial news for BMY dated on 2018-08-08: Atlantic Equities Upgrades Bristol-Myers Squibb to Neutral

Financial news for BMY dated on 2018-08-07: Trump Says Administration Will Be Making an Announcement Next Week Regarding Reducing Drug Prices

Financial news for BMY dated on 2018-08-07: The Highs And Lows Of Earnings Season Dominate July's IMX Results

Financial news for BMY dated on 2018-08-07: Investor Movement Index July Summary

Financial news for BMY dated on 2018-08-01: Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Financial news for BMY dated on 2018-07-26: BZ NOTE On Exelixis Spike Higher: Traders Likely Viewing Co.'s Renal Cancer Treatment Optimistically Following Comment on Bristol-Myers Q2 Earnings Conference Call It Will Receive Negative CHMP Opinion For OPDIVO, A Potential Renal Cancer Treatment

Financial news for BMY dated on 2018-07-26: Bristol-Myers Says It Strongly Disagrees With CHMP Opinion, Says It Will Pursue A Reexamination

Financial news for BMY dated on 2018-07-26: Exelixis Shares Spike 2.8% Higher, Could Be Related To Chatter Of Negative CHMP Opinion For Renal Cell Carcinoma Treatment Discussed On Bristol-Myers Q2 Earnings Conference Call

Financial news for BMY dated on 2018-07-26: Bristol-Myers Shares Fall 2.3% Over Last Min. As Traders Circulate Chatter Of Comment From Conference Call Suggesting Exec Said They Will Be Receiving Negative Opinion From CHMP for OPDIVO In Renal Cancer; Conference Call Just Recently Started At 10:30 a.m. EDT

Financial news for BMY dated on 2018-07-26: UPDATE: Bristol-Myers Raises FY18 Adj. EPS Outlook From \$3.35-\$3.45 To \$3.55-\$3.65 vs \$3.42 Estimate

Financial news for BMY dated on 2018-07-26: Bristol-Myers Raises FY18 Outlook

Financial news for BMY dated on 2018-07-26: Bristol-Myers Squibb Q2 EPS \$1.01 Beats \$0.88 Estimate, Sales \$5.704B Beat \$5.44B Estimate

Financial news for BMY dated on 2018-07-26: Earnings Scheduled For July 26, 2018

Financial news for BMY dated on 2018-07-25: Q2 Earnings Preview For Bristol-Myers Squibb

Financial news for BMY dated on 2018-07-23: Morgan Stanley: Newly Public Neon Therapeutics Has Outperformance Potential

Financial news for BMY dated on 2018-07-23: Bristol-Myers Squibb Announces Departure of Chief Commercial Officer Murdo Gordon

Financial news for BMY dated on 2018-07-23: BMO Capital Maintains Market Perform on

Bristol-Myers Squibb, Raises Price Target to \$51

Financial news for BMY dated on 2018-07-19: Bristol-Myers Squibb Reports Clinical Research Collaboration With Gritstone Oncology To Evaluate Novel Immunotherapy Approach In Advanced Solid Tumors

Financial news for BMY dated on 2018-07-11: Bristol-Meyers Squibb Announces Opdivo With Low-Dose Yervoy Received FDA Approval For Treatment Of MSI-H And dMMR

Financial news for BMY dated on 2018-07-09: Bristol-Myers Squibb Says Immuno-Oncology Combination Therapy Approved By Health Canada

Financial news for BMY dated on 2018-07-09: The Week Ahead: Trump Goes To London, Big Banks Herald Earnings Season's Return

Financial news for BMY dated on 2018-07-08: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for BMY dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for BMY dated on 2018-07-05: UPDATE: Bristol-Myers Squibb Is Looking To Sell It's French Over-The-Counter Business Which Is Valued At More Than E\$1B

Financial news for BMY dated on 2018-07-05: Bristol-Myers Squibb Announces European Commission Has Approved Expanded Indication For Sprycel To Include Treatment Of Children With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia In Chronic Phase

Financial news for BMY dated on 2018-06-30: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Financial news for BMY dated on 2018-06-24: Dapagliflozin as Adjunct Therapy to Insulin for People with Type 1 Diabetes May Improve Glycemic Control

Financial news for BMY dated on 2018-06-22: Benzinga's Daily Biotech Pulse: FDA Greenlights Tandem Diabetes' Insulin Pump, More IPOs On Tap

Financial news for BMY dated on 2018-06-21: Bristol-Myers Announces FDA Accepts Application For Opdivo Plus Low-Dose Yervoy For Treatment of First-Line Non-Small Cell Lung Cancer In Patients With Tumor Mutational Burden ≥ 10 mut/Mb

Financial news for BMY dated on 2018-06-18: Bristol-Myers Squibb On Sunday Announced Empliciti (elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone Reduces Risk Of Disease Progression By 46% Versus Pomalidomide/Dexamethasone Alone In Patients With Relapsed Or Refractory Multiple Myeloma

Financial news for BMY dated on 2018-06-15: Bristol-Myers Squibb Announces That The China National Drug Administration Has Approved Opdivo For NSCLC, Says It's The First And Only PD-1 Inhibitor Approved In China

Financial news for BMY dated on 2018-06-14: Apexigen, Yale Cancer Center Report Clinical Collaboration To Evaluate APX005M, Cabiralizumab, Opdivo In Patients Whose Disease Has Progressed On Anti-PD-1/PD-L1 Therapy

Financial news for BMY dated on 2018-06-13: Bristol-Myers Squibb to Present New Research Findings on the Treatment of Patients with Early RA at EULAR 2018

Financial news for BMY dated on 2018-06-12: Galmed Shares More Than Double As It Hits Bullseye With Fatty Liver Candidate

Financial news for BMY dated on 2018-06-08: Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And More

Financial news for BMY dated on 2018-06-08: Intercept Pharma Shares Up 3.2%; Traders Circulating Word Bristol-Myers Could Be Interested In NASH Space

Financial news for BMY dated on 2018-06-04: Nektar Therapeutics Shares Down ~43.5% Ahead Of Close Following Prelim. Data From Co., Bristol-Myers Related To NKTR-214 In Combo With Opdivo

Financial news for BMY dated on 2018-06-04: Mid-Afternoon Market Update: Dow Up 180 Points; Nektar Therapeutics Shares Plummet

Financial news for BMY dated on 2018-06-04: 5 Biotech Stocks Moving On ASCO Presentations

Financial news for BMY dated on 2018-06-04: Bristol-Myers Announces Opdivo Phase 3 CheckMate Trial Results From ASCO Meeting Presentation; Continues To Demonstrate

Statistically Longer Survival In Follow Up Of 24 Months

Financial news for BMY dated on 2018-06-04: Bristol-Myers Squibb Gives Data it Plans to Present at ASCO; In Other News, Late Friday FDA Removed Partial Hold On CheckMate-602

Financial news for BMY dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for BMY dated on 2018-06-02: Nektar, Bristol-Myers Squibb Announce Preliminary Data for NKTR-214 in Combination with Opdivo for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at #ASCO2018

Financial news for BMY dated on 2018-06-01: Bristol-Myers Says Opdivo Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma in CheckMate-214 Study

Financial news for BMY dated on 2018-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for BMY dated on 2018-05-22: UBS Global Healthcare Conference 2018 Continues Today, Presenters Include: Civitas Solutions, Revance, Akebia Therapeutics, Bristol-Myers, Senseonics, Lantheus, Acceleron Pharma, and HCA Healthcare

Financial news for BMY dated on 2018-05-21: Benzinga's Top Upgrades, Downgrades For May 21, 2018

Financial news for BMY dated on 2018-05-21: UBS Downgrades Bristol-Myers Squibb to Neutral

Financial news for BMY dated on 2018-05-20: Unique Notches Bullish Initiation On Gene Therapy Prospects

Financial news for BMY dated on 2018-05-18: Merck, Bristol Myers Shares Move On Alleged FDA Alert On Keytruda

Financial news for BMY dated on 2018-05-18: Merck Shares Dip Lower, Bristol-Myers Squibb Shares Spike Higher Following FDA Alert On Issue Found In Trials Of Keytruda, Tecentriq

Financial news for BMY dated on 2018-05-16: Q1 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolio

Financial news for BMY dated on 2018-05-16: Jim Cramer Advises His Viewers On Consolidated Edison, L Brands And More

Financial news for BMY dated on 2018-05-15: 13F From Cooperman's Omega Shows New 468K Share Stake In Bristol-Myers Squibb

Financial news for BMY dated on 2018-05-04: Portola Pharma Rips 20% Higher After FDA Approves Andexxa Antidote

Financial news for BMY dated on 2018-04-27: BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position

Financial news for BMY dated on 2018-04-27: Benzinga's Top Upgrades, Downgrades For April 27, 2018

Financial news for BMY dated on 2018-04-27: BMO Capital Upgrades Bristol-Myers Squibb to Market Perform

Financial news for BMY dated on 2018-04-26: Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings

Financial news for BMY dated on 2018-04-26: A Peek Into The Markets: US Stock Futures Rise Ahead Of Earnings

Financial news for BMY dated on 2018-04-26: Bristol-Myers Squibb Q1 Adj. EPS \$0.94 Beats \$0.85 Est., Sales \$5.193B Misses \$5.24B Est.

Financial news for BMY dated on 2018-04-26: 16 Stocks To Watch For April 26, 2018

Financial news for BMY dated on 2018-04-26: Earnings Scheduled For April 26, 2018

Financial news for BMY dated on 2018-04-25: Bristol-Myers Reports European Commission Approves Opdivo 4-Week Dosing Schedule

Financial news for BMJ dated on 2018-04-24: 19 Companies Google Could Buy With Its \$102 Billion In Cash

Financial news for BMJ dated on 2018-04-24: Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure

Financial news for BMJ dated on 2018-04-24: Best Buy, ExxonMobil, And 3 Other Stocks In Strong Trends This Week

Financial news for BMJ dated on 2018-04-23: Stocks That Made New 52-Week Lows Today Include: Kimberly-Clark, Philip-Morris, CenterPoint Energy, Fortune Brands Home, Mallinckrodt, Clorox, Bristol-Myers, Simon Property Group, Pepsi, Kimco Realty, Hasbro, and Procter & Gamble

Financial news for BMJ dated on 2018-04-22: Benzinga's Bulls & Bears Of The Week: Dropbox, GE, Microsoft, Twitter And More

Financial news for BMJ dated on 2018-04-20: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for BMJ dated on 2018-04-20: Stocks That Made New 52-Week Lows Today Include: L Brands, Campbell Soup, Ventas, Kimco Realty, Bristol-Myers, Molson Coors, Kraft Heinz, Mattel, Kimberly-Clark, PepsiCo

Financial news for BMJ dated on 2018-04-19: Bristol-Myers Stock Makes New 52-Week Low of \$51.55

Financial news for BMJ dated on 2018-04-18: Bristol-Myers Reports FDA Acceptance of sBLA For Opdivo in Previously Treated Patients with Small Cell Lung Cancer, Grants Priority Review

Financial news for BMJ dated on 2018-04-18: Benzinga's Top Analyst Calls From April 18, 2018

Financial news for BMJ dated on 2018-04-18: Bank of America Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to \$61.00

Financial news for BMJ dated on 2018-04-17: One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings

Financial news for BMJ dated on 2018-04-17: Stock Market Gets Lift From Earnings As Geopolitical Fears Wane

Financial news for BMJ dated on 2018-04-17: 7 Biggest Price Target Changes For Tuesday

Financial news for BMJ dated on 2018-04-17: Benzinga's Top Upgrades, Downgrades For April 17, 2018

Financial news for BMJ dated on 2018-04-17: The Market In 5 Minutes: Netflix Surges, Tesla Pauses, Cohen-Hannity And More

Financial news for BMJ dated on 2018-04-17: Morgan Stanley Downgrades Bristol-Myers Squibb to Equal-Weight

Financial news for BMJ dated on 2018-04-17: Morgan Stanley Downgrades Bristol-Myers Squibb to Equal Weight from Overweight; Lowers PT to \$58 from \$78

Financial news for BMJ dated on 2018-04-16: Bristol-Myers Announces Collaboration With Johnson & Johnson's Janssen to Develop and Commercialize Next-Gen Cardiovascular Therapy

Financial news for BMJ dated on 2018-04-16: Bristol-Myers Announces Data From CM-141 Presented At AACR Meeting

Financial news for BMJ dated on 2018-04-16: U.S. Food and Drug Administration Approves Opdivo + Yervoy Combo As First-Line Treatment For Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

Financial news for BMJ dated on 2018-04-16: The Week Ahead: Netflix Earnings, Big Bank Results, FDA Actions Abound

Financial news for BMJ dated on 2018-04-16: UPDATE: Bristol Highlights 'Near doubling of overall response rate with the combination (45.3%) versus chemotherapy (26.9%); 68% of responders had ongoing responses at one year (25% with chemotherapy)'

Financial news for BMJ dated on 2018-04-16: Bristol-Myers Squibb Reports Opdivo Plus Low-Dose Yervoy Combo Reduced Risk Of Progression, Death By 42% vs Chemo In First-Line Lung Cancer Patients With High Tumor Mutational Burden

Financial news for BMY dated on 2018-04-16: REMINDER: Bristol-Myers Has PDUFA Date Today For Checkmate-214, Opdivo+Yervoy in First-line Renal Cell Carcinoma

Financial news for BMY dated on 2018-04-13: UPDATE: Bristol-Myers Says Efficacy, Safety Of Opdivo In Predominantly Chinese Patient Population With Advanced NSCLC Were Consistent With Results Of CheckMate -017, -057 Studies

Financial news for BMY dated on 2018-04-13: UPDATE: Bristol-Myers Says Opdivo Response Rates 17% vs 4% For Docetaxel, Median Duration Of Response Was Not Reached With Opdivo vs 5.3 Mos. With Docetaxel

Financial news for BMY dated on 2018-04-13: Bristol-Myers Squibb Reports Opdivo Phase 3 CheckMate -078 Trial Reduced Risk Of Death By 32% vs. Chemo

Financial news for BMY dated on 2018-04-13: Bristol-Myers Squibb, Illumina Report Strategic Collaboration To Develop, Commercialize Companion Diagnostics For Bristol's Oncology Immunotherapies

Financial news for BMY dated on 2018-04-13: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for BMY dated on 2018-04-03: Nektar Therapeutics Announces Bristol-Myers' Collaboration Effective Today, Resulting In Nektar's Receipt Of \$1B Upfront Cash Payment

Financial news for BMY dated on 2018-04-03: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for BMY dated on 2018-04-02: What's NeuVax? Wainwright Says Sellas' Cancer Vaccine Candidate Makes It A Buy

Financial news for BMY dated on 2018-03-29: Biotech Stock Roundup: Protagonist Therapeutics, Verona, Amgen And More

Financial news for BMY dated on 2018-03-27: Bristol-Myers Squibb's Supplemental Biologics License Application for Opdivo is Accepted by the FDA

Financial news for BMY dated on 2018-03-26: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma

Financial news for BMY dated on 2018-03-12: Biohaven Restructures License Agreement With Bristol-Myers Squibb to Reduce Royalties Payable on its Migraine Product Candidates

Financial news for BMY dated on 2018-03-11: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for BMY dated on 2018-03-06: An Eventful February Took Its Toll On TD Ameritrade's Investor Index

Financial news for BMY dated on 2018-03-06: Investor Movement Index February Summary

Financial news for BMY dated on 2018-03-06: Bristol-Myers Squibb's Opdivo Label Update for Flexible Flat-Dosing Every Two and Four Weeks Approved by the FDA

Financial news for BMY dated on 2018-03-05: The Week Ahead: Discount Retailers Close Out Earnings Season

Financial news for BMY dated on 2018-03-05: REMINDER: Bristol-Myers Has FDA PDUFA Date for Opdivo Dosing sBLAs Today

Financial news for BMY dated on 2018-03-02: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for BMY dated on 2018-03-02: Jim Cramer Weighs In On Albemarle, Square And More

Financial news for BMY dated on 2018-02-28: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Financial news for BMY dated on 2018-02-28: DZ Bank Downgrades Bristol-Myers Squibb to Hold

Financial news for BMY dated on 2018-02-18: Benzinga's Bulls & Bears Of The Week: Bristol-Myers, GE, Target, Under Armour And More

Financial news for BMY dated on 2018-02-16: Stocks That Made New 52-Wk Highs Earlier

Include: Accenture, M&T Bank, PNC, Ansys, Lockheed Martin, Deere, Raytheon, Intuit, Comerica, Interpublic, Northrop Grumman, VeriSign, Estee Lauder, Bristol-Myers, Red Hat, Nike, NVIDIA and Global Payments

Financial news for BMY dated on 2018-02-15: Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight

Financial news for BMY dated on 2018-02-15: Morgan Stanley Upgrades Bristol-Myers Squibb Company to Overweight

Financial news for BMY dated on 2018-02-15: Leerink Partners Global Healthcare Conf. Concludes Today, Presenters Include: Synlogic, Quanterix, Acorda Therapeutics, Bristol-Myers, Alnylam, and HCA Healthcare

Financial news for BMY dated on 2018-02-14: Adam Feuerstein Tweet:For \$BMY -- Paying a ton for NKTR-214 doesn't exactly inspire confidence in Opdivo business, as is. What is lurking under the hood of the -227 study we haven't seen?

Financial news for BMY dated on 2018-02-14: Bristol-Myers Squibb, Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar's CD122-biased Agonist, NKTR-214; Nektar To Pay \$1.85B Upfront Comprised Of \$1B In Cash & Purchase Of 8.28M Shares At \$102.60/Share

Financial news for BMY dated on 2018-02-12: Bristol Myers Squibb To Make and Upfront Payment and Potential Future Payments to Sirenas

Financial news for BMY dated on 2018-02-06: Leerink Swann Maintains Outperform on Bristol-Myers Squibb, Raises Price Target to \$76.00

Financial news for BMY dated on 2018-02-05: Mid-Afternoon Market Update: Dow Tumbles Over 400 Points; Crude Oil Down 2%

Financial news for BMY dated on 2018-02-05: The Week Ahead: IPOs Ramp Up Just As Earnings Season Fades

Financial news for BMY dated on 2018-02-05: Mid-Day Market Update: Dow Falls Over 250 Points; Enphase Energy Shares Spike Higher

Financial news for BMY dated on 2018-02-05: Mid-Morning Market Update: Markets Open Lower; Bristol-Myers Profit Tops Expectations

Financial news for BMY dated on 2018-02-05: Benzinga Pro's 5 Stocks To Watch Today

Financial news for BMY dated on 2018-02-05: Bristol-Meyers Squibb Company Shares Up 3.94% Premarket After Q4 Earnings Beat

Financial news for BMY dated on 2018-02-05: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for BMY dated on 2018-02-05: Adam Feuerstein Tweets: I guess it's okay to change up your biomarkers in a ph3 clinical trial, as long as you're Big Pharma and not a micro-cap biotech? \$BMY

Financial news for BMY dated on 2018-02-05: Bristol-Myers Squibb Company Announces Phase 3 CHeckMate -227 Met Its Co-Primary Endpoint Of Progression-Free SURvival With Opdivo And Yervoy

Financial news for BMY dated on 2018-02-05: Bristol-Myers Squibb Sees FY18 Adj. EPS \$3.15 to \$3.30 vs \$3.23 Est.

Financial news for BMY dated on 2018-02-05: Bristol-Myers Squibb Reports Q4 Adj. EPS \$0.68 vs \$0.67 Est., Sales \$5.45B vs \$5.35B Est.

Financial news for BMY dated on 2018-02-05: Earnings Scheduled For February 5, 2018

Financial news for BMY dated on 2018-02-05: 7 Stocks To Watch For February 5, 2018

Financial news for BMY dated on 2018-01-31: PreMarket Opening NYSE Imbalance Update: Abbott 28k Shares To Sell; Bristol-Myers 10k To Sell; Alibaba 39k To Buy; Twitter 57k To Buy; BofA 81k To Buy; Goldman 54k To Sell;

Financial news for BMY dated on 2018-01-25: Five Prime Therapeutics Receives \$25M Milestone Payment From Bristol-Myers

Financial news for BMY dated on 2018-01-22: Bristol-Myers Squibb's Yervoy Approved by the European Commission for the Treatment of Pediatric Patients

Financial news for BMY dated on 2018-01-21: Bristol-Myers Squibb Announces Opdivo in Combination with Yervoy Demonstrates Clinical Activity in Previously Treated Patients

with dMMR or MSI-H Metastatic Colorectal Cancer

Financial news for BMY dated on 2018-01-19: The Top 10 Value Stocks In The S&P 500

Financial news for BMY dated on 2018-01-11: Key Takeaways From The J.P. Morgan Healthcare Conference

Financial news for BMY dated on 2018-01-08: UPDATE: Five Prime Says Is Eligible To Receive Up To \$300M In Future Development, Regulatory, Sales-Based Milestone Payments

Financial news for BMY dated on 2018-01-08: UPDATE: Five Prime Says Bristol Extended Research Term Of Collaboration Deal With Co. For Second Time

Financial news for BMY dated on 2018-01-08: Five Prime Therapeutics Reports Earned IND Milestone Payment Of \$5M Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb

Financial news for BMY dated on 2018-01-02: 4 Reasons To Consider Adding Celldex To Your Portfolio

Financial news for BMY dated on 2017-12-27: HTG Molecular's Deal With Merck KGaA 'Provides Further Validation' For EdgeSeq Technology

Financial news for BMY dated on 2017-12-20: After Hitting Support, Vetr Issues Buy Rating On Bristol Myers

Financial news for BMY dated on 2017-12-20: Bristol-Myers Reports FDA Approval For Opdivo As Adjuvant Therapy In Patients With Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease

Financial news for BMY dated on 2017-12-20: TARIS Biomedical, Bristol-Myers Squibb Reports Clinical Trial Collaboration For TAR-200 With Opdivo For Treatment Of Muscle Invasive Bladder Cancer

Financial news for BMY dated on 2017-12-18: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Yervoy for the Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma

Financial news for BMY dated on 2017-12-15: Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More

Financial news for BMY dated on 2017-12-14: STAT News' Adam Feuerstein Responds To Tweet Highlighting '\$PFE \$AGN rumor - no source': 'The other day I heard \$PFE for \$BMY,' 'Also \$ABBV for \$BMY'

Financial news for BMY dated on 2017-12-14: Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment

Financial news for BMY dated on 2017-12-13: Bristol-Myers Reports FDA Accepted Application For Opdivo Plus Yervoy Combo For Intermediate, Poor-Risk Patients With ARCC; Grants Priority Review

Financial news for BMY dated on 2017-12-12: PsiOxus Therapeutics Receives \$15M Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves

Financial news for BMY dated on 2017-12-11: PreMarket Opening NYSE Imbalance Update: ExxonMobil 128k Shares To Sell; Deere 69k Shares To Sell; Bristol-Myers Squibb 45k Shares To Sell; Visa 51k Shares To Sell;

Financial news for BMY dated on 2017-12-09: Bristol-Myers Squibb Announces Sprycel Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive ALL at #ASH2017

Financial news for BMY dated on 2017-12-07: Bristol-Myers Raises Qtr. Dividend From \$0.39/Share To \$0.40/Share

Financial news for BMY dated on 2017-12-01: FDA Decisions In November: The Month In Review

Financial news for BMY dated on 2017-12-01: Bristol-Myers Shares Indicated Up ~0.6% Premarket Following Late Thurs. Release Highlighting Its CheckMate -078 Opdivo Lung Cancer Trial Was Stopped Early For Showing Superior Overall Survival

Financial news for BMY dated on 2017-11-29: A Lazarus Act For This Pharma ETF

Financial news for BMY dated on 2017-11-28: Bristol-Myers Shares Volatile At Session Highs Following Large Block Trade: 2.8M Shares At \$62.56/Share; Order Was Worth ~\$175M

Financial news for BMY dated on 2017-11-28: UPDATE: CytomX FDA Acceptance Of INDA Triggers \$10M Milestone Payment From Bristol-Myers Squibb

Financial news for BMY dated on 2017-11-28: Bristol-Myers Says the European Medicines Agency Validates its Type II Variation Application for Opdivo Plus Yervoy in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma

Financial news for BMY dated on 2017-11-27: How Digital Pills Could Change The Health Insurance Game

Financial news for BMY dated on 2017-11-16: PreMarket NYSE Imbalance Update: GE 294k Shares To Buy; BABA 105k Shares To Buy; SQ 125k Shares To Buy; VZ 49k Shares To Sell; SNAP 59k Shares To Buy; PFE 88k Shares To Sell; BMY 39k Shares To Sell

Financial news for BMY dated on 2017-11-15: Jefferies 2107 London Healthcare Conference Begins Today, Presenters Include: Alkermes, Bristol-Myers, Immunogen, and Eagle Pharmaceuticals

Financial news for BMY dated on 2017-11-15: LabCorp Reports New Expanded Use For PD-L1 Test With Bristol's OPDIVO

Financial news for BMY dated on 2017-11-15: Ultragenyx Seeks An FDA Win For Biologic Therapy Candidate

Financial news for BMY dated on 2017-11-13: Analyst: Nektar Has A Handful Of Milestones Ahead In 2018

Financial news for BMY dated on 2017-11-12: Nektar Therapeutics, Bristol-Myers Squibb Announce First Presentation of Data from PIVOT-02 Phase 1/2 Study Showing Potential Benefits Presented at SITC 2017

Financial news for BMY dated on 2017-11-10: Bristol Myers Announces 'Encouraging' Response with Opdivo Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003

Financial news for BMY dated on 2017-11-10: FDA Expands Approval of Bristol-Myers Squibb's Sprycel to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Financial news for BMY dated on 2017-11-09: Pharma ETFs Down Post Q3 Earnings

Financial news for BMY dated on 2017-11-09: REMINDER: Bristol-Myers Has FDA PDUFA Date For Sprycel sNDA Today

Financial news for BMY dated on 2017-11-09: Bristol-Myers Squibb, Five Prime Report Phase 1a/1b Data Evaluating Cabiralizumab With Opdivo In Patients With Advanced Solid Tumors

Financial news for BMY dated on 2017-11-07: Pre-Market Imbalance Update: General Electric 258k Shares To Buy; Alibaba 121k Shares To Buy; Square 168k Shares To Buy; Pfizer 41k Shares To Sell; Bristol-Myers 51k Shares To Sell; Disney 70k Shares To Buy

Financial news for BMY dated on 2017-11-06: Pharma Stock Roundup: Pfizer, Teva, Novartis, And More

Financial news for BMY dated on 2017-11-06: The Week Ahead: Earnings Season Continues, Several IPOs, Notable Conferences On The Docket

Financial news for BMY dated on 2017-11-06: UPDATE: Bristol-Myers Says Opdivo Reduced 'the risk of death by 26% versus everolimus in the phase 3 CheckMate -025 study'

Financial news for BMY dated on 2017-11-06: Bristol-Myers Reports Opdivo Showed Superior 3-Year Survival Benefit For Patients Previously Treated With RCC

Financial news for BMY dated on 2017-10-31: Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon

Financial news for BMY dated on 2017-10-30: The Bull Thesis For Merck Is Evaporating

Financial news for BMY dated on 2017-10-30: Analyst Grows Cautious On Merck's Keytruda After Company Withdraws European Application

Financial news for BMY dated on 2017-10-30: 8 Technical Levels Highlighted On Monday's PreMarket Prep

Financial news for BMY dated on 2017-10-30: Benzinga's Top Upgrades, Downgrades For October 30, 2017

Financial news for BMY dated on 2017-10-26: 11 Technical Levels Discussed On Thursday's PreMarket Prep

Financial news for BMY dated on 2017-10-26: Pre-Market Imbalance Update: GE 365K Shares To Sell, AT&T 329K To Buy, Twitter 164K To Buy, Cat 78K To Sell, Square 63K To Buy, Bristol-Myers 49K To Sell, GM 38K To Sell, Alibaba 26K To Buy

Financial news for BMY dated on 2017-10-26: A Peek Into The Markets: U.S. Stock Futures Edge Higher; Alphabet, Amazon Earnings In Focus

Financial news for BMY dated on 2017-10-26: Bristol-Myers Squibb Increases FY17 Adj. EPS From \$2.90-\$3.00 to \$2.95-\$3.05

Financial news for BMY dated on 2017-10-26: Bristol-Myers Squibb Increases FY17 Adj. EPS

Financial news for BMY dated on 2017-10-26: Bristol-Myers Squibb Reports Q3 Adj. EPS \$0.75 vs \$0.77 Est., Sales \$5.3B vs \$5.2B Est.

Financial news for BMY dated on 2017-10-26: 15 Stocks To Watch For October 26, 2017

Financial news for BMY dated on 2017-10-26: Earnings Scheduled For October 26, 2017

Financial news for BMY dated on 2017-10-24: Healthcare ETFs Set To Soar As Q3 Earnings Unfold

Financial news for BMY dated on 2017-10-23: Benzinga's Option Alert Recap From October 23

Financial news for BMY dated on 2017-10-23: Is A Beat In Store For Bristol-Myers In Q3 Earnings?

Financial news for BMY dated on 2017-10-22: A Preview Of Next Week's Blue-Chip Earnings

Financial news for BMY dated on 2017-10-18: Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever

Financial news for BMY dated on 2017-10-16: Bristol-Myers Says FDA Accepted Opdivo for Priority Review and Breakthrough Therapy Designation

Financial news for BMY dated on 2017-10-16: Bristol-Myers Stock May Have Exhausted Its Upside For Now

Financial news for BMY dated on 2017-10-16: Benzinga's Top Upgrades, Downgrades For October 16, 2017

Financial news for BMY dated on 2017-10-16: The Market In 5 Minutes: Health Insurers, Tesla Firings And Big Analyst Rating Changes

Financial news for BMY dated on 2017-10-16: Jefferies Downgrades Bristol-Myers Squibb to Hold

Financial news for BMY dated on 2017-10-16: Bristol-Myers Squibb Announces Opdivo Alone or Combined with Yervoy Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden, in Exploratory Analysis from Phase 1/2 Study CheckMate -032

Financial news for BMY dated on 2017-10-13: Bank Of America Sees NewLink Genetics As 'Undervalued'

Financial news for BMY dated on 2017-10-13: Lightning Round: Jim Cramer Weighs In On Bristol-Myers Squibb, Mazor Robotics And More

Financial news for BMY dated on 2017-10-12: Bristol-Myers Reports Extension Of Strategic Partnership With TARGET PharmaSolutions For TARGET-NASH

Financial news for BMY dated on 2017-10-11: 5 Biggest Price Target Changes For Wednesday

Financial news for BMY dated on 2017-10-10: These Were The Most Bought And Sold Stocks In September

Financial news for BMY dated on 2017-09-29: Najarian Brothers See Unusual Options Activity In BlackBerry And Bristol-Myers Squibb

Financial news for BMY dated on 2017-09-28: Attention Biotech Investors, Here's Your PDUFA Primer For October

Financial news for BMY dated on 2017-09-25: Infinity Pharma and Bristol-Myers Expand Clinical Collaboration Evaluating IPI-549 in Combination with Opdivo

Financial news for BMY dated on 2017-09-22: The Street Has Finally Recognized The Exelixis Clinical Program Potential

Financial news for BMY dated on 2017-09-22: Bristol-Myers' Opdivo Approved by the Japanese Ministry of Health, Labor and Welfare for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy

Financial news for BMY dated on 2017-09-22: AbbVie and Bristol-Myers Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors

Financial news for BMY dated on 2017-09-20: Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers

Financial news for BMY dated on 2017-09-15: Mirati Therapeutics Sitravatinib Data, Explained

Financial news for BMY dated on 2017-09-14: The Market In 5 Minutes

Financial news for BMY dated on 2017-09-14: Bristol-Myers and Halozyme Enter Collaboration and License Agreement Using Halozyme's ENHANZE, Halozyme to Receive \$105M Upfront

Financial news for BMY dated on 2017-09-12: This Analyst Predicts Bullish Growth Outlook For Incyte

Financial news for BMY dated on 2017-09-11: Array BioPharma And Others Shine At The ESMO 2017 Congress

Financial news for BMY dated on 2017-09-11: Bristol-Myers In Collaboration With Transgene Receives FDA Approval To Launch Phase 2 Trial Of TG4010 and NIVOLUMAB

Financial news for BMY dated on 2017-09-11: Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers

Financial news for BMY dated on 2017-09-11: Pre-Market Imbalance Update: Bristol-Myers Squibb 152K Shares To Sell, GE 145K To Sell, Pfizer 108K to Sell, Home Depot 102K Shares To Buy, Alibaba 101K Shares To Buy, USG 94K To Buy, Lowe's 48K To Buy, Heritage Insurance 43K To Buy, Rockwell Collins 38K

Financial news for BMY dated on 2017-09-10: Bristol-Myers Squibb Announces Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma in Phase 3 CheckMate-214 Trial at ESMO 2017

Financial news for BMY dated on 2017-09-09: What Pharmaceuticals Spend On Lobbying To Influence Trump

Financial news for BMY dated on 2017-09-08: European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5

Financial news for BMY dated on 2017-09-08: Watch These 5 Huge Put Purchases In Friday Trade

Financial news for BMY dated on 2017-09-07: Benzinga's Option Alert Recap From September 7

Financial news for BMY dated on 2017-09-07: Bristol Myers Squibb Option Alert: Dec 15 \$50 Puts at the Ask: 3750 @ \$0.331 vs 2253 OI; Ref=\$62.86

Financial news for BMY dated on 2017-09-07: Bristol Myers Squibb Option Alert: Fri \$62 Calls Sweep (10) at the Bid: 621 @ \$1.045 vs 96 OI; Ref=\$62.94

Financial news for BMY dated on 2017-09-07: Bristol-Myers Reports CheckMate -214 Study Evaluating Opdivo In Combo With Yervoy Stopped Early For Showing Overall Survival Benefit In Patients With Previously Untreated Advanced, Metastatic Renal Cell Carcinoma

Financial news for BMY dated on 2017-09-01: Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts

Financial news for BMY dated on 2017-08-31: Jim Cramer Shares His Thoughts On Genworth Financial, AeroVironment And Bristol-Myers Squibb

Financial news for BMY dated on 2017-08-28: Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo and DS-8201

Financial news for BMY dated on 2017-08-28: Bristol-Myers Squibb, Pfizer Present Observational Real-World Data Analysis on Effectiveness and Safety of Eliquis vs to Warfarin in Select High-Risk Patients with NVAf

Financial news for BMY dated on 2017-08-18: Bristol-Myers Squibb, Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation and Treating Deep Vein Thrombosis/Pulmonary Embolism at ESC Congress 2017

Financial news for BMY dated on 2017-08-18: Bristol-Myers Squibb Receives FDA Orphan Drug Designation for Nivolumab and Ipilimumab for Treatment of Mesothelioma

Financial news for BMY dated on 2017-08-16: Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive'

Financial news for BMY dated on 2017-08-15: Bristol-Myers Announces Top-line Results From Phase 3 Opdivo Study, Met 1 Co-Primary Endpoint, Missed Another; Study Will Continue To Evaluate 3rd Co-Primary Endpoint

Financial news for BMY dated on 2017-08-14: 13F From Rosenstein's JANA Shows Liquidated ~716K Share Stake In Bristol-Myers Squibb

Financial news for BMY dated on 2017-08-03: Bristol-Myers Squibb to Acquire IFM Therapeutics For \$300M Upfront With Potential Of Up To \$1.01B In Milestones

Financial news for BMY dated on 2017-08-01: Seattle Genetics Buys Bothell Manufacturing Facility From Bristol-Myers Squibb

Financial news for BMY dated on 2017-08-01: Key FDA Events To Watch Out For In August 2017

Financial news for BMY dated on 2017-08-01: Bristol-Myers Shares Plunge ~\$1 Over Last Min., Stock Now Down 1.9% For Session

Financial news for BMY dated on 2017-08-01: August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Financial news for BMY dated on 2017-08-01: Bristol-Myers Squibb Receives FDA Approval for Opdivo

Financial news for BMY dated on 2017-07-31: Bristol-Myers and Clovis Oncology to Collaborate on Opdivo and Rubraca In Phase 2 and Phase 3 Trials

Financial news for BMY dated on 2017-07-28: 5 Biggest Price Target Changes For Friday

Financial news for BMY dated on 2017-07-27: 20 Biggest Mid-Day Losers For Thursday

Financial news for BMY dated on 2017-07-27: Why Is AstraZeneca Sinking Today?

Financial news for BMY dated on 2017-07-27: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for BMY dated on 2017-07-27: Bristol-Myers Squibb Reports Q2 Adj. EPS \$0.74, Inline, Sales \$5.1B vs \$5.09B Est.

Financial news for BMY dated on 2017-07-27: 15 Stocks To Watch For July 17, 2017

Financial news for BMY dated on 2017-07-27: Earnings Scheduled For July 27, 2017

Financial news for BMY dated on 2017-07-24: Bristol-Myers Reports FDA Acceptance Of sBLAs For Opdivo 4-Week Dosing Schedule, Action Date March 5, 2018

Financial news for BMY dated on 2017-07-24: Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers

Financial news for BMY dated on 2017-07-24: Bristol-Meyers' Yervoy FDA Approval Expanded to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma

Financial news for BMY dated on 2017-07-17: These Were The Most Popular Buys And Sells Among Retail Investors In June

Financial news for BMY dated on 2017-07-12: Novartis Shares Spike to \$84 High Following Panel Approval, Now Relatively Unaffected; Shares Of Bristol Myers Fell 1.8%

Financial news for BMY dated on 2017-07-10: TD Ameritrade's Investor Movement Index (IMX) For June 2017

Financial news for BMY dated on 2017-07-10: Bristol-Myers sNDA Accepted by the FDA to Include an Indication for Sprycel

Financial news for BMY dated on 2017-07-06: Bristol-Myers Squibb's ORENCIA Receives FDA Approval

Financial news for BMY dated on 2017-07-05: Opdivo News Doesn't Give Bristol-Myers Much Of A Boost

Financial news for BMY dated on 2017-07-05: Pre-Market Imbalance Update: Ford 279K Shares To Sell, NIKE 223K To Sell, JP Morgan 82K Shares To Buy, Disney 65K To Buy, Wells Fargo 58K To Buy, Bristol-Myers 51K To Buy, ExxonMobil 50K To Sell, Visa 47K To Buy

Financial news for BMY dated on 2017-07-05: A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Fed Minutes

Financial news for BMY dated on 2017-07-02: Barron's Picks And Pans: Bristol-Myers, Texas Instruments, Altaba And More

Financial news for BMY dated on 2017-06-30: Stocks Going Ex Dividend The First Week of July

Financial news for BMY dated on 2017-06-26: A Surprisingly Clean, Straightforward Approval Gives Portola Pharma Shares A Shot Of Upside

Financial news for BMY dated on 2017-06-24: Bristol-Myers Squibb Company Announces Four-Year Follow-up with Empliciti Plus Lenalidomide/Dexamethasone in Patients with Advanced Multiple Myeloma Shows Long-term Efficacy in ELOQUENT-2 Trial #EHA2017

Financial news for BMY dated on 2017-06-22: Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma

Financial news for BMY dated on 2017-06-16: Bristol-Myers Squibb Reports ORR of 65% or Greater For Opdivo In Adult Patients With Relapsed or Progressed Classical Hodgkin Lymphoma Regardless Of Prior brentuximab vedotin Therapies

Financial news for BMY dated on 2017-06-16: Bristol-Myers Squibb to Sell Manufacturing Facility in Swords, Ireland to SK Biotech; Terms Not Disclosed

Financial news for BMY dated on 2017-06-15: A Deep Dive On The May IMX's Most Bought And Sold Stocks

Financial news for BMY dated on 2017-06-15: UPDATE: Seattle Genetics, Bristol-Myers Reports Combo Data Show 85% Objective Response Rate, 63% Complete Response Rate with an Acceptable Safety Profile

Financial news for BMY dated on 2017-06-15: Seattle Genetics, Bristol-Myers Reports Interim Phase 1/2 Data Evaluating Combo Of ADCETRIS, Opdivo In Relapsed Hodgkin Lymphoma

Financial news for BMY dated on 2017-06-15: Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS and OPDIVO

Financial news for BMY dated on 2017-06-08: Bristol-Myers Squibb Announces Availability of New ORENCIA Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis

Financial news for BMY dated on 2017-06-08: Bristol-Myers Squibb Reports Availability of New ORENCIA Subcutaneous Administration Option for Patients 2 Years of Age and Older With JIA

Financial news for BMY dated on 2017-06-05: Bristol-Myers Squibb Reports New Collaboration to Evaluate Combo Therapy in Colorectal Cancer: Phase 1/2 study to evaluate the combination of Opdivo, Opdivo + Yervoy regimen with Mekinist

Financial news for BMY dated on 2017-06-05: Investor Movement Index (IMX) For May 2017: Tech Buying Continues

Financial news for BMY dated on 2017-06-05: Incyte and Bristol-Myers Give Update on Phase 1/2 ECHO Trial

Financial news for BMY dated on 2017-06-04: Bristol-Myers Squibb Announces New Data Evaluating Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy 3 mg/kg and 10 mg/kg in Resected High-Risk Melanoma Patients #ASCO17

Financial news for BMY dated on 2017-06-03: Bristol-Myers Squibb, QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

Financial news for BMY dated on 2017-06-03: Bristol-Myers Squibb Announces Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy #ASCO17

Financial news for BMY dated on 2017-06-02: Bristol-Myers Squibb Reports EC Approved Co.'s Opdivo for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy

Financial news for BMY dated on 2017-06-02: Bristol-Myers Gives Update on CHeckMate -358

Financial news for BMY dated on 2017-06-02: Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo and ADCETRIS in Phase 3 Trial

Financial news for BMY dated on 2017-05-30: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for BMY dated on 2017-05-30: A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Economic Data

Financial news for BMY dated on 2017-05-30: Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo

Financial news for BMY dated on 2017-05-30: Array BioPharma and Bristol Myeres to Collaborate on Array's MEK Inhibitor

Financial news for BMY dated on 2017-05-24: FDA Accepts Priority Review For Bristol-Myers Squibb's Application For Opdivo In Previously Treated Hepatocellular Carcinoma, Action Date Is Sept. 24th 2017

Financial news for BMY dated on 2017-05-22: UBS Global Health Care Conference Begins Today; Presenters Include: AbbVie, Aetna, Universal Health, Mylan, Community Health, Tenet Healthcare, & Bristol-Myers Squibb

Financial news for BMY dated on 2017-05-19: The Most Notable Abstracts Released Ahead Of ASCO 2017

Financial news for BMY dated on 2017-05-19: EMA Validates Application for Bristol-Myers Squibb's Sprycel in Children with Chronic Myelogenous Leukemia

Financial news for BMY dated on 2017-05-16: Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns

Financial news for BMY dated on 2017-05-12: Appaloosa Dissolves Stake In Bristol Myers Squibb, JC Penny

Financial news for BMY dated on 2017-05-12: Sympathy Moves, Explained: Unsympathetic Earnings Season Continues As Nvidia, Advanced Micro Devices Diverge

Financial news for BMY dated on 2017-05-11: Here's What The FDA Approval Of Keytruda Means For Merck, And For Bristol-Myers

Financial news for BMY dated on 2017-05-10: Bristol-Myers Squibb, Calithera Biosciences Expand Collaboration Evaluating Opdivo in Combination with CB-839 into NSCLC, Melanoma

Financial news for BMY dated on 2017-05-06: Near-Term Events Cast Shadow Of Uncertainty On Bristol-Myers

Financial news for BMY dated on 2017-05-05: Watch These 5 Huge Put Purchases In Friday Trade

Financial news for BMY dated on 2017-05-04: Benzinga's Option Alert Recap From May 4

Financial news for BMY dated on 2017-05-04: Option Alert: Bristol Myers Sq; Jun \$50 Put; 3850 @Bid @\$0.17; Ref=\$55.52

Financial news for BMY dated on 2017-05-04: Deutsche Bank Health Care Conference Concludes Today, Presenters Include: Eagle Pharma, Foamix, Universal Health Services, NovoCure, & Bristol-Myers

Financial news for BMY dated on 2017-05-03: Benzinga's Top Upgrades, Downgrades For May 3, 2017

Financial news for BMY dated on 2017-05-03: The Market In 5 Minutes

Financial news for BMY dated on 2017-05-03: A Peek Into The Markets: U.S. Stock Futures Down; All Eyes On Fed Decision

Financial news for BMY dated on 2017-05-03: BMO Capital Downgrades Bristol-Myers Squibb to Underperform

Financial news for BMY dated on 2017-05-02: Companies Holding Shareholder Meetings Today Include Valeant Pharmaceuticals, Ally Financial, Bristol-Myers, Ally Financial, Eli Lilly, DryShips, Insys, Kona Grill And Sprouts Farmers Market

Financial news for BMY dated on 2017-05-02: Watch These 8 Huge Call Purchases In Tuesday Trade

Financial news for BMY dated on 2017-05-01: Benzinga's Option Alert Recap From May 1

Financial news for BMY dated on 2017-05-01: Option Alert: Bristol Myers Squibb Sep 62.5 Calls Sweep: 999 @ ASK \$1.05: 1081 traded vs 3097 OI: Earnings 7/27 Before Open [est] \$56.71 Ref

Financial news for BMY dated on 2017-04-28: Bristol-Myers Gets Chinese Approval for an Antiviral Regimen of Daklinza and Sunvepra

Financial news for BMY dated on 2017-04-27: Adam Feuerstein Tweets: New \$BMY CSO Tom Lynch is VERY good on conference calls.

Financial news for BMY dated on 2017-04-27: D.C. Issues, Including Tax Plan, Steal Some Thunder From Big Earnings Day

Financial news for BMY dated on 2017-04-27: Bristol Myers Squibb Raises FY 2017 Guidance from \$2.70 - \$2.90 to \$2.85 - \$3.00 vs \$2.80 Est

Financial news for BMY dated on 2017-04-27: Bristol-Myers Squibb Q1 EPS \$0.84 vs \$0.74 Est, Sales \$4.93B vs \$4.72B Est

Financial news for BMY dated on 2017-04-27: 12 Stocks To Watch For April 27, 2017

Financial news for BMY dated on 2017-04-27: Earnings Scheduled For April 27, 2017

Financial news for BMY dated on 2017-04-25: With More Than 100% Upside Seen In Idera Pharma Shares, Baird Initiates At Outperform

Financial news for BMY dated on 2017-04-25: Transgene, Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line NSCLC

Financial news for BMY dated on 2017-04-24: Spell Out Relief: French Vote As Expected, So Attention Turns To Earnings, Tax Reform

Financial news for BMY dated on 2017-04-22: Bristol-Myers Squibb Announces BMS-986036 Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with NASH in Phase 2 Trial at EASL

Financial news for BMY dated on 2017-04-21: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo For Treatment Of Type Of Bladder Cancer

Financial news for BMY dated on 2017-04-20: Exclusive: Idera CEO Discusses The Potential For His Company's Lead Drug Candidate

Financial news for BMY dated on 2017-04-17: Bristol-Myers Squibb, Nordic Bioscience Report Collaboration for Fibrosis Biomarker Technology

Financial news for BMY dated on 2017-04-13: A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Initial Jobless Claims Report

Financial news for BMY dated on 2017-04-13: UPDATE: Bristol-Myers Says Will Receive Combined \$470M Upfront

Financial news for BMY dated on 2017-04-13: Bristol-Myers Squibb Reports Separate Deals with Biogen, Roche to License Anti-eTau, Anti-Myostatin Compounds, Respectively

Financial news for BMY dated on 2017-04-11: Bristol-Myers Squibb, Apexigen, Inc. Report Clinical Collaboration to Evaluate Opdivo In Combination With APX005M IN Advanced Solid Tumors

Financial news for BMY dated on 2017-04-04: Bristol-Myers Squibb Announces FDA Accepts Priority Review For Opdivo In Previously Treated dMMR or MSI-H Metastatic

Colorectal Cancer

Financial news for BMY dated on 2017-04-03: Bristol-Myers Squibb Reports CheckMate -143 Did Not Meet Primary Endpoint

Financial news for BMY dated on 2017-04-03: Bristol-Myers Reports Opdivo in Combo with Yervoy, Opdivo Monotherapy Significantly Improved Overall Survival vs Yervoy Alone in Patients with Previously Untreated Advanced Melanoma

Financial news for BMY dated on 2017-04-03: Bristol-Myers Reports First Report of 5-Year Overall Survival Data from Phase 1 Dose-Ranging Study CA209-003 Evaluating Opdivo in Patients

Financial news for BMY dated on 2017-04-02: Bristol-Myers Squibb, Incyte Announce Agreement to Advance the Combination of Opdivo and Epacadostat into First-line Registrational Trials

Financial news for BMY dated on 2017-03-30: Bristol-Myers Reports Collaboration Deal to Leverage Foundation Medicine's Molecular Info Platform

Financial news for BMY dated on 2017-03-29: Watch These 8 Huge Call Purchases In Wednesday Trade

Financial news for BMY dated on 2017-03-28: Benzinga's Option Alert Recap From March 28

Financial news for BMY dated on 2017-03-28: Option Alert: Bristol Myers Apr 65.0 Calls: 7000 @ ASK \$0.10: 21k traded vs 3041 OI: Earnings 4/27 Before Open \$56.24 Ref

Financial news for BMY dated on 2017-03-24: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck

Financial news for BMY dated on 2017-03-22: FDA.gov Drug Safety Communication Page On Diabetes Drug Metformin Updated Today; Features Revised Warnings On Use In Patients With Reduced Kidney Function; Potential Negative For Bristol-Myers

Financial news for BMY dated on 2017-03-20: Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide

Financial news for BMY dated on 2017-03-20: 12 Biggest Mid-Day Gainers For Monday

Financial news for BMY dated on 2017-03-20: Mid-Day Market Update: Nektar Surges After Positive Results From NKTR-181 Study; Cerulean Pharma Shares Drop

Financial news for BMY dated on 2017-03-20: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for BMY dated on 2017-03-20: Bristol-Myers Squibb, CytomX Therapeutics Extend Worldwide Partnership to Discover Probody Therapeutics for the Treatment of Cancer and Other Diseases; CytomX To Receive \$200M Upfront Payment

Financial news for BMY dated on 2017-03-15: Barclays Global Healthcare Conference Continues Today; Presenters Include HCA Holdings, Valeant, Incyte, Celgene, Cotiviti, Aetna, Anthem, Seattle Genetics, Teva Pharma, Pfizer, & Bristol-Myers

Financial news for BMY dated on 2017-03-15: Watch These 8 Huge Call Purchases In Wednesday Trade

Financial news for BMY dated on 2017-03-14: Benzinga's Option Alert Recap From March 14

Financial news for BMY dated on 2017-03-14: Option Alert: Bristol Myers Mar 60.0 Calls: 3000 @ ASK \$0.06: 6189 traded vs 52k OI: Earnings 4/27 Before Open \$56.95 Ref

Financial news for BMY dated on 2017-03-13: Transgene Announces First Patient in Phase 2 Trial Evaluating Co.'s TG4010 in Combo with Bristol-Myers' Opdivo for Second Line Treatment of Metastatic NSCLC

Financial news for BMY dated on 2017-03-08: Bristol-Myers Names Dr. Thomas Lynch Chief Scientific Officer

Financial news for BMY dated on 2017-03-06: Cowen Annual Healthcare Conference Begins Today; Presenters Include Insulet, PARAXEL, Zoetis, Alexion, Bristol-Myers, Acadia, Alnylam, Axovant, Ardelyx, Aurinia Pharma, And Puma Biotech

Financial news for BMY dated on 2017-03-04: Icahn's (Potential) Move Into Biotech

Financial news for BMY dated on 2017-03-02: The Unlikely Story Of How Amicus Therapeutics Came To Be

Financial news for BMY dated on 2017-03-01: Bristol-Myers Squibb Announced Equity Investment And Research Collaboration With GRAIL For Early Cancer Detection

Financial news for BMY dated on 2017-03-01: Short Sellers Pile On Pfizer After Buyout Rumors

Financial news for BMY dated on 2017-02-27: Is Carl Icahn Losing His Midas Touch?

Financial news for BMY dated on 2017-02-24: Carl Icahn's Track Record In Big Pharma

Financial news for BMY dated on 2017-02-24: AutoNation, Bristol-Myers, General Electric, Oracle: Fast Money Picks For February 24

Financial news for BMY dated on 2017-02-22: Activist Investors Are Back And More Active Than Ever

Financial news for BMY dated on 2017-02-22: Jim Cramer: Maybe Investors Aren't Paying As Much For Corporate Earnings

Financial news for BMY dated on 2017-02-22: Bristol-Myers Oncology Growth Potential Remains High

Financial news for BMY dated on 2017-02-22: The Market In 5 Minutes

Financial news for BMY dated on 2017-02-22: Wall Street's M&A Chatter From February 21

Financial news for BMY dated on 2017-02-21: Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?

Financial news for BMY dated on 2017-02-21: BZ NOTE: Earlier This Morning, Bristol-Myers Reported A \$2B Accelerated Buyback

Financial news for BMY dated on 2017-02-21: Icahn Sees Bristol-Myers as Possible Takeover Target

Financial news for BMY dated on 2017-02-21: Icahn Takes Stake in Bristol Myers; See Value in Pipeline -DJ

Financial news for BMY dated on 2017-02-21: Dow Jones Reporting Carl Icahn Takes Stake In Bristol Myers, Sees Co. As Possible Takeover Target

Financial news for BMY dated on 2017-02-21: Bristol Myers Spikes to High of \$57.21 on Report of Possible Icahn Stke

Financial news for BMY dated on 2017-02-21: Bristol-Myers Squibb Says It Expects To Incur \$1.5-\$2.0B Through 2020 In Connection With Oct. 2016 Restructuring Announcement

Financial news for BMY dated on 2017-02-15: Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers

Financial news for BMY dated on 2017-02-15: Leerink Partners Global Healthcare Conference Began Today; Presenters Include Mannkind, Universal Health Services, Celgene, Inogen, Endologix, Biogen, GW Pharma, Regulus, Fate Therapeutics, Puma Biotech, Allergan, Bristol Myers And Synergy Pharma

Financial news for BMY dated on 2017-02-15: Deutsche Bank on Bristol-Myers Unconfirmed Takeover Chatter Tuesday: 'we would be surprised to see PFE make a move on BMY at this stage'

Financial news for BMY dated on 2017-02-14: Valeant's Stock Having One Of Its Best Days Of 2017

Financial news for BMY dated on 2017-02-14: Bristol-Myers Shares Up \$0.40 Over Last Min as Hearing Unconfirmed Chatter of Interest in Co.

Financial news for BMY dated on 2017-02-13: Key Presenters At Leerink's Healthcare Conference

Financial news for BMY dated on 2017-02-05: How China Lifting Its One-Child Policy Played Into Reckitt Benckiser's \$90/Share Offer For Mead Johnson

Financial news for BMY dated on 2017-02-02: Bristol-Myers Reports Received FDA Approval for Opdivo in Previously Treated Locally Advanced or Metastatic Urothelial

Carcinoma, a Type of Bladder Cancer

Financial news for BMY dated on 2017-02-02: FDA Has Granted Accelerated Approval for Bristol-Myers' Nivolumab for Treatment of Locally Advanced, Metastatic Urothelial Carcinoma

Financial news for BMY dated on 2017-02-02: FDA Grants Accelerated Approval To Bristol-Myers Squibb's nivolumab For Treatment Of Urothelial Carcinoma

Financial news for BMY dated on 2017-02-01: UPDATE: Bristol-Myers Says EPO Upheld Decision Related to Patent '038

Financial news for BMY dated on 2017-02-01: Bristol-Myers Reports European Patent Office Decision on Sprycel

Financial news for BMY dated on 2017-01-30: Pre-Market Prep Host Dennis Dick Tweets: Notable opening imbalances: \$BABA -105K, \$C -115K, \$BAC -139K, \$MS -92K, \$BA -109K, \$GE -170K, \$PFE +111K, \$BMY +69K

Financial news for BMY dated on 2017-01-30: Martin Shkreli In Facebook Post Says 'I think I like \$BMY long - anyone following closely?'

Financial news for BMY dated on 2017-01-26: Bristol-Myers CFO Lowers FY17 Outlook Due To Foreign Exchange Rates, Potential For Earlier-Than-Expected Entry Of Merck's Keytruda/Chemo Combo In May

Financial news for BMY dated on 2017-01-26: Bristol-Myers Squibb Hits Lowest Level In 2 Years After Mixed Q4 Report

Financial news for BMY dated on 2017-01-26: In Lockstep: Dow 20,000 Significance Magnified By Record Highs For SPX

Financial news for BMY dated on 2017-01-26: Merck's Keytruda Gains Momentum At The Expense Of Bristol-Myers

Financial news for BMY dated on 2017-01-26: The Market In 5 Minutes: Earnings, Trump And Dow20k

Financial news for BMY dated on 2017-01-26: Bristol-Myers Affirms FY17 Adj. EPS Outlook \$2.70-\$2.90 vs \$2.86 Est.

Financial news for BMY dated on 2017-01-26: Bristol-Myers Reports Q4 Adj. EPS \$0.63 vs \$0.67 Est., Sales \$5.2B vs \$5.13B Est.

Financial news for BMY dated on 2017-01-26: 15 Stocks To Watch For January 26, 2017

Financial news for BMY dated on 2017-01-26: Earnings Scheduled For January 26, 2017

Financial news for BMY dated on 2017-01-25: Which Pharma Players Dominate The Lung Cancer Space?

Financial news for BMY dated on 2017-01-25: Trump Helps Send Markets To New Highs With Keystone Pipeline Order

Financial news for BMY dated on 2017-01-20: UPDATE: Merck's Payment To Bristol-Myers Will Be Recorded In Its Q4 And FY16 Results, Excluded From Non-GAAP Results

Financial news for BMY dated on 2017-01-20: Merck Announces Settlement With Bristol-Myers Resolving KEYTRUDA Patent Litigation, Will Pay \$625M And Provide Royalties On KEYTRUDA In Any Market In Which It's Approved

Financial news for BMY dated on 2017-01-20: Mid-Afternoon Market Update: Skyworks Surges After Strong Earnings Report; Affirmed Shares Drop

Financial news for BMY dated on 2017-01-20: 15 Biggest Mid-Day Losers For Friday

Financial news for BMY dated on 2017-01-20: Mid-Day Market Update: Crude Oil Up 2.8%; Bristol-Myers Squibb Shares Slide After Opdivo Decision

Financial news for BMY dated on 2017-01-20: Bristol-Myers Squibb Falls 10% After Opdivo Decision

Financial news for BMY dated on 2017-01-20: Mid-Morning Market Update: Markets Open Higher; General Electric Revenue Misses Views

Financial news for BMY dated on 2017-01-20: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for BMY dated on 2017-01-20: Bristol-Myers Squibb -4.7% Premarket @

\$52.86; Co Said Will Not Seek Faster Opdivo/Yervoy Lung Cancer Approval

Financial news for BMY dated on 2017-01-19: Bristol-Myers Offers Regulatory Update Related to First-line Lung Cancer: Says Decided Not to Pursue Accelerated Regulatory Pathway for Combo of Opdivo Plus Yervoy in First-Line Lung Cancer

Financial news for BMY dated on 2017-01-19: Bristol-Myers Squibb Reports Opdivo Demonstrated 37% Reduction Of Death Risk vs. Placebo, 12 Month Overall Survival Rates of 26.6% vs. 10.9% In Placebo Patients

Financial news for BMY dated on 2017-01-12: The Best BioPharma Plays Amid Uncertainty From Trump Comments

Financial news for BMY dated on 2017-01-11: Here's What Merck's Keytruda News Means For Bristol-Myers

Financial news for BMY dated on 2017-01-11: Technical Alert: Bristol Meyers Squibb Lower Following Good News For Merck's Keytruda

Financial news for BMY dated on 2017-01-10: Bristol-Myers Shares Down 2.2% After Hours as Merck Shares Trade Up ~2.5% Following News KEYTRUDA Accepted for Supplemental BLA

Financial news for BMY dated on 2017-01-10: JP Morgan Healthcare Conf. Continues Today; Presenters Include Cooper Companies, McKesson, Dexcom, CVS, Bristol-Myers, & NanoString

Financial news for BMY dated on 2017-01-06: Bristol-Myers Opdivo Study Halt Due To Having Reached Pre-Registration Limit As No Safety Issues/Adverse Events Reported

Financial news for BMY dated on 2017-01-06: Bristol-Myers Shares at Session Lows as Traders Passing Around Word of 3 Opdivo-Related Trial Suspensions; BZ NOTE: There was Similar Discussion on Thurs.

Financial news for BMY dated on 2017-01-06: Bristol Myers Announces Exploratory Biomarker Research Collaboration with GeneCentric

Financial news for BMY dated on 2017-01-06: Alphabet, Bristol-Myers And More: Fast Money Picks For January 6

Financial news for BMY dated on 2017-01-05: Seattle Genetics, Bristol-Myers Study of Opdivo and Adcetris Combo Halted Pending Protocol Amendment To Allow Additional Patients To Be Enrolled and Treated To Further Characterize Safety And Efficacy

Financial news for BMY dated on 2017-01-05: Hearing JANA Partners Takes New Stake in Bristol-Myers

Financial news for BMY dated on 2017-01-05: Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo in Combination with Darzalex

Financial news for BMY dated on 2017-01-04: Five Prime Therapeutics, Bristol-Myers Squibb Extend Research Term in Partner to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways

Financial news for BMY dated on 2017-01-04: Watch These 7 Huge Call Purchases In Wednesday Trade

Financial news for BMY dated on 2016-12-23: 6 Worst Biotech Stocks Of 2016

Financial news for BMY dated on 2016-12-22: Momenta Pharma Shares Sell Off Below \$15.20 Level as Hearing Co. Has Lost Patent Challenge Against Bristol-Myers Related to '239 Orencia Patent

Financial news for BMY dated on 2016-12-21: Mid-Afternoon Market Update: Crude Oil Down 1.5%; Merus Shares Spike Higher

Financial news for BMY dated on 2016-12-21: 12 Biggest Mid-Day Gainers For Wednesday

Financial news for BMY dated on 2016-12-21: Mid-Morning Market Update: Markets Edge Lower; Finish Line Misses Q3 Expectations

Financial news for BMY dated on 2016-12-21: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for BMY dated on 2016-12-21: Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Financial news for BMY dated on 2016-12-20: Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, Bristol to Make \$50M Upfront Payment

Financial news for BMY dated on 2016-12-19: Jefferies' 2017 Global Pharma Outlook

Financial news for BMY dated on 2016-12-19: Jefferies' Huge Pharma Pair Trade: Bristol-Myers Upgraded To Buy, Merck Downgraded To Sell

Financial news for BMY dated on 2016-12-19: Benzinga's Top Upgrades, Downgrades For December 19, 2016

Financial news for BMY dated on 2016-12-19: The Market In 5 Minutes: 'Rogue One', Bullish Commentary Pumps Disney Up

Financial news for BMY dated on 2016-12-19: Portola Pharmaceuticals Enters into \$50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa

Financial news for BMY dated on 2016-12-19: A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Yellen Speech

Financial news for BMY dated on 2016-12-19: Jefferies Upgrades Bristol-Myers Squibb to Buy, Raises Target to \$69.00

Financial news for BMY dated on 2016-12-19: Japan to Review Drug Prices Each Year vs Every Two Years Previously -Reuters

Financial news for BMY dated on 2016-12-13: Bristol-Myers Squibb Strengthens Capabilities with Evolution of its U.S. Geographic Footprint

Financial news for BMY dated on 2016-12-13: CytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration, Will Receive \$2M Milestone Payment

Financial news for BMY dated on 2016-12-08: Bristol-Myers Raises Qtr. Dividend from \$0.38 to \$0.39/Share

Financial news for BMY dated on 2016-12-08: Bristol-Myers Squibb To Pay \$19.5M In Multi-State Settlement Over Alleged Off-Label Promotion of Anti-Psychotic Drug

Financial news for BMY dated on 2016-12-07: Pfizer, J&J, Other Big Pharma Names Dip Lower Just After the Open

Financial news for BMY dated on 2016-12-07: Citi Global Healthcare Conf. Takes Place Today; Presenters Include Pfizer, Aerie Pharmaceuticals, Bristol-Myers, Alexion, Illumina, & Envision Healthcare

Financial news for BMY dated on 2016-12-06: Bristol Myers Announces Updated Opdivo Phase 1/2 Results; No New Safety Signals Observed

Financial news for BMY dated on 2016-12-05: Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell

Financial news for BMY dated on 2016-12-01: Forbes Healthcare Summit Concludes Today; Presenters Include Express Scripts, Allergan, IBM, Bristol-Myers Squibb, Merck, Anthem, Eli Lilly, And Regeneron

Financial news for BMY dated on 2016-11-25: Heat Biologics Shares Continue Higher (Up 22%) on Heavy Volume Fri. Following 27% Run-Up on Wed. as \$1.50 Resistance Level Breached; BZ NOTE: Co. Announced Last Thursday It will Be Reporting Phase Ib Results for HS-110 In Combo with Bristol's Opdivo Dec.

Financial news for BMY dated on 2016-11-25: Bristol-Myers Squibb, Cerner, General Motors, Monsanto: Fast Money Picks For November 25

Financial news for BMY dated on 2016-11-22: European Commission Approves Bristol-Myers Squibb's Opdivo for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin

Financial news for BMY dated on 2016-11-22: QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to Generate Real World Insights On Usage of Anti-Cancer Therapies Across Europe

Financial news for BMY dated on 2016-11-16: Stifel Healthcare Conference Continues Today

Financial news for BMY dated on 2016-11-16: Bristol-Myers Squibb, Enterome Announce

Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules

Financial news for BMY dated on 2016-11-11: UPDATE: Chardan On Bristol-Myers: 'the safety signal presented by HBV reactivation relative to competing HCV DAAs creates the potential for accelerated declines in Daklinza revenues versus consensus'

Financial news for BMY dated on 2016-11-11: UPDATE: Chardan Sees Safety Risks To Bristol-Myers Saying 'Safety risks from HBV reactivation has the potential to slow Daklinza revenues faster than consensus',

Financial news for BMY dated on 2016-11-11: Hearing Chardan Issuing Negative Comments of Bristol-Myers

Financial news for BMY dated on 2016-11-10: Bristol-Myers Reports Opdivo Received FDA Approval for Immuno-Oncology Treatment, Based on Overall Survival in Head and Neck Cancer

Financial news for BMY dated on 2016-11-10: Bristol-Myers Reports Opdivo Showed Overall Survival Benefit in Patients With Unresectable Advanced or Recurrent Gastric Cancer in Phase 3 Study

Financial news for BMY dated on 2016-11-09: Can Trump Make Your Portfolio Great Again?

Financial news for BMY dated on 2016-11-09: Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%

Financial news for BMY dated on 2016-11-09: Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo in Combination with IPI-549 in Advanced Solid Tumors

Financial news for BMY dated on 2016-11-07: Lexicon Pharmaceuticals Acquires Exclusive Rights To Development Candidate For Neuropathic Pain From Its Alliance With Bristol-Myers Squibb

Financial news for BMY dated on 2016-11-03: BZ NOTE Related to Traders Passing Around CNBC Story on New Cancer Drugs Possibly Damaging the Heart: NBC News via AP Published the Same Story ~7 p.m. EDT Wed. Evening

Financial news for BMY dated on 2016-11-03: Traders Passing Around Recent CNBC Article on Cancer Treatments: 'New cancer drugs may damage the heart'

Financial news for BMY dated on 2016-11-01: The Election Can't Come Soon Enough For Biotechs

Financial news for BMY dated on 2016-10-31: Bristol-Myers Squibb Gets Approval From Health Canada For Opdivo & Yervoy Regimen For Unresectable Or Metastatic Melanoma

Financial news for BMY dated on 2016-10-28: Hilliard Lyons Upgrades Bristol-Myers Squibb Company Common Stock to Long-Term Buy

Financial news for BMY dated on 2016-10-27: Technical Alert: Bristol-Myers Squibb Higher After Q3 Beat

Financial news for BMY dated on 2016-10-27: 20 Biggest Mid-Day Gainers For Thursday

Financial news for BMY dated on 2016-10-27: Bristol-Myers Says Expects Opdivo to Face Pressure from New Roche Treatment for Second-line Lung Cancer -Reuters

Financial news for BMY dated on 2016-10-27: It's Big Tech Day, With Amazon, Alphabet, Twitter Stepping To The Plate

Financial news for BMY dated on 2016-10-27: The Market In 5 Minutes: Twitter, Tesla Earnings And Jobless Claims Fall

Financial news for BMY dated on 2016-10-27: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for BMY dated on 2016-10-27: A Peek Into The Markets: U.S. Stock Futures Up; Twitter Shares Gain Following Earnings Beat

Financial news for BMY dated on 2016-10-27: Investors Cheer Bristol-Myers' Q3 Results, Outlook

Financial news for BMY dated on 2016-10-27: Bristol-Myers Increases FY16 Guidance From EPS \$2.55-\$2.65 To \$2.80-\$2.90; FY17 \$2.85-\$3.05 vs. Est. \$2.91

Financial news for BMY dated on 2016-10-27: Bristol-Myers Squibb Reports Q3 EPS \$0.77 vs. Est. \$0.65, Rev. \$4.922B vs. Est. \$4.79B

Financial news for BMY dated on 2016-10-27: 15 Must Watch Stocks for October 27, 2016

Financial news for BMY dated on 2016-10-27: Earnings Scheduled For October 27, 2016

Financial news for BMY dated on 2016-10-25: 6 Big Pharma Companies Left To Report September Quarterly Figures

Financial news for BMY dated on 2016-10-25: Citi Launches Positive Coverage On Five Prime Therapeutics

Financial news for BMY dated on 2016-10-25: Bristol-Myers Squibb Reports Data In Expanded Population Of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients

Financial news for BMY dated on 2016-10-21: Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments

Financial news for BMY dated on 2016-10-19: Roche Group, Competitor To Bristol-Myers And Merck, Has PDUFA Date For Tecentriq Drug

Financial news for BMY dated on 2016-10-14: European Medicine Agency's CHMP Committee Released Its Monthly Drug Opinions Earlier Today; Called For Extensions Of Indications For Lucentis, Opdivo, And Trisenox

Financial news for BMY dated on 2016-10-14: Bristol-Myers Reports Received Positive CHMP Opinion for Opdivo for Treatment of Adults with Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin

Financial news for BMY dated on 2016-10-10: These Were The Most And Least Popular Stocks In September

Financial news for BMY dated on 2016-10-10: Investor Movement Index for September 2016

Financial news for BMY dated on 2016-10-10: The ESMO Conference Proves Its Ability To Move Stocks

Financial news for BMY dated on 2016-10-10: Technical Alert: Bristol-Myers Squibb Under \$50 For The First Time Since October 2014

Financial news for BMY dated on 2016-10-10: 8 Biggest Mid-Day Losers For Monday

Financial news for BMY dated on 2016-10-10: This Wasn't A Great ESMO For Bristol-Myers Squibb, But 2017 Could Be A Much Better Year

Financial news for BMY dated on 2016-10-10: Stocks Hitting 52-Week Lows

Financial news for BMY dated on 2016-10-10: Bristol-Myers' Opdivo Vs. Merck's Keytruda In Front-Line Lung Treatment

Financial news for BMY dated on 2016-10-10: SunTrust Cuts Target On Bristol-Myers As Opdivo Estimates Revised Lower

Financial news for BMY dated on 2016-10-10: Mid-Morning Market Update: Markets Open Higher; Dover Lowers Full-Year Forecast

Financial news for BMY dated on 2016-10-10: 16 Stocks Moving In Monday's Pre-Market Session

Financial news for BMY dated on 2016-10-09: Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer at ESMO 2016

Financial news for BMY dated on 2016-10-09: Bristol-Myers Squibb to Present Opdivo Stabilized Patient-reported Outcomes in Patients With Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in Pivotal Phase 3 CheckMate -141 Study at ESMO 2016

Financial news for BMY dated on 2016-10-09: Bristol-Myers Squibb Announces Yervoy Improves Overall Survival in Fully Resected Stage III Melanoma Patients From Phase 3 Study

Financial news for BMY dated on 2016-10-08: Jim Cramer Shares His Thoughts On Bristol-Myers Squibb Co And Sirius XM Holdings Inc.

Financial news for BMY dated on 2016-09-30: Brean Likes Nektar Therapeutics' Upcoming Launches; Assumes Coverage At Buy

Financial news for BMY dated on 2016-09-29: Technical Alert: Bristol-Myers Squibb Makes New Low For The Move

Financial news for BMY dated on 2016-09-28: Fast Money Halftime Report Final Trades For September 28

Financial news for BMY dated on 2016-09-27: The Drug Price Increase Debate: Separating The Winners From The Losers

Financial news for BMY dated on 2016-09-27: Bristol-Myers, Nektar Therapeutics Report Oncology Clinical Collaboration to Evaluate Combo of Opdivo, NKTR-214

Financial news for BMY dated on 2016-09-22: The Market In 5 Minutes: No Interest Rate Hike...Yet

Financial news for BMY dated on 2016-09-22: Can You Guess This Chart?

Financial news for BMY dated on 2016-09-20: 7 Biggest Price Target Changes For Tuesday

Financial news for BMY dated on 2016-09-20: Citi Research Reevaluates Bristol-Myers, Lowers Price Target

Financial news for BMY dated on 2016-09-20: Bristol Myers Announces European Medicines Agency Validated Type II Variation Application

Financial news for BMY dated on 2016-09-15: Seattle Genetics No Longer On Goldman Sachs' Sell List

Financial news for BMY dated on 2016-09-14: Technical Alert: Bristol-Myers SQUIBB Finds Support At The \$55 Area Again

Financial news for BMY dated on 2016-09-12: 2100: Goldman Sachs Is A Short-Term Bear, But A Long-Term Bull

Financial news for BMY dated on 2016-09-09: Barclays Raises Target On Merck, Lowers Target On Bristol-Myers

Financial news for BMY dated on 2016-09-06: Retail Investors Loved Beat Up Stocks In August

Financial news for BMY dated on 2016-09-06: Investor Movement Index (IMX) for August 2016

Financial news for BMY dated on 2016-09-06: European Commission Approves Bristol-Myers Squibb's ORENCIA for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate

Financial news for BMY dated on 2016-09-02: Technical Alert: Bristol-Myers Continues Lower

Financial news for BMY dated on 2016-08-17: Technical Alert: Bristol-Myers Squibb Makes New For Move

Financial news for BMY dated on 2016-08-17: Brean Downgrades The Healthcare Sector On Technical Indicators

Financial news for BMY dated on 2016-08-17: Bristol-Myers Squibb Sells Off to Low of \$58.82 After Open on Volume

Financial news for BMY dated on 2016-08-16: Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain

Financial news for BMY dated on 2016-08-11: 7 Biggest Price Target Changes For Thursday

Financial news for BMY dated on 2016-08-11: Benzinga's Top Downgrades

Financial news for BMY dated on 2016-08-11: The Market In 5 Minutes: Valeant's Fraud, Macy's Beat, And Arianna's Departure

Financial news for BMY dated on 2016-08-11: Berenberg Downgrades Bristol-Myers Squibb, Says Competitors Better Exposed For Near-Term Upside

Financial news for BMY dated on 2016-08-11: A Peek Into The Markets: U.S. Stock

Futures Rise Ahead Of Jobless Claims Report

Financial news for BMY dated on 2016-08-11: Berenberg Downgrades Bristol-Myers Squibb to Hold, Lowers PT to \$70.00

Financial news for BMY dated on 2016-08-10: Argus: Bristol-Myers Selloff Is Overdone, Reiterating \$90 Target

Financial news for BMY dated on 2016-08-09: Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict

Financial news for BMY dated on 2016-08-09: Bristol-Myers Hit With A Trio Of Analyst Price Target Cuts

Financial news for BMY dated on 2016-08-08: Deutsche Analysts React To Bristol-Myers Clinical Trial Disappointment

Financial news for BMY dated on 2016-08-08: Technical Alert - Bristol Meyers Squibb Continues To Tumble

Financial news for BMY dated on 2016-08-08: After Roaring To New Highs on Jobs Data, Market Faces Retail Sales, Job Openings

Financial news for BMY dated on 2016-08-08: CheckMate Miss Is A Game Changer; Credit Suisse Downgrades Bristol, Upgrades Merck

Financial news for BMY dated on 2016-08-08: 8 Biggest Price Target Changes For Monday

Financial news for BMY dated on 2016-08-08: Benzinga's Top Downgrades

Financial news for BMY dated on 2016-08-08: Citi Doesn't See Merck's Lung Cancer Success Lasting Long

Financial news for BMY dated on 2016-08-08: Credit Suisse Downgrades Bristol-Myers Squibb to Neutral, Lowers PT to \$63.00

Financial news for BMY dated on 2016-08-08: Watch These 7 Huge Call Purchases In Monday Trade

Financial news for BMY dated on 2016-08-06: Friday Market Wrap: Stock Market Jumps On Employment Numbers

Financial news for BMY dated on 2016-08-05: Deutsche Downgrades Ligand As Risk/Reward Becomes Challenging

Financial news for BMY dated on 2016-08-05: Moody's Says Bristol's Lung Cancer Trial Result is Major Setback

Financial news for BMY dated on 2016-08-05: Technical Alert - Bristol Meyers Squibb Revisits March 24 Low After Opdivo Trial Misses Endpoint

Financial news for BMY dated on 2016-08-05: 18 Biggest Mid-Day Losers For Friday

Financial news for BMY dated on 2016-08-05: 25 Biggest Mid-Day Gainers For Friday

Financial news for BMY dated on 2016-08-05: Benzinga's Volume Movers

Financial news for BMY dated on 2016-08-05: Option Alert: BMY Jan 2018 70.0 Calls: 4094 @ Above Ask! \$4.65: 5290 traded vs 678 OI: \$62.48 Ref

Financial news for BMY dated on 2016-08-05: Stocks Hitting 52-Week Highs

Financial news for BMY dated on 2016-08-05: Bristol's Opdivo Misses Endpoint In Late-Stage Trial; Merck Rallies Sharply Amid Keytruda Potential

Financial news for BMY dated on 2016-08-05: The Market In 5 Minutes: Blowout Jobs Report Pushes Markets Higher

Financial news for BMY dated on 2016-08-05: Bristol-Myers Shares Down ~\$13 Upon Resumption

Financial news for BMY dated on 2016-08-05: Bristol-Myers Squibb Sells off to Low of \$58.10 Following Resumption

Financial news for BMY dated on 2016-08-05: UPDATE: Merck's KEYTRUDA is Viewed as Strongest Competitor to Bristol's Opdivo

Financial news for BMY dated on 2016-08-05: Merck Spike in Price Likely Attributed to Negative Results on Bristol-Myers' Opdivo

Financial news for BMY dated on 2016-08-05: Bristol-Myers Squibb Reports Results from CheckMate -026 Study, Opdivo Did Not Meet Primary Endpoint

Financial news for BMY dated on 2016-08-05: Gilead Shares Indicated Higher, Up ~0.4%; BZ NOTE: Co. Was Discussed as a Possible Takeover Candidate for Bristol-Myers, as Recently as Aug. 1

Financial news for BMY dated on 2016-08-05: Bristol-Myers Squibb Co. Halted; Pending News

Financial news for BMY dated on 2016-08-02: Biogen, JC Penney And More: Fast Money Picks For August 2

Financial news for BMY dated on 2016-08-01: Merck's Q2 Good, But Not Good Enough, Says BMO

Financial news for BMY dated on 2016-08-01: Option Alert: BMY Aug16 77.5 Calls Sweep: 503 @ ASK \$0.84: 5612 traded vs 6710 OI: \$75.91 Ref

Financial news for BMY dated on 2016-08-01: Option Alert: BMY Aug16 77.5 Calls Sweep: 3535 @ ASK \$0.73: 5074 traded vs 6710 OI: \$75.60 Ref

Financial news for BMY dated on 2016-08-01: UPDATE: Free Cash-Flow For Bristol-Myers Squibb Has Been Negative For 2 Straight Quarters

Financial news for BMY dated on 2016-08-01: Gilead Spikes to High; Hearing Unconfirmed Market Chatter Co Talking With BMY Regarding Merger

Financial news for BMY dated on 2016-07-28: Technical Alert: Finding Support In Bristol-Myers After Q2 Report

Financial news for BMY dated on 2016-07-28: UPDATE: Bristol-Myers Raises FY16 Adj. EPS \$2.55-\$2.65

Financial news for BMY dated on 2016-07-28: Bristol-Myers Reports Q2 Adj. EPS \$0.69, Sales \$4.9B; Raises FY16 Outlook

Financial news for BMY dated on 2016-07-28: 15 Stocks To Watch For July 28, 2016

Financial news for BMY dated on 2016-07-28: Earnings Scheduled For July 28, 2016

Financial news for BMY dated on 2016-07-27: Can Keytruda Deliver Earnings Growth For Merck?

Financial news for BMY dated on 2016-07-27: Watch These 10 Huge Call Purchases In Wednesday Trade

Financial news for BMY dated on 2016-07-26: Option Alert: BMY Fri 9/2 77.5 Calls (Wkly) Sweep: 500 @ ASK \$0.94: 500 traded vs 1 OI: Earnings 7/28 Before Open \$75.06 Ref

Financial news for BMY dated on 2016-07-26: Bristol-Myers Squibb Announces New Research Collaboration with Janssen in Immuno-Oncology Focused on Lung Cancer

Financial news for BMY dated on 2016-07-25: AbbVie And Bristol-Myers Squibb Strike Oncology Clinical Alliance To Assess Rova-T plus Opdivo And Opdivo + Yervoy Regimen

Financial news for BMY dated on 2016-07-25: Bristol-Myers Squibb Gets CHMP's Positive Opinion For ORENCIA

Financial news for BMY dated on 2016-07-25: AbbVie, Bristol-Myers Report Clinical Trial Collaboration to Evaluate Safety, Tolerability, Efficacy of AbbVie's Rova-T In Combo with Bristol's Opdivo

Financial news for BMY dated on 2016-07-25: Bristol-Myers Reports CHMP Opinion for ORENCIA for Treatment of Highly Active, Progressive Disease in Adult Patients with RA

Financial news for BMY dated on 2016-07-24: Barron's Picks And Pans: Pharmacy-Benefit Managers, Mortgage Insurers And More

Financial news for BMY dated on 2016-07-20: Bristol-Myers Squibb Says FDA-Approved ORENCIA Is Available For Adults With Moderate To Severe Rheumatoid Arthritis

Financial news for BMY dated on 2016-07-20: Jim Cramer Shares His Thoughts On Bristol-Myers Squibb And The RNC

Financial news for BMY dated on 2016-07-20: Bristol-Myers Reports Availability of FDA-Approved ORENCIA ClickJect

Financial news for BMY dated on 2016-07-18: BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations

Financial news for BMY dated on 2016-07-18: Bristol-Myers Squibb Reveals Regulatory Approvals For Opdivo Marketing Application

Financial news for BMY dated on 2016-07-18: Bristol-Myers Squibb Announces Regulatory Updates for Opdivo in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, FDA And EMA Accept Marketing Applications In This Patient Population

Financial news for BMY dated on 2016-07-11: U.S. Companies On Hiring Sprees Across The Country

Financial news for BMY dated on 2016-07-05: A Peek Into The Markets: U.S. Stock Futures Drop Ahead Of Factory-Orders Report

Financial news for BMY dated on 2016-07-05: Bristol-Myers Squibb Buys Privately Held Cormorant Pharmaceuticals

Financial news for BMY dated on 2016-07-05: Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals For \$95M, With Additional Consideration Of Up To \$425M Upon Development & Regulatory Milestones

Financial news for BMY dated on 2016-06-30: Bristol-Myers Squibb, PsiOxus Therapeutics Announce Immuno-Oncology Clinical Partnership to Evaluate the Combination of Opdivo and Enadenotucirev; Bristol-Myers To Make One-Time Payment Of \$10M To PsiOxus

Financial news for BMY dated on 2016-06-27: Bristol-Myers Squibb's Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer

Financial news for BMY dated on 2016-06-20: Bristol-Myers Announces Murdo Gordon Appointed Executive Vice President and Chief Commercial Officer

Financial news for BMY dated on 2016-06-14: 5 Pharmaceutical Price Target Raises From Jefferies

Financial news for BMY dated on 2016-06-13: SunTrust Highlights Upcoming Pharma Calendar, Favorite Names

Financial news for BMY dated on 2016-06-13: Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators

Financial news for BMY dated on 2016-06-10: Bristol-Myers Squibb Announces New Data on Opdivo Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial at EHA

Financial news for BMY dated on 2016-06-09: Bristol-Myers Squibb to Present New Data Demonstrating Continued Research Expansion and Immuno-Oncology Advancements Across Multiple Blood Cancers

Financial news for BMY dated on 2016-06-08: Bristol-Myers Squibb Reveals Fresh Rheumatoid Arthritis Research And Real-World Data At European Congress Of Rheumatology

Financial news for BMY dated on 2016-06-08: Option Alert: BMY Jun16 73.5 Puts Sweep: 2137 @ ASK \$0.89: 2157 traded vs 155 OI: Earnings 7/28 \$73.78 Ref

Financial news for BMY dated on 2016-06-08: Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology, Held June 8-11 In London

Financial news for BMY dated on 2016-06-07: Bristol-Myers And MD Anderson Cancer Center Makes Fresh Research Alliance In Immuno-Oncology Focused On Lung-Cancer

Financial news for BMY dated on 2016-06-07: Bristol-Myers, MD Anderson Report New Research Collab in Immuno-Oncology Focused on Lung Cancer

Financial news for BMY dated on 2016-06-06: 4 Key Takeaways From ASCO

Financial news for BMY dated on 2016-06-06: Mid-Afternoon Market Update: Helios and Matheson Analytics Jumps Amid News Of Merger With Zone Technologies; ProNAi Therapeutics Shares Drop

Financial news for BMY dated on 2016-06-06: Vascular Biogenics Surges 80% Off Double Catalyst

Financial news for BMY dated on 2016-06-06: Unconfirmed Chatter That Vascular Biogenics May Be Takeover Candidate For Bristol Myers Squibb

Financial news for BMY dated on 2016-06-04: Bristol-Myers Squibb Announces Opdivo, Yervoy Combination Regimen Shows Clinically Meaningful Responses in First-Line Advanced NSCLC, In Updated Phase 1b Study CheckMate -012; Data to be Presented at #ASCO16

Financial news for BMY dated on 2016-06-03: Ouch! Jobs Report Miss Sends Rate Hike Odds Down, Raises Questions

Financial news for BMY dated on 2016-05-26: Seeing Late Day Options Activity In BMY Jun \$65 Calls, 23,973 contracts trade

Financial news for BMY dated on 2016-05-24: Bristol-Myers Squibb Reports Health Canada Approval of Daklinza in Combo with Sofosbuvir

Financial news for BMY dated on 2016-05-23: Option Alert: BMY Fri 5/27 70.0 Calls (Wkly) Sweep: 4519 @ Above Ask! \$0.62: 4623 traded vs 54 OI: \$69.78 Ref

Financial news for BMY dated on 2016-05-23: Chardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy Competitiveness

Financial news for BMY dated on 2016-05-19: Inovalon And Bristol-Myers Squibb Strike Deal To Focus On Real World Outcomes & Value-Based Contracting Initiatives

Financial news for BMY dated on 2016-05-19: JPMorgan's Take On Big Pharma's New ASCO Abstracts

Financial news for BMY dated on 2016-05-18: Bristol-Myers Squibb Announces Opdivo Granted First Approval of PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA1

Financial news for BMY dated on 2016-05-17: Fitch Says Drug Approvals Are Driving Targeted Acquisitions In U.S. Pharma

Financial news for BMY dated on 2016-05-16: Option Alert: SWEEP (SELL) - BMY June \$75 Call - 23999 @ 0.99 in 3 orders. 26122 traded. OI: 6008

Financial news for BMY dated on 2016-05-13: Mid-Day Market Update: NVIDIA Gains On Earnings Beat; ConforMIS Shares Drop

Financial news for BMY dated on 2016-05-13: Mid-Morning Market Update: Markets Mixed; J C Penney Sales Miss Estimates

Financial news for BMY dated on 2016-05-12: HTG Molecular Diagnostics Reports Immuno-Oncology Research Collaboration Deal with Bristol-Myers

Financial news for BMY dated on 2016-05-11: Bristol-Myers, AbbVie Report EC Approval of Empliciti for Treatment of Multiple Myeloma in Adults

Financial news for BMY dated on 2016-05-11: Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead

Financial news for BMY dated on 2016-05-11: The Market In 5 Minutes: Don't Stop Me Now

Financial news for BMY dated on 2016-05-03: TheStreet's Adam Feuerstein Tweets '\$MRK \$BMY are not working with \$NWBO on cancer immunotherapy combination clinical trials, per their respective spokespersons.'

Financial news for BMY dated on 2016-04-28: Bristol-Myers Squibb Target, Estimates Under Review At Goldman Sachs

Financial news for BMY dated on 2016-04-28: UPDATE: Bristol-Myers Raises Adj. EPS \$2.50-\$2.60 vs \$2.40 Est.

Financial news for BMY dated on 2016-04-28: Bristol-Myers Raises FY16 Outlook

Financial news for BMY dated on 2016-04-28: Bristol-Myers Reports Q1 Adj. EPS \$0.74 vs \$0.65, Sales \$4.39B vs \$4.25B Est.

Financial news for BMY dated on 2016-04-28: Earnings Scheduled For April 28, 2016

Financial news for BMY dated on 2016-04-27: Check-up on Energy: XOM and CVX Earnings Preview

Financial news for BMY dated on 2016-04-25: Bristol-Myers Squibb Canada Says Health Canada Approves Opdivo

Financial news for BMY dated on 2016-04-25: The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers

Financial news for BMY dated on 2016-04-25: The Market In 5 Minutes: Monday, April 25, 2016

Financial news for BMY dated on 2016-04-25: Bristol Myers Receives Breakthrough Therapy Designation for Opdivo

Financial news for BMY dated on 2016-04-20: Bristol-Myers Squibb Chooses Medidata Clinical Cloud to Drive Drug Development and Business Transformation

Financial news for BMY dated on 2016-04-20: Eiger BioPharmaceuticals Reports It Has Licensed Pegylated Interferon Lambda-1a Worldwide Rights From Bristol-Myers Squibb For HDV Franchise

Financial news for BMY dated on 2016-04-17: Bristol-Myers Squibb Announces First Presentation of Two-Year Overall Survival Data for Opdivo in Combination with Yervoy Showed Superior Efficacy vs Yervoy Alone in Advanced Melanoma

Financial news for BMY dated on 2016-04-14: Bristol-Myers Announces FDA Accepts Priority Review for sBLA for Opdivo for Treatment of Classical Hodgkin Lymphoma Patients

Financial news for BMY dated on 2016-04-12: Benzinga's M&A Chatter for Tuesday April 12, 2016

Financial news for BMY dated on 2016-04-12: Option Alert: BMY Jun16 70.0 Calls Sweep: 500 @ ASK \$1.38: 562 traded vs 20k OI: Earnings 4/28 Before Open \$67.06 Ref

Financial news for BMY dated on 2016-04-12: Celgene Shares Move to High of \$105.10; Unconfirmed Market Chatter of Potential Merger with Bristol Myers Squibb

Financial news for BMY dated on 2016-04-06: SocGen Picks New Favorites In Big Pharma

Financial news for BMY dated on 2016-04-06: Societe Generale Initiates Coverage on Bristol-Myers Squibb at Sell

Financial news for BMY dated on 2016-04-06: European Commission Approves Expanded Use of Opdivo to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Financial news for BMY dated on 2016-04-01: Bristol-Myers Squibb Reports Received Positive CHMP Opinion for Opdivo in Combo with Yervoy for Advanced Melanoma

Financial news for BMY dated on 2016-03-30: EMA Validates Bristol-Myers Squibb's Application for Opdivo for the Treatment of Classical Hodgkin Lymphoma Patients

Financial news for BMY dated on 2016-03-29: Citi Downgrades Novartis Following SAG Investigation

Financial news for BMY dated on 2016-03-23: The Market In 5 Minutes: Can I Kick It?

Financial news for BMY dated on 2016-03-23: Bristol-Myers Squibb Reports Will Buy Padlock Therapeutics, \$225M in Milestone Payments, Added \$375M in Contingent Consideration

Financial news for BMY dated on 2016-03-17: Organovo Is A Company 3D Printing Human Tissue And Its CEO Is Excited About Creating Livers

Financial news for BMY dated on 2016-03-16: Bristol-Myers Squibb to Present New Overall Survival Data for Opdivo as Monotherapy and in Combination with Yervoy at the AACR 2016 Annual Meeting

Financial news for BMY dated on 2016-03-16: Allied-Bristol Life Sciences Launches ibeCa Therapeutics to Develop Novel Cancer Therapeutics Targeting the Wnt Signalling Pathway

Financial news for BMY dated on 2016-03-11: Morgan Stanley Calls AMGN, BMY, BIIB, MCK, STJ It's Favorite Health Care Names

Financial news for BMY dated on 2016-03-08: Jimmy Carter Boosts Social Media Buzz For Merck's Blockbuster Drug

Financial news for BMY dated on 2016-03-08: Bristol-Myers Squibb Spokesperson Says Company has Voluntarily Stopped Certain Initiatives in China; Says Continues to

Review Activities, Build Upon Business Model In China -Reuters

Financial news for BMY dated on 2016-03-03: Bristol-Myers Squibb Names Peter J. Arduini to Board of Directors

Financial news for BMY dated on 2016-03-01: Stocks To Watch During Cowen's 36th Annual Healthcare Conference

Financial news for BMY dated on 2016-02-29: 3 Mega Biotechs Leerink Loves

Financial news for BMY dated on 2016-02-29: Bristol Myers Squibb Selects Veeva Vault Registrations And Submissions Archive To Manage Registration Tracking

Financial news for BMY dated on 2016-02-26: Bristol-Myers Squibb Receives Two Positive CHMP Opinions for Opdivo for Patients with Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer and Renal Cell Carcinoma

Financial news for BMY dated on 2016-02-22: Data Presented at APASL from First Completed Phase 3 Trial of All-oral Chronic Hepatitis C Regimen in Chinese Patient Population Shows Daclatasvir and Asunaprevir DUAL Therapy Demonstrated High Cure Rates Among HCV Genotype 1b Patients

Financial news for BMY dated on 2016-02-17: Bristol-Myers Looks To A Promising Future

Financial news for BMY dated on 2016-02-16: Morgan Stanley Adam Parker Overweight On Healthcare, First Time Since 2014, Adds BMY & AMGN To Portfolio

Financial news for BMY dated on 2016-02-14: Barron's: Are Trump And Sanders Killing The Market?

Financial news for BMY dated on 2016-02-14: Barron's Picks And Pans: Bristol-Myers Squibb, KeyCorp, Core-Mark And More

Financial news for BMY dated on 2016-02-13: Schroer: Biotech Will Turn Around

Financial news for BMY dated on 2016-02-08: Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place

Financial news for BMY dated on 2016-02-04: BristolMyersSquibb Declines Comment on Rumored Takeover Talks With Celgene

Financial news for BMY dated on 2016-02-04: Hearing Unconfirmed Market Chatter of Potential Bristol Myers Bid for Celgene

Financial news for BMY dated on 2016-02-03: Is Big Pharma Hinting At A SMID-Cap Biotech Rally?

Financial news for BMY dated on 2016-02-02: Hearing Intercept Pharma hires JPM to Handle Interest from Pfizer, Gilead, BristolMyers -Daily Mail

Financial news for BMY dated on 2016-02-01: UPDATE: Portola Pharma Licensing Deals for Andexanet Alfa in Japan Valued at Up to \$120M

Financial news for BMY dated on 2016-02-01: Bristol-Myers and Pfizer Announce Collaboration with Portolao Pharma

Financial news for BMY dated on 2016-01-29: Hearing EMA Issues Jan. Recommendations: Approval of Bristol's Elotuzumab Under Accelerated Assessment

Financial news for BMY dated on 2016-01-28: Earnings Recap For January 28

Financial news for BMY dated on 2016-01-28: European Commission Approves Daklinza for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV

Financial news for BMY dated on 2016-01-28: Vetr Top Raters Upgrade Bristol-Myers Squibb, Over 80% Bullish

Financial news for BMY dated on 2016-01-28: Bristol Myers Ticks Higher Following Q4 Beat, Encouraging Guidance

Financial news for BMY dated on 2016-01-28: Bristol Myers Sees FY EPS \$2.30 to \$2.40 vs \$2.30 est

Financial news for BMY dated on 2016-01-28: Bristol-Myers Squibb Phase 3 Opdivo Head & Neck Trial Stopped Early

Financial news for BMY dated on 2016-01-28: Bristol Myers Q4 EPS \$0.38 vs \$0.28 est, Revenue \$4.3B vs \$4.15B est

Financial news for BMY dated on 2016-01-28: 12 Stocks To Watch For January 28, 2016

Financial news for BMY dated on 2016-01-28: Earnings Scheduled For January 28, 2016

Financial news for BMY dated on 2016-01-25: JNJ Kicks Off Health Care Earnings--What About Deals, Buybacks?

Financial news for BMY dated on 2016-01-25: US Big Pharma: What To Watch For In Q4 Results

Financial news for BMY dated on 2016-01-25: Stock Marquee Crowded With Oil, Apple, And The Fed

Financial news for BMY dated on 2016-01-25: Benzinga's Top Downgrades

Financial news for BMY dated on 2016-01-25: BMO Downgrades Whole Foods And Bristol-Myers Squibb To Start Week: Why?

Financial news for BMY dated on 2016-01-25: BMO Capital Downgrades Bristol-Myers Squibb to Market Perform

Financial news for BMY dated on 2016-01-24: Bristol-Myers Squibb's Opdivo + Yervoy Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1

Financial news for BMY dated on 2016-01-22: Berenberg Upgrades Bristol-Myers Squibb To Buy, Sees \$77 Price Target

Financial news for BMY dated on 2016-01-22: Benzinga's Top Upgrades

Financial news for BMY dated on 2016-01-22: Berenberg Upgrades Bristol-Myers Squibb to Buy

Financial news for BMY dated on 2016-01-12: Fast Money Traders Share Their Biotech Picks

Financial news for BMY dated on 2016-01-04: Fast Money Final Trades Of 2015

Financial news for BMY dated on 2015-12-24: Option Alert: BMY Jun16 75.0 Calls Sweep: 2217 @ ASK \$2.16: 2228 traded vs 1015 OI: Earnings 1/28 Before Open \$68.58 Ref

Financial news for BMY dated on 2015-12-23: Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS in Combination with Opdivo in Relapsed or Refractory Non-Hodgkin Lymphoma

Financial news for BMY dated on 2015-12-19: Credit Suisse Offers 2016 U.S. Large-Cap Pharma Outlook

Financial news for BMY dated on 2015-12-18: 3 Biotechs Atlantic Equities Loves And 1 It's Avoiding

Financial news for BMY dated on 2015-12-18: Atlantic Equities Initiates Coverage on Bristol-Myers Squibb at Underweight, Announces \$57.00 T

Financial news for BMY dated on 2015-12-18: Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare for \$350M Upfront Plus Milestone Payments

Financial news for BMY dated on 2015-12-17: Shares of Eli Lilly Up ~0.6% After Credit Suisse Adds to 'Focus List'; Shares of Bristol-Myers Down ~0.7% as Stock Removed from Same List

Financial news for BMY dated on 2015-12-17: Bristol Myers Squibb Dropped From Credit Suisse Focus List, Outperform Rating Maintained & PT \$81

Financial news for BMY dated on 2015-12-15: Fast Money Picks For December 15

Financial news for BMY dated on 2015-12-14: Bristol-Myers Reports Collaboration Deal with UCLA for Immuno-Oncology Rare Population Malignancy Research Program

Financial news for BMY dated on 2015-12-12: Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds

Financial news for BMY dated on 2015-12-10: 9 Healthcare Picks For 2016

Financial news for BMY dated on 2015-12-08: Bristol-Myers Squibb, Princeton University Establish Center For Molecular Synthesis; Financial Terms Not Disclosed

Financial news for BMY dated on 2015-12-08: Bristol-Myers Squibb Increases Qtr.

Dividend From \$0.37 To \$0.38/Share

Financial news for BMY dated on 2015-12-05: Bristol-Myers Squibb Company New Longer-Term Data for Efficacy Showed Continued Progression-Free Survival Benefit in Patients with Relapsed or Refractory Multiple Myeloma #ASH2015

Financial news for BMY dated on 2015-12-04: Bristol-Myers Reports Receive Multiple Myeloma Research Foundation's '15 Collaborator Award

Financial news for BMY dated on 2015-12-01: Barclays' Biopharmaceuticals Blueprint For 2016

Financial news for BMY dated on 2015-11-30: Bristol-Myers, AbbVie Release Confirms Earlier FDA Approval of Efficacy

Financial news for BMY dated on 2015-11-30: FDA Reports Approval of Bristol-Myers' Efficacy to Treat Multiple Myeloma

Financial news for BMY dated on 2015-11-24: European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo European Marketing Authorization Application

Financial news for BMY dated on 2015-11-24: Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma

Financial news for BMY dated on 2015-11-23: FDA Approves Opdivo to Treat Advanced Form of Kidney Cancer -Reuters

Financial news for BMY dated on 2015-11-20: Bristol Myers Squibb Spikes To \$69

Financial news for BMY dated on 2015-11-17: Bristol-Myers Squibb Spokesperson Declines Comment on Earlier Chatter of Gilead Interest in Co.

Financial news for BMY dated on 2015-11-17: Hearing Unconfirmed Market Chatter of Gilead Deal to Acquire BMY

Financial news for BMY dated on 2015-11-17: Shares of Bristol-Myers Break Above \$65.50 Level Over Last Min, Now Up to \$66

Financial news for BMY dated on 2015-11-09: Pamela Anderson And Hepatitis C: Which Drug Makers Are Working On A Cure?

Financial news for BMY dated on 2015-11-02: Bristol-Myers Squibb Acquires Cardioxyl Pharma. For \$300M Near-Term Payments, With Potential Consideration Of \$1.775B

Financial news for BMY dated on 2015-10-28: UPDATE: FDA Broadens Use of Bristol-Myer's Yervoy to Lower Risk That Melanoma Will Return Following Surgery

Financial news for BMY dated on 2015-10-28: FDA Approves Yervoy for Adjuvant Therapy in Stage III Melanoma -Adam F

Financial news for BMY dated on 2015-10-28: @adamfeuerstein tweets: \$BMY - FDA approves Yervoy for adjuvant therapy in stage III melanoma.

Financial news for BMY dated on 2015-10-27: 13 Stocks To Watch In The Healthcare Space

Financial news for BMY dated on 2015-10-27: These Three Pharma Giants Just Crushed Earnings

Financial news for BMY dated on 2015-10-27: Bristol-Myers Sees FY15 Adj. EPS \$1.85-\$1.90 vs \$1.84 Est.

Financial news for BMY dated on 2015-10-27: Bristol-Myers Reports Q3 Adj. EPS \$0.39 vs \$0.35 Est., Sales \$4.1B vs \$3.86B Est.

Financial news for BMY dated on 2015-10-27: Earnings Scheduled For October 27, 2015

Financial news for BMY dated on 2015-10-26: Earnings Boom This Week: Big Pharma, E-Commerce Giant BABA And More

Financial news for BMY dated on 2015-10-26: Fed Meeting A Mid-Week Bump In Flurry Of Earnings News

Financial news for BMY dated on 2015-10-21: Bristol-Myers Squibb to Present Data from Multiple Studies of Difficult-to-Treat Chronic Hepatitis C Patients at AASLD

Financial news for BMY dated on 2015-10-19: How Five Prime's Bristol-Myers

Partnership Helps Investors

Financial news for BMY dated on 2015-10-16: Hearing Unconfirmed Market Chatter of Pfizer Bid for BMY; \$75+/Share

Financial news for BMY dated on 2015-10-15: Bristol-Myers Squibb Says NICE Recommends Daklinza for Treatment of Certain Patients with Chronic Hep C Genotypes 1, 3 and 4

Financial news for BMY dated on 2015-10-15: Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares Slip On Weak Preliminary Q3 Results

Financial news for BMY dated on 2015-10-15: Mid-Day Market Update: Crude Oil Down 2%; Five Prime Therapeutics Shares Spike Higher

Financial news for BMY dated on 2015-10-15: Benzinga's Volume Movers

Financial news for BMY dated on 2015-10-15: Mid-Morning Market Update: Markets Rise; Citigroup Profit Tops Estimates

Financial news for BMY dated on 2015-10-15: Morning Market Gainers

Financial news for BMY dated on 2015-10-15: Benzinga's Top #PreMarket Gainers

Financial news for BMY dated on 2015-10-15: Five Prime Therapeutics +68% Premarket Following Announcement of Worldwide License, Collaboration Agreement on CSF1R Antibody Program With Bristol-Myers Squibb

Financial news for BMY dated on 2015-10-15: Bristol-Myers Squibb, Five Prime Therapeutics Announce Worldwide License, Collaboration Agreement on CSF1R Antibody Program

Financial news for BMY dated on 2015-10-15: Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody Program

Financial news for BMY dated on 2015-10-14: Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy Fund

Financial news for BMY dated on 2015-10-09: Bristol-Myers Squibb's Opdivo Receives Expanded FDA Approval in Previously-Treated Metastatic Non-Small Cell Lung Cancer , Offering Improved Survival to More Patients

Financial news for BMY dated on 2015-10-09: FDA Expands Approved Usage For Opdivo In Advanced Lung Cancer Scenarios

Financial news for BMY dated on 2015-10-07: Seattle Genetics Announces Initiation of Phase 1/2 Clinical Trial of ADCETRIS(r) (Brentuximab Vedotin) in Combination with Opdivo(r) (Nivolumab) in Second-line Hodgkin Lymphoma

Financial news for BMY dated on 2015-10-06: Bristol Myers Announces FDA Granted Daklinza Priority Review

Financial news for BMY dated on 2015-10-05: Full SEC Comments Regarding Bristol-Myers Squibb FCPA Violations

Financial news for BMY dated on 2015-10-05: Hearing SEC Has Charged Bristol-Myers with FCPA Violations, Co. to Pay \$14M+ to Settle

Financial news for BMY dated on 2015-10-02: Bristol-Myers Spikes to High Following FDA Approval of Merck's Keytruda

Financial news for BMY dated on 2015-10-02: Hearing Unconfirmed Market Chatter of Potential Bids from Bristol Myers, Pfizer for Celgene

Financial news for BMY dated on 2015-10-02: Fast Money Picks For October 2

Financial news for BMY dated on 2015-10-01: Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma

Financial news for BMY dated on 2015-09-29: UBS On Bristol-Myers Squibb: 'We Like This Opportunity Right Here Right Now'

Financial news for BMY dated on 2015-09-29: Benzinga's Top Upgrades

Financial news for BMY dated on 2015-09-29: US Stock Futures Rise Ahead Of Housing, Consumer Confidence Data

Financial news for BMY dated on 2015-09-29: UBS Upgrades Bristol-Myers Squibb to Buy,

Raises PT to \$75.00

Financial news for BMY dated on 2015-09-27: Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer in CheckMate -057

Financial news for BMY dated on 2015-09-25: Bristol-Myers Squibb Reports FDA Regulatory Filing Update for Opdivo_Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma

Financial news for BMY dated on 2015-09-25: Bristol-Myers Squibb, Moffitt Cancer Center Report Entering Into of Collab Deal Related to Rare Population Malignancy Program

Financial news for BMY dated on 2015-09-22: Bristol-Myers Squibb's Kidney Opportunity Is Bigger Than Some Thought

Financial news for BMY dated on 2015-09-21: Fast Money Picks For September 21

Financial news for BMY dated on 2015-09-18: Make The World A Better Place With...Stock Picks?

Financial news for BMY dated on 2015-09-18: Bristol-Myers Squibb Foundation Awards Additional Grants to Promote Cervical Cancer Screenings and Services for Women Living with HIV in Tanzania

Financial news for BMY dated on 2015-09-17: Filing from Bristol-Myers Shows Registration for Automatic Mixed Securities Shelf Offering

Financial news for BMY dated on 2015-09-16: Cramer's Stock To Buy After A Fed Rate Hike

Financial news for BMY dated on 2015-09-16: Bristol-Myers Squibb's Opdivo Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma

Financial news for BMY dated on 2015-09-16: Jim Cramer Shares His Thoughts On Home Depot, Bristol-Myers Squibb, Marathon Oil, Exelixis

Financial news for BMY dated on 2015-09-14: Amgen And Biogen Lead Short Interest Surge In Biotechs

Financial news for BMY dated on 2015-09-14: Biotechs Coming Off One Of The Busiest Weeks In Recent Memory

Financial news for BMY dated on 2015-09-10: Fast Money Picks For September 10

Financial news for BMY dated on 2015-09-10: Mike Khouw Sees Unusual Options Activity In Bristol-Myers Squibb

Financial news for BMY dated on 2015-09-09: Bristol-Myers, Pfizer Report Enrollment of First Patient in Phase 4 AUGUSTUS Trial for Evaluation of Safety of Eliquis

Financial news for BMY dated on 2015-09-07: BMY Announces CheckMate -017, -063 Trials Evaluating Opdivo in Previously Treated Squamous NSCLC Show Sustained Survival Benefit

Financial news for BMY dated on 2015-09-07: BMY Announces Opdivo+Yervoy Dosing Schedules Showed Acceptable Tolerability Profile

Financial news for BMY dated on 2015-09-02: Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer (WCLC) Highlights

Financial news for BMY dated on 2015-09-02: U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients

Financial news for BMY dated on 2015-09-01: It's Not Shopping, It's Market Research: Talking Investing Trends With TD Ameritrade's Nicole Sherrod

Financial news for BMY dated on 2015-09-01: U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies

Financial news for BMY dated on 2015-08-31: Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel PRM-151 in Development for Fibrotic Diseases

Financial news for BMY dated on 2015-08-27: Benzinga's M&A Chatter for Thursday August 27, 2015

Financial news for BMY dated on 2015-08-27: Hearing Unconfirmed Market Chatter of Gilead Deal to Acquire BMY

Financial news for BMY dated on 2015-08-27: Allied-Bristol Life Sciences Licenses Platform Technology and Lead Molecules from Yale University

Financial news for BMY dated on 2015-08-24: Morgan Stanley Lists Stocks With \$5B in Market Cap Possessing Best 1 Year Opportunity

Financial news for BMY dated on 2015-08-24: Piper Jaffray Upgrades Bristol-Myers Squibb, Sees Valuation As Fair

Financial news for BMY dated on 2015-08-24: Bristol-Myers, Pfizer Will Present New Data on Eliquis at ESC Congress '15

Financial news for BMY dated on 2015-08-24: Piper Jaffray Upgrades Bristol-Myers Squibb to undefined, Maintains \$61.00 PT

Financial news for BMY dated on 2015-08-20: Bristol-Myers Squibb Announces Health Canada Approves Daklinza for Treatment of Chronic Hepatitis C Infection Across Multiple Genotypes Including Genotype 3

Financial news for BMY dated on 2015-08-18: Buy The Dip On Bristol-Myers Squibb: J.P. Morgan

Financial news for BMY dated on 2015-08-17: R-Pharm Acquires Ixempra From Bristol-Myers Squibb, Launches U.S. Commercial Operations

Financial news for BMY dated on 2015-08-14: Credit Suisse: Top 11 Large-Cap Growth Stocks

Financial news for BMY dated on 2015-08-13: Bristol-Myers Squibb Reports FDA Approval of US Product Labeling Update for Sprycel, Will Include Five-Year First-Line, Seven-Year Second-Line Efficacy, Safety Data

Financial news for BMY dated on 2015-08-12: U.S. FDA Extends Action Date for Supplemental Biologics License Application for Opdivo in Previously Untreated Advanced Melanoma

Financial news for BMY dated on 2015-08-10: uniQure Receives Additional \$53M from Bristol-Myers Squibb for Target Selection Payment and Additional Equity Investment

Financial news for BMY dated on 2015-07-31: Hearing Renewed Unconfirmed Market Chatter of Pfizer Interest in Bristol-Myers

Financial news for BMY dated on 2015-07-27: European Medicines Agency Validates, Grants Accelerated Assessment of Marketing Authorization Application for Empliciti For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies

Financial news for BMY dated on 2015-07-24: Daklinza Approved By FDA For Hepatitis C Genotype 3 Infections Treatment

Financial news for BMY dated on 2015-07-23: Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls

Financial news for BMY dated on 2015-07-23: From Conf Call: Bristol Myers Says Lung Business to Eclipse Melanoma Business

Financial news for BMY dated on 2015-07-23: Bristol-Myers Squibb Posts Upbeat Q2 Results, Lifts Profit Forecast

Financial news for BMY dated on 2015-07-23: Bristol-Myers Squibb Raises FY15 Adj. EPS from \$1.60-\$1.70 to \$1.70-\$1.80 vs \$1.77 Est., Sales \$15.5B-\$15.9B vs \$15.42B Est.

Financial news for BMY dated on 2015-07-23: Bristol-Myers Squibb Reports Q2 EPS \$0.53 Vs Est \$0.36, Sales \$4.2B

Financial news for BMY dated on 2015-07-23: US Stock Futures Rise Ahead Of General Motors, McDonald's Earnings

Financial news for BMY dated on 2015-07-23: European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe

Financial news for BMY dated on 2015-07-23: Bristol Myers Announces EMA Validates Two

Parallel Type II Variation Applications to Extend Opdivo Indication in Europe

Financial news for BMY dated on 2015-07-23: Earnings Scheduled For July 23, 2015

Financial news for BMY dated on 2015-07-22: What's Coming For Large-Cap Pharma Stocks This Earnings Season?

Financial news for BMY dated on 2015-07-22: Did McDonald's, Caterpillar & Amazon Lose Sizzle To Strong Dollar?

Financial news for BMY dated on 2015-07-21: Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development

Financial news for BMY dated on 2015-07-21: Bristol-Myers Squibb Given U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients

Financial news for BMY dated on 2015-07-20: Bristol-Myers Announces European Commission Has Approved Nivolumab BMS in Europe

Financial news for BMY dated on 2015-07-20: CheckMate -025, a Pivotal Phase III Opdivo Renal Cell Cancer Trial, Stopped Early

Financial news for BMY dated on 2015-07-16: Bristol-Myers' HIV-1 Drug Approved In Europe

Financial news for BMY dated on 2015-07-16: European Commission Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults

Financial news for BMY dated on 2015-07-12: Benzinga's Weekend M&A Chatter

Financial news for BMY dated on 2015-07-10: Hearing Unconfirmed Market Chatter of Potential Pfizer Bid for Bristol Myers Squibb; Rumored Offer is \$80+

Financial news for BMY dated on 2015-07-10: CNBC's Meg Tirrel Speculates About Gilead's New Acquisition

Financial news for BMY dated on 2015-07-07: Fast Money Picks For July 7

Financial news for BMY dated on 2015-06-30: Fast Money Picks For June 30

Financial news for BMY dated on 2015-06-26: Bristol-Myers Shares Spike Higher

Financial news for BMY dated on 2015-06-22: Portola, Bristol-Myers Squibb, Pfizer Announce Complete Phase 3 ANNEXA-A Study Results

Financial news for BMY dated on 2015-06-22: Allied-Bristol Life Sciences Licenses Intellectual Property from Harvard University

Financial news for BMY dated on 2015-06-19: European Commission Approves Bristol-Myers Squibb's Opdivo, the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients

Financial news for BMY dated on 2015-06-17: The Note Moving Pharma Giants Today

Financial news for BMY dated on 2015-06-17: Benzinga's Top Initiations

Financial news for BMY dated on 2015-06-17: Piper Jaffray Initiates Bristol-Myers Squibb With Underperform

Financial news for BMY dated on 2015-06-17: Piper Jaffray Initiates Coverage on Bristol-Myers Squibb at Underperform, Announces \$60.00 PT

Financial news for BMY dated on 2015-06-15: Morgan Stanley's Positive Comments On Bristol-Myers Squibb

Financial news for BMY dated on 2015-06-15: Morgan Stanley Issues Positive Comments on Bristol-Myers, Models Opdivo 2015 Sales At \$1.1B Growing To \$9.7B In 2020

Financial news for BMY dated on 2015-06-11: PeptiDream Announces Milestone in Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb

Financial news for BMY dated on 2015-06-09: New Post Hoc Breakdown of Phase 3b Data Examine Treatment with Orencia (abatacept) Plus Methotrexate (MTX) in Patients with Early Moderate to Severe Rheumatoid Arthritis (RA) and Markers of Poor Prognosis

Financial news for BMY dated on 2015-06-04: 2 M&A Rumors Moving The Market

Financial news for BMY dated on 2015-06-04: Pfizer Issues Statement Related Bristol-Myers Chatter: Co. 'Does Not Comment on Market Rumor or Speculation'

Financial news for BMY dated on 2015-06-04: Bristol-Myers Squibb Spokesperson Declines Comment on Chatter of Co. Deal with Pfizer

Financial news for BMY dated on 2015-06-04: Option Alert: Bristol Myers June 5 \$66 Call; 1220 Contract Trade above Ask @\$0.38

Financial news for BMY dated on 2015-06-04: Hearing Unconfirmed Market Chatter of Potential Pfizer Bid for Bristol Myers Squibb

Financial news for BMY dated on 2015-06-03: Bristol-Myers Squibb to Report Data from 14 Abstracts on Orencia at the European League Against Rheumatism 2015 Annual Meeting

Financial news for BMY dated on 2015-06-02: Genmab Gains Exclusive License from Bristol-Myers Squibb for Human Antibodies against CD19 Target for \$4M

Financial news for BMY dated on 2015-06-01: 16 Biotech Stocks Moving Off The ASCO Conference

Financial news for BMY dated on 2015-06-01: Options Outlook: Market In 'Headline' And 'Sentiment' Mode

Financial news for BMY dated on 2015-06-01: U.S. FDA Supplemental Biologics License Application for Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma

Financial news for BMY dated on 2015-05-31: Bristol-Myer Opdivo Demonstrates Superior Survival Compared to Ocotaxel for Previously-Treated Squamous NSCLC in Phase 3 Trial

Financial news for BMY dated on 2015-05-31: Bristol-Myers Announced Positive Results of Phase III Trial Evaluating Opdivo+Yervoy Regimen

Financial news for BMY dated on 2015-05-29: Bristol-Myers Shares Spike Lower Following Results of Phase I/II Opdivo Trial

Financial news for BMY dated on 2015-05-29: Phase I/II Opdivo (nivolumab) Trial Displays Bristol-Myers Squibb's PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma

Financial news for BMY dated on 2015-05-29: Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Better Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial

Financial news for BMY dated on 2015-05-26: Fast Money Picks For May 27

Financial news for BMY dated on 2015-05-26: uniQure Report Closing of Strategic Partnership with Bristol-Myers Squibb to Develop Cardiovascular Disease Gene Therapies

Financial news for BMY dated on 2015-05-22: Bristol-Myers Squibb Given Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients

Financial news for BMY dated on 2015-05-22: CHMP Grants Positive Opinion for Bristol-Myers' Nivolumab BMS

Financial news for BMY dated on 2015-05-22: EMA Recommends Approval of Bristol-Myers Squibb HIV Drug Evotaz

Financial news for BMY dated on 2015-05-20: Bristol-Myers Squibb Granted Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen

Financial news for BMY dated on 2015-05-14: Berenberg Initiates Bristol-Myers Squibb With Hold

Financial news for BMY dated on 2015-05-14: Benzinga's Top Initiations

Financial news for BMY dated on 2015-05-14: Benzinga's Top #PreMarket Losers

Financial news for BMY dated on 2015-05-14: Bristol-Myers Squibb to Present Data at 2015 American Society of Clinical Oncology from its Broad Immuno-Oncology Portfolio Across Solid Tumors (Last Night)

Financial news for BMY dated on 2015-05-14: Berenberg Initiates Coverage on Bristol-

Myers Squibb at Hold, Announces \$70.00 PT

Financial news for BMY dated on 2015-05-05: Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers

Financial news for BMY dated on 2015-05-04: Report Bristol-Myers Has Been Rejected by US Supreme Court Related to Baraclude Patent

Financial news for BMY dated on 2015-04-29: Bristol-Myers Reports FDA Acceptance Supplemental BLA for Opdivo in Patients with Previously-Untreated Advanced Melanoma

Financial news for BMY dated on 2015-04-29: Bristol-Myers Squibb's Next 8 Months: What To Expect

Financial news for BMY dated on 2015-04-28: Bristol-Myers Raises FY15 Adj. EPS Outlook from \$1.55-\$1.70 to \$1.60-\$1.70 vs \$1.71 Est.

Financial news for BMY dated on 2015-04-28: Bristol-Myers Squibb Reports Q1 Adj. EPS \$0.71 vs. Est.\$0.50, REv. \$4.041B vs. Est. \$3.80B

Financial news for BMY dated on 2015-04-28: Earnings Scheduled For April 28, 2015

Financial news for BMY dated on 2015-04-27: Bristol-Myers Squibb Earnings: Experts & Crowd Expect 10% EPS Growth

Financial news for BMY dated on 2015-04-27: Bristol-Myers Reports ALLY-1 Trial Showed Investigational Daclatasvir-Based Regimen Cures 94% of Post-Live Transplant Patients, Met Primary Endpoint

Financial news for BMY dated on 2015-04-26: Benzinga's Weekend M&A Chatter

Financial news for BMY dated on 2015-04-26: U.S. Tech, Dollar & Health Care ETFs To Watch This Week

Financial news for BMY dated on 2015-04-24: Why A Bristol-Myers Squibb Bid On Celgene Is Plausible

Financial news for BMY dated on 2015-04-24: SunTrust Biotech Analyst On Bristol-Myers Squibb, Celgene Rumor-"Is It Possible? Yes It Could Be, All Biotech Names In Play For Large Pharma Looking For Cancer Assets"

Financial news for BMY dated on 2015-04-24: Hearing Unconfirmed Market Chatter of Bristol Myers Bid for Celgene of \$138/Share

Financial news for BMY dated on 2015-04-24: Bristol-Myers Receives Positive CHMP Opinion in EU for Opdivo for Treatment of Advance Melanoma

Financial news for BMY dated on 2015-04-24: EMA Recommends Approval of Bristol-Myers Squibb Melanoma Drug Nivolumab

Financial news for BMY dated on 2015-04-21: Benzinga's Top Upgrades

Financial news for BMY dated on 2015-04-21: Morgan Stanley Says 'Buy The Leader In IO,' Upgrades Bristol-Myers To Overweight

Financial news for BMY dated on 2015-04-21: Morgan Stanley Upgrades Bristol-Myers Squibb to Overweight, Raises PT to \$80.00

Financial news for BMY dated on 2015-04-20: CAR-T Therapy Stocks Hit Hard Following AACR Data

Financial news for BMY dated on 2015-04-20: Bristol-Myers Squibb Reports First Randomized Study Evaluating Opdivo+Yervoy Regimen Shows Superior Efficacy Related to Yervoy Alone

Financial news for BMY dated on 2015-04-17: It's A Big Weekend For Biotech

Financial news for BMY dated on 2015-04-17: Why Bristol-Myers Squibb Ending A Drug Trial Early Is A Good Thing

Financial news for BMY dated on 2015-04-17: With Bristol-Myers Trial Stopped Early, 'What's Next?'

Financial news for BMY dated on 2015-04-17: Bristol-Myers Up Big After Drug Study Stopped Early

Financial news for BMY dated on 2015-04-17: Bristol-Myers Squibb Announces CheckMate -057 Trial Stopped Early

Financial news for BMY dated on 2015-04-17: Bristol-Myers Squibb Announces CheckMate-057 Trial Stopped Early

Financial news for BMY dated on 2015-04-16: Lilly, Bristol-Myers Squibb Restructure Erbitux Pact In North America; Lilly Gets Full Commercialization Rights While Bristol-Myers Gets Tiered Royalties On Product Sales

Financial news for BMY dated on 2015-04-14: Morgan Stanley's Major Pharma Q1 Preview

Financial news for BMY dated on 2015-04-13: Benzinga's M&A Chatter for Monday April 13, 2015

Financial news for BMY dated on 2015-04-13: Option Alert: Bristol-Myers Squibb Apr \$66.5 Call; 1500 Contract Trade at Ask @\$0.24

Financial news for BMY dated on 2015-04-13: Hearing Renewed Unconfirmed Market Chatter of Pfizer Interest in Bristol-Myers

Financial news for BMY dated on 2015-04-08: Hearing Unconfirmed Market Chatter of Bristol-Myers Stake in Coronado Biosciences

Financial news for BMY dated on 2015-04-08: Bristol-Myers Squibb Reports Closing of Previously-Announced Purchase of Flexus Biosciences

Financial news for BMY dated on 2015-04-06: 3 Pharma Stories JPMorgan Is Watching

Financial news for BMY dated on 2015-04-06: Benzinga's Volume Movers

Financial news for BMY dated on 2015-04-06: Stocks Hitting 52-Week Highs

Financial news for BMY dated on 2015-04-06: Morning Market Gainers

Financial news for BMY dated on 2015-04-06: UPDATE: uniQure Share Rise 53% Premarket Following Announcement of Deal With Bristol-Myers Squibb

Financial news for BMY dated on 2015-04-06: Benzinga's Top #PreMarket Gainers

Financial news for BMY dated on 2015-04-06: uniQure Share Rise 14% Premarket on Light Trading, Following Announcement of Deal With Bristol-Myers Squibb,

Financial news for BMY dated on 2015-04-06: UPDATE: uniQure to Receive \$50M Upfront Payment at Close of Transaction; Bristol-Myers-Squibb to Acquire Additional 5% Ownership Before December 31, 2015 at 10% Premium

Financial news for BMY dated on 2015-04-06: Bristol-Myers Squibb, uniQure Report Deal Providing Bristol Exclusive Access to uniQure's Gene Therapy Technology Platform for Multiple Targets in CV Diseases

Financial news for BMY dated on 2015-03-30: Bristol-Myers Squibb Is Re-Testing Its Breakout Level

Financial news for BMY dated on 2015-03-24: Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for Discovery Research Program on Autoimmune Diseases

Financial news for BMY dated on 2015-03-23: SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms

Financial news for BMY dated on 2015-03-12: Bristol-Myers Says FDA Approves Re-submission Of Daclatasvir NDA For Hep C Treatment

Financial news for BMY dated on 2015-03-11: 18 Biotech Stocks These Wall Street Analysts Are Tracking

Financial news for BMY dated on 2015-03-10: 8 Healthcare Names Cowen & Co Are Talking About

Financial news for BMY dated on 2015-03-05: Fast Money Halftime Report Final Trade From March 5

Financial news for BMY dated on 2015-03-05: What Analysts Said After Bristol-Myers' Quick Lung Drug Approval

Financial news for BMY dated on 2015-03-04: Bristol-Myers Squibb Hits All-Time High Off FDA Approval For Expanded Use Of Opvido

Financial news for BMY dated on 2015-03-04: Shares of Rigel Pull Back on Report They are Not Partners with Bristol Myers on Opdivo for Lung Cancer

Financial news for BMY dated on 2015-03-04: Bristol-Myers Opdivo Expanded Use

Approved To Treat Lung Cancer

Financial news for BMY dated on 2015-03-04: Bristol-Myers Squibb to Pay Bavarian Nordic Up to \$975M for PROSTVAC License

Financial news for BMY dated on 2015-03-03: Bristol-Myers Squibb Canada Announces Hepatitis C Cure Rate of 97% in Study of Patients Co-infected with HIV Given 12-week Combination Treatment of Daclatasvir and Sofosbuvir in ALLY-2 Trial

Financial news for BMY dated on 2015-03-02: UPDATE: USDA Approves Supplemental Biologics License

Financial news for BMY dated on 2015-03-02: USDA Accepts Supplemental Biologics License Application for Yervoy As Adjuvant Treatment for Patients with Stage 3 Melanoma Who Are at High Risk of Recurrence

Financial news for BMY dated on 2015-02-26: BMY Announced ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After Ribavirin-Free Investigational 12-Week Regimen of Daclatasvir and Sofosbuvir

Financial news for BMY dated on 2015-02-26: Bristol Myers Reports Data Supporting Clinical Development Of BMS-955176

Financial news for BMY dated on 2015-02-25: Bristol-Myers Has Said BMS-955176 Supports Candidate as Viable Compound, Expecting to Begin Phase 2b Studies in Q2, Primary Endpoint of Change in HIV-1 Met

Financial news for BMY dated on 2015-02-25: Bristol-Myers Squibb Launches Phase III Trial Of HIV Drug

Financial news for BMY dated on 2015-02-25: Bristol Myers Announces Data From Phase IIb Trial of BMS-663068

Financial news for BMY dated on 2015-02-23: Morning Market Gainers

Financial news for BMY dated on 2015-02-23: Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications

Financial news for BMY dated on 2015-02-23: Bristol-Myers Reports Deal to Purchase Flexus Biosciences for Total Consideration \$1.25B, Including \$800M Upfront, Development Milestones Which Could Total as Much as ~\$450M

Financial news for BMY dated on 2015-02-23: Evercore ISI Technical Analysis: The 'Single Best Idea'

Financial news for BMY dated on 2015-02-20: Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices

Financial news for BMY dated on 2015-01-29: FDA Approves Bristol-Myers Squibb's Evotaz

Financial news for BMY dated on 2015-01-29: Bristol-Myers Announces FDA Has Approved Evotaz for Treatment of HIV-1 Infection for Adults

Financial news for BMY dated on 2015-01-29: Celldex Therapeutics, Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo

Financial news for BMY dated on 2015-01-27: Tuesday Morning Movers: Microsoft, Procter & Gamble Tumble Following Earnings

Financial news for BMY dated on 2015-01-27: UPDATE: Bristol-Meyers Squibb Posts Upbeat Q4 Results, Issues Downbeat Forecast

Financial news for BMY dated on 2015-01-27: Bristol-Myers Sees FY15 Adj. EPS \$1.55-\$1.70 vs \$1.73 Est., Sales \$14.4-\$15B vs \$15.64B Est.

Financial news for BMY dated on 2015-01-27: Bristol-Myer Squibb Reports Q4 EPS \$0.46 Vs. Est. \$0.41, Revenues Of \$4.26B Vs. \$4.03B

Financial news for BMY dated on 2015-01-27: Earnings Scheduled For January 27, 2015

Financial news for BMY dated on 2015-01-20: Bristol-Myers Squibb Names Caforio CEO, Andreotti To Become Chairman

Financial news for BMY dated on 2015-01-20: Bristol-Myers Squibb Appoints Giovanni Caforio As CEO; Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become Chairman

Financial news for BMY dated on 2015-01-15: 10 Biotech Stories You Might've Missed This Week

Financial news for BMY dated on 2015-01-13: Bloomberg Reporting That Bristol-Myers' Ulocuplumab Treatment Granted FDA Orphan Status

Financial news for BMY dated on 2015-01-13: Fast Money Picks For January 13: SanDisk, Tiffany & Co., Frontline, Bristol-Myers Squibb

Financial news for BMY dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

Financial news for BMY dated on 2015-01-12: Morning Market Gainers

Financial news for BMY dated on 2015-01-12: 4 Stocks Trending On Social Media This Monday

Financial news for BMY dated on 2015-01-12: Seattle Genetics and Bristol Myers Announces Collaboration on Two Drugs

Financial news for BMY dated on 2015-01-11: Bristol-Myers Announces Phase 3 Study of Opdivo vs Docetaxel in Patients with Second-Line Squamous Cell NSCLC Met Endpoint

Financial news for BMY dated on 2015-01-11: Credit Suisse: Keep An Eye On These 6 Healthcare Stocks In 2015

Financial news for BMY dated on 2015-01-09: What Investors Should Expect From Portola Pharmaceutical's Upcoming Data Readouts

Financial news for BMY dated on 2015-01-06: Jim Cramer Advises His Viewers On Wynn Resorts And Second Sight Medical Products

Financial news for BMY dated on 2015-01-05: Bristol-Myers Squibb and California Institute for Biomedical Research Sign Worldwide Research Collaboration and License Agreement Focused on New Treatment Approaches for Fibrotic Diseases

Financial news for BMY dated on 2014-12-22: Bristol-Myers Squibb Receives Accelerated Approval Of Opdivo

Financial news for BMY dated on 2014-12-22: Bristol-Myers Nivolumab Opdivo Cleared BY FDA For Advanced Melanoma

Financial news for BMY dated on 2014-12-11: Fitch Revises Bristol-Myers Squibb's Outlook to Stable; Affirms IDR at 'A-'

Financial news for BMY dated on 2014-12-10: US Stock Futures Edge Lower Ahead Of Federal Budget

Financial news for BMY dated on 2014-12-10: Ono Pharmaceutical, Bristol-Myers Squibb, Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo and Mogamulizumab in Advanced Solid Tumors

Financial news for BMY dated on 2014-12-09: Bristol-Myers Declares Raised Qtr. Dividend from \$0.36 to \$0.37/Share

Financial news for BMY dated on 2014-12-08: Bristol-Myers, Pfizer Report Results of First-Human Study Evaluating Reversal of Anticoagulant Effect of Eliquis: Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subjects

Financial news for BMY dated on 2014-12-06: BMS Reports Opdivo Demonstrates Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma

Financial news for BMY dated on 2014-12-05: UPDATE: Pfizer Declines Comment on Rumored Bid for Bristol-Myers Squibb

Financial news for BMY dated on 2014-12-05: UPDATE: Bristol-Myers Squibb Spokesperson Declines Comment on Rumored Talks with Pfizer

Financial news for BMY dated on 2014-12-05: Option Alert: Bristol-Myers Squibb Dec 5 \$59.5 Call; 3,167 Contracts Traded vs 130 OI; Currently \$59.59

Financial news for BMY dated on 2014-12-05: UPDATE: Hearing Unconfirmed Market Chatter of Potential \$70-\$72 Bid for Bristol-Myers Squibb by Pfizer

Financial news for BMY dated on 2014-12-05: Hearing Unconfirmed Market Chatter of Potential Pfizer Bid for Bristol Myers Squibb

Financial news for BMY dated on 2014-12-04: Jefferies Maintains Hold on Bristol-Myers Squibb Company, Raises PT to \$54.00

Financial news for BMY dated on 2014-11-26: Bristol-Myers Receives CRL Letter From FDA; Requesting Added Data For Daclatasvir

Financial news for BMY dated on 2014-11-26: Bristol-Myers Squibb Receives CRL from FDA for Daclatasvir

Financial news for BMY dated on 2014-11-24: Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration

Financial news for BMY dated on 2014-11-18: Allied-Bristol Life Sciences Announces Strategic Partnership with Synergy Partners R&D Solutions

Financial news for BMY dated on 2014-11-17: UPDATE: Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)

Financial news for BMY dated on 2014-11-17: Portola , Bristol-Myers Squibb, Pfizer Report Statistically Significant Results from First Part of Phase 3 ANNEXA-A Studies of Andexanet Alfa with Eliquis

Financial news for BMY dated on 2014-11-16: Bristol-Myers Squibb Reports CheckMate -066 Study Met Primary Endpoint of Overall Survival

Financial news for BMY dated on 2014-11-14: Bristol-Myers Squibb to Construct Large-Scale Biologics Manufacturing Facility In Cruiserath, Ireland; Will Create 300-400 Manufacturing Jobs

Financial news for BMY dated on 2014-11-13: Morgan Stanley Downgrades Bristol-Myers On Valuation

Financial news for BMY dated on 2014-11-13: Bristol-Myers Squibb Reports High Cure Rates For Genotype 3 Hepatitis C Using Combination Of Daclatasvir, Sofosbuvir in ALLY-3 Trial

Financial news for BMY dated on 2014-11-13: Morgan Stanley Downgrades Bristol-Myers Squibb Company to Equal-weight, Maintains \$60.00 PT

Financial news for BMY dated on 2014-11-08: Bristol-Myers Squibb Announces Late-Breaking Data from ALLY Trial

Financial news for BMY dated on 2014-11-06: Traders Highlighting Section in Tekmira Earnings/Corporate Update Release Related to Expiration of Collaboration with Bristol-Myers Squibb

Financial news for BMY dated on 2014-11-03: Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor

Financial news for BMY dated on 2014-10-31: #Premarket Prep Technical Update - Bristol-Myers Squibb Trading Finds Resistance

Financial news for BMY dated on 2014-10-31: Dan Nathan Sees Unusual Options Activity In Bristol-Myers Squibb Co

Financial news for BMY dated on 2014-10-30: #Premarket Prep Technical Update - Bristol-Myers Squibb Makes New All Time High

Financial news for BMY dated on 2014-10-30: Bristol-Myers Squibb & Lonza Announce Multi-year Manufacturing Agreement Expansion

Financial news for BMY dated on 2014-10-30: Bristol-Myers Squibb Announces Results From CheckMate -063, a Phase 2 single-arm, Open-Label Study of Opdivo

Financial news for BMY dated on 2014-10-28: Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy

Financial news for BMY dated on 2014-10-27: #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line With Expectations

Financial news for BMY dated on 2014-10-24: From Conf Call: Bristol-Myer Says Encouraged By Clinical Trial Data from "069" Melanoma Trial of Combo Of Yervoy, Opdivo Immuno-Oncology Drugs

Financial news for BMY dated on 2014-10-24: UPDATE: Bristol-Myers Squibb Q3 Earnings Top Estimates

Financial news for BMY dated on 2014-10-24: #PreMarket Primer: Friday, October 24: Ebola Fears Weigh On Markets

Financial news for BMY dated on 2014-10-24: Bristol-Myers Squibb Company Sees FY2014 Sales \$15.20B-15.80B vs \$15.59B Est

Financial news for BMY dated on 2014-10-24: Bristol-Myers Squibb Company Reports Q3 EPS of \$0.45 vs \$0.42 Est; Revenue of \$3.92B vs \$3.80B Est

Financial news for BMY dated on 2014-10-24: Earnings Scheduled For October 24, 2014

Financial news for BMY dated on 2014-10-24: Must Watch Stocks for Today

Financial news for BMY dated on 2014-10-22: Drug ETFs Attractive Buys On Pullback

Financial news for BMY dated on 2014-10-19: Benzinga Weekly Preview: Earnings Season Is In Full Swing

Financial news for BMY dated on 2014-10-16: BMO Capital Upgrades Bristol-Myers Squibb Company to Outperform, Maintains \$55.00 PT

Financial news for BMY dated on 2014-10-13: Markets Debut Week On Negative Note; S&P 500 Falls Through Key Level

Financial news for BMY dated on 2014-10-13: Jefferies Maintains Hold on Bristol-Myers Squibb Company, Raises PT to \$50.00

Financial news for BMY dated on 2014-10-13: 5 Companies That Could Develop An Enterovirus Treatment

Financial news for BMY dated on 2014-10-13: Bristol-Myers, Pharmacoclics, Janssen Report Clinical Collaboration of Evaluate OPDIVO, IMBRUVICA in NHL

Financial news for BMY dated on 2014-10-08: Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S

Financial news for BMY dated on 2014-10-07: Shares of Achillion Pharm Edging Into Positive Territory as Hearing UBS Commenting on Bristol-Myers Squibb Look Into Strategic Assets as Boding Well for Co.

Financial news for BMY dated on 2014-10-07: Bristol-Myers Squibb Statement About Asunaprevir In The US, Withdraws NDA

Financial news for BMY dated on 2014-10-06: 2 Mutual Funds Holding Hospital Stocks

Financial news for BMY dated on 2014-10-06: Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration in Immuno-Oncology Focused on Leukemia and Hematologic Malignancies

Financial news for BMY dated on 2014-10-06: Novartis, Bristol-Myers Squibb Collaborate on Novel Immunotherapy in Combination Treatments for NSCLC

Financial news for BMY dated on 2014-10-03: What Are The Best-Selling Drugs Of 2014?

Financial news for BMY dated on 2014-10-02: NeurOp Receives Milestone Payment As Bristol-Myers Squibb Nominates NMDA Receptor Compound As Candidate For Drug Development

Financial news for BMY dated on 2014-10-02: Morgan Stanley Believes Bristol-Myers Squibb Co. Could Move Significantly Over Next Several Months

Financial news for BMY dated on 2014-10-02: Guggenheim Securities Initiates Coverage on Bristol-Myers Squibb Company at Neutral, Announces \$57.00 PT

Financial news for BMY dated on 2014-09-30: UPDATE: Bristol-Myers Says No Added Cash Contributions by Co. Are Required, No Change to Monthly Retirement Benefit Payment

Financial news for BMY dated on 2014-09-30: Bristol-Myers Squibb to Transfer \$1.4 Billion in U.S. Pension Obligations to Prudential

Financial news for BMY dated on 2014-09-29: Fast Money Picks For September 29 - Yahoo! Inc., Exxon Mobil Corporation And More

Financial news for BMY dated on 2014-09-29: Bristol-Myers Squibb Presents Positive Phase 3 Data for Opdivoin Advanced Melanoma Patients Previously Treated with Yervoy

Financial news for BMY dated on 2014-09-26: Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo In U.S & EU

Financial news for BMY dated on 2014-09-16: Bristol-Myers Announces Health Canada Approves Yervoy for First-Line Treatment of Adults With Metastatic Melanoma

Financial news for BMY dated on 2014-09-05: Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug

Financial news for BMY dated on 2014-09-05: Shares of Bristol-Myers Edge Off Session Lows as Bloomberg Reporting Co. Has Filed Suit Against Merck Related to Patent for Immunotherapy Drugs

Financial news for BMY dated on 2014-09-04: Merck Wins FDA Approval For Pembrolizumab In Melanoma

Financial news for BMY dated on 2014-08-30: Bristol-Myers, Pfizer Announce Eliquis Significantly Reduced Risk of All-Cause Hospitalization vs Placebo in Patients With VTE

Financial news for BMY dated on 2014-08-27: Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend

Financial news for BMY dated on 2014-08-27: FDA Site Shows Teva Has Received Approval for Generic Version of Bristol-Myer's Baraclude as of Aug. 26th

Financial news for BMY dated on 2014-08-27: Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold

Financial news for BMY dated on 2014-08-27: US Stock Futures Edge Higher Ahead Of Tiffany Earnings

Financial news for BMY dated on 2014-08-27: Deutsche Bank Initiates Coverage on Bristol-Myers Squibb Company at Hold, Announces \$52.00 PT

Financial news for BMY dated on 2014-08-27: EC Approves Bristol-Myers Squibb's Daklinza Across Multiple Genotypes for Treatment of Chronic Hepatitis C Infection

Financial news for BMY dated on 2014-08-21: Bristol, Pfizer Report Eliquis Approved for DVT, PE by FDA

Financial news for BMY dated on 2014-08-20: Bristol-Myers And Celgene Announce Clinical Collaboration For an Immunotherapy and Chemotherapy Combination

Financial news for BMY dated on 2014-08-11: Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments

Financial news for BMY dated on 2014-08-08: FDA Site Shows Bristol-Myer's Nivolumab Has Won FDA Orphan Drug Designation

Financial news for BMY dated on 2014-08-07: Leica Biosystems, Bristol-Myers Squibb to Collaborate on Companion Diagnostics That Support Targeted Therapies

Financial news for BMY dated on 2014-08-04: Allied Minds, Bristol-Myers Squibb form Allied-Bristol Life Sciences

Financial news for BMY dated on 2014-08-01: Achillion Pharmaceuticals Shares Move Higher on Unconfirmed Market Chatter of Potential Bid from Bristol-Myers Squibb

Financial news for BMY dated on 2014-07-29: Bristol Myers and Pfizer Announces European Approval of Eliquis

Financial news for BMY dated on 2014-07-24: Thursday Morning Earnings Reports

Financial news for BMY dated on 2014-07-24: Bristol-Myers Squibb Company Sees FY2014 EPS \$1.70-1.80 vs \$1.77 Est

Financial news for BMY dated on 2014-07-24: Bristol-Myers Squibb Company Reports Q2 EPS of \$0.48 vs \$0.44 Est

Financial news for BMY dated on 2014-07-24: Earnings Scheduled For July 24, 2014

Financial news for BMY dated on 2014-07-22: Galectin Therapeutics Reports First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combo with Ipilimumab in Metastatic Melanoma

Financial news for BMY dated on 2014-07-18: Benzinga Weekly Preview: Earnings Season Continues With Geopolitical Tensions As A Backdrop

Financial news for BMY dated on 2014-07-17: Bristol-Myers, Pfizer Report First-Patient Enrollment Phase IV EMANATE Trial for Assessment of Eliquis

Financial news for BMY dated on 2014-07-15: Sarepta Declines Comment on Rumored Partnership with Bristol-Myers Squibb

Financial news for BMY dated on 2014-07-15: Hearing Merger Market Says Bristol-Meyers Interested in DMD Partnership with Sarepta

Financial news for BMY dated on 2014-07-14: Dow Sets New Intraday High; Citigroup Impresses With Earnings

Financial news for BMY dated on 2014-07-10: Bristol-Myers Announces Plans To File Biologics License Application For Opdivo in Q3

Financial news for BMY dated on 2014-07-02: Markets Little Changed Ahead Of 4th Of July Break

Financial news for BMY dated on 2014-07-02: Barclays Downgrades Pharmaceutical Sector

Financial news for BMY dated on 2014-07-02: UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target By 41%

Financial news for BMY dated on 2014-07-02: Benzinga's Top Downgrades

Financial news for BMY dated on 2014-07-02: Barclays Downgrades Bristol-Myers Squibb Company to Equal-weight, Lowers PT to \$46.00

Financial news for BMY dated on 2014-07-01: Ex-Dividends For July 1, 2014

Financial news for BMY dated on 2014-06-30: Bristol-Myers Reports Issuance of Voluntary Recall of COUMADIN for Injection, Cites Presence of Particulate Matter

Financial news for BMY dated on 2014-06-27: Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

Financial news for BMY dated on 2014-06-27: US Stock Futures Drop Ahead Of Consumer Sentiment Report

Financial news for BMY dated on 2014-06-27: Phiser and Bristol's Eliquis Gets Positive Opinion From EMA

Financial news for BMY dated on 2014-06-27: Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza for Treatment of Chronic Hepatitis C in the European Union

Financial news for BMY dated on 2014-06-24: UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab Stopped Early, Showed Superior Overall Survival vs Davarbazine

Financial news for BMY dated on 2014-06-24: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab Stopped Early, Showed Superior Overall Survival vs Davarbazine

Financial news for BMY dated on 2014-06-24: Bristol-Myers Announces Expansion of Access to Clinical Trial Data Through Collaboration with Academic Research Institute

Financial news for BMY dated on 2014-06-19: Edward Jones Reinstates Hold on Bristol-Myers Squibb Company

Financial news for BMY dated on 2014-06-17: Pennsylvania Supreme Court Has Vacated \$28M Judgement Related to Drug Pricing of Bristol-Myers, 13 Other Drug Cos. - Bloomberg

Financial news for BMY dated on 2014-06-16: Benzinga's M&A Chatter for Monday June 16, 2014

Financial news for BMY dated on 2014-06-12: Bristol-Myers Has Lost Appeals Court Ruling Related to Baraclude Patent - Bloomberg

Financial news for BMY dated on 2014-06-11: Takeover Whispers Add To Achillion Pharmaceuticals' Momentum

Financial news for BMY dated on 2014-06-09: Hearing Leering Says JNJ, AbbVie, Bristol-Myers Squibb Could Target Achillion Pharmaceuticals

Financial news for BMY dated on 2014-06-04: ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

Financial news for BMY dated on 2014-06-04: ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

Financial news for BMY dated on 2014-06-03: Bristol-Myers, Syngene Extend Drug Discovery, Development Collaboration in India by Five Years

Financial news for BMY dated on 2014-06-02: Phase 3 Study Evaluating Yervoy(r) (Ipilimumab) for Melanoma in an Adjuvant Setting Meets Primary Endpoint of Recurrence-Free Survival

Financial news for BMY dated on 2014-05-29: #Premarket Prep Technical Update - Bristol-Myers Squibb Trading Higher

Financial news for BMY dated on 2014-05-27: Bristol-Myers Squibb, CytomX Therapeutics Announce Worldwide Collaborations

Financial news for BMY dated on 2014-05-27: Bristol-Myers Squibb, Incyte Enter Clinical Collaboration Agreement

Financial news for BMY dated on 2014-05-19: 13G Filing from Alder Biopharma on Bristol Myers Shows 5.35% Stake

Financial news for BMY dated on 2014-05-19: Breaking Biotech: Bristol Does It Again

Financial news for BMY dated on 2014-05-19: Bristol-Myers, AbbVie Will Receive FDA Breakthrough Therapy for Elotuzumab

Financial news for BMY dated on 2014-05-16: #PreMarket Primer: Friday, May 16: Wall Street Giants Take Up Positions In Telecom Sector

Financial news for BMY dated on 2014-05-15: Market Wrap For May 15: Bears Return In Full-Force As Dow Suffers Triple-Digit Point Loss

Financial news for BMY dated on 2014-05-15: Mid-Afternoon Market Update: Markets Remain Red Despite Slight Recovery; Zendesk IPO Goes Off Without A Hitch

Financial news for BMY dated on 2014-05-15: Mid-Day Market Update: Dow Drops Over 200 Points; Cisco Shares Jump On Upbeat Results

Financial news for BMY dated on 2014-05-15: UPDATE: BMO Downgrades Bristol-Myers Squibb

Financial news for BMY dated on 2014-05-15: Mid-Morning Market Update: Markets Tumble; Wal-Mart Posts Lower Profit

Financial news for BMY dated on 2014-05-15: UPDATE: Morgan Stanley Reiterates On Bristol-Myers Squibb On Disappointing Combo Data

Financial news for BMY dated on 2014-05-15: Morning Market Losers

Financial news for BMY dated on 2014-05-15: Benzinga's Top #PreMarket Losers

Financial news for BMY dated on 2014-05-15: Benzinga's Top Downgrades

Financial news for BMY dated on 2014-05-15: Barclays, Cowen, Leerink, and William Blair Maintain Outperform/Overweight Ratings on Bristol Myers Squibb

Financial news for BMY dated on 2014-05-15: Redburn Maintains Neutral on Bristol-Myers Squibb Company

Financial news for BMY dated on 2014-05-15: Bernstein Maintains Market Perform on Bristol-Myers Squibb Company, Maintains \$48.00 PT

Financial news for BMY dated on 2014-05-15: BMO Capital Downgrades Bristol-Myers Squibb Company to Market Perform, Lowers PT to \$55.00

Financial news for BMY dated on 2014-05-14: Bristol-Myers Squibb Announces Nivolumab in Combo with Yervoy in Phase 2 and 1b Trials Shows Anti-Tumor Activity

Financial news for BMY dated on 2014-05-14: Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab

Financial news for BMY dated on 2014-05-14: Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab

Financial news for BMY dated on 2014-05-14: Bristol-Myers, Celldex Therapeutics Reports Clinical Trial Collaboration

Financial news for BMY dated on 2014-05-12: #Premarket Prep Technical Update - Bristol-Myers Squibb Trading Higher

Financial news for BMY dated on 2014-04-29: ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, TWTR)

Financial news for BMY dated on 2014-04-29: UPDATE: Bristol-Myers Posts Higher Q1 Profit

Financial news for BMY dated on 2014-04-29: Bristol-Myers Squibb Company Reports Q1 EPS of \$0.46 vs \$0.43 Est

Financial news for BMY dated on 2014-04-29: US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

Financial news for BMY dated on 2014-04-29: Bristol-Myers Squibb Acquires iPierian for \$175M, Potential Milestone Payments of \$550M

Financial news for BMY dated on 2014-04-29: Earnings Scheduled For April 29, 2014

Financial news for BMY dated on 2014-04-29: Stocks To Watch For April 29, 2014

Financial news for BMY dated on 2014-04-27: Earnings Expectations For The Week Of April 28: Big Oil, Big Pharma And More

Financial news for BMY dated on 2014-04-25: Benzinga Weekly Preview: Earnings Season Continues As Biotech & Pharmaceutical Companies Report

Financial news for BMY dated on 2014-04-22: Bristol-Myers Squibb, Samsung BioLogics Expand Manufacturing Agreement

Financial news for BMY dated on 2014-04-14: UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose Combo Tablet for Atazanavir Sulfate with Cobicistate

Financial news for BMY dated on 2014-04-14: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose Combo Tablet for Atazanavir Sulfate with Cobicistate for People Living with HIV-1

Financial news for BMY dated on 2014-04-10: Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C Patients

Financial news for BMY dated on 2014-04-07: Bristol-Myers Announces NDAS Submitted for Daclatasvir, Asunaprevir

Financial news for BMY dated on 2014-03-31: Innate Pharma Announces Bristol-Myers Squibb Conducting Phase I Trial with Lirilumab and Nivolumab in Selected Solid Tumors

Financial news for BMY dated on 2014-03-27: Bristol-Myers Squibb, Pfizer Announce Found Consistent Results for Eliquis as Warfarin

Financial news for BMY dated on 2014-03-24: Bristol-Myers Squibb Announces 12 Abstracts have been Accepted for Presentation at ILC

Financial news for BMY dated on 2014-03-21: Hearing Unconfirmed Market Chatter of Icahn Stake in Bristol-Myers Squibb

Financial news for BMY dated on 2014-03-17: US Stock Futures Jump Ahead Of Economic Data

Financial news for BMY dated on 2014-03-17: Five Prime Therapeutics, Bristol-Myers Squibb Announce Collaboration Agreement

Financial news for BMY dated on 2014-03-14: FDA Approves Eliquis to Reduce Risk of Blood Clots Following Hip or Knee Replacement Surgery

Financial news for BMY dated on 2014-03-06: Bristol-Myers Squibb Trading Lower

Financial news for BMY dated on 2014-02-25: Market Wrap For February 25: Markets End The Day Relatively Flat

Financial news for BMY dated on 2014-02-24: Market Wrap For February 24: Markets Showing Strength To Start The Week

Financial news for BMY dated on 2014-02-24: Bristol-Myers Receives US FDA Breakthrough Therapy Designation for Daclatasvir Regimen for Chronic Hep C

Financial news for BMY dated on 2014-02-21: Britsol-Meyers, Pfizer Report Eliquis Reduced Risk of Stroke and Demonstrated Fewer Major Bleeding Events vs Warfarin

Financial news for BMY dated on 2014-02-10: UPDATE: BMO Capital Markets Upgrades Bristol-Myers Squibb on More Positive Outlook

Financial news for BMY dated on 2014-02-10: BMO Capital Upgrades Bristol-Myers Squibb

Company to Outperform, Raises PT to \$60.00

Financial news for BMY dated on 2014-02-03: Bristol-Myers Squibb Completes Sale of Global Diabetes Business to AstraZeneca

Financial news for BMY dated on 2014-01-27: #PreMarket Primer: Monday, January 27: Markets Open The Week On Edge

Financial news for BMY dated on 2014-01-24: Top Earnings-Related Movers for Week of Jan. 20th

Financial news for BMY dated on 2014-01-24: Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

Financial news for BMY dated on 2014-01-24: UPDATE: Bristol-Myers Spikes Lower; 29,170 Contract Sale in Feb \$60 Call

Financial news for BMY dated on 2014-01-24: From Bristol-Myers Call: Reaffirms FY Outlook, Sees Gross Margin Slightly Above 75%

Financial news for BMY dated on 2014-01-24: Bristol Meyers Squibb Spikes to Low

Financial news for BMY dated on 2014-01-24: Bristol-Myers Squibb Company Reports Q4 EPS of \$0.51 vs \$0.43 Est; Revenue of \$4.44B vs \$4.29B Est

Financial news for BMY dated on 2014-01-24: #PreMarket Primer: Friday, January 24: Growth Fears Drag Down Emerging Markets

Financial news for BMY dated on 2014-01-24: Earnings Scheduled For January 24, 2014

Financial news for BMY dated on 2014-01-24: Stocks To Watch For January 24, 2014

Financial news for BMY dated on 2014-01-15: UPDATE: Galectin Therapeutics Supports Investigational New Drug Application for its Galectin Inhibitor GR-MD-02 in Metastatic Melanoma

Financial news for BMY dated on 2014-01-14: Bristol-Myers CEO Andreotti at JP Morgan Healthcare Conf. Says Buybacks Are Possible

Financial news for BMY dated on 2014-01-13: Portola Pharma Announces Second Clinical Pact with Bristol-Myers, Will Study Andexanet Alfa with Eliquis, Will Receive Upfront, Milestone Payments

Financial news for BMY dated on 2014-01-10: Barclays Upgrades Bristol-Myers Squibb Company to Overweight, Raises PT to \$65.00

Financial news for BMY dated on 2014-01-08: AstraZeneca, Bristol-Myers Report FDA Approval of Farxiga

Financial news for BMY dated on 2014-01-08: Market Wrap For January 8: Fed Minutes Released

Financial news for BMY dated on 2014-01-08: FDA Approves Farxiga to Treat Type 2 Diabetes

Financial news for BMY dated on 2014-01-08: Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by EMA

Financial news for BMY dated on 2014-01-07: From Bristol-Myers Presentation: CEO Says Co. Will Use Cash on Dividends, Will Reconsider a Buyback Plan

Financial news for BMY dated on 2014-01-07: Bristol-Myers CEO Andreotti Speaking at Goldman Conference: Says Opportunities for Top Line, Sees Improvements in Cost of Goods, SG&A Lines

Financial news for BMY dated on 2013-12-24: Benzinga's Top #PreMarket Losers

Financial news for BMY dated on 2013-12-23: Fitch Affirms Bristol-Myers; Lowers Outlook to Negative

Financial news for BMY dated on 2013-12-23: Benzinga's Top #PreMarket Losers

Financial news for BMY dated on 2013-12-20: Market Wrap For December 20: Markets Gain On GDP Data

Financial news for BMY dated on 2013-12-20: UPDATE: Credit Suisse Reiterates on Bristol-Myers Squibb on Divestiture of Stake in Diabetes Joint Venture

Financial news for BMY dated on 2013-12-20: Credit Suisse Maintains Outperform on Bristol-Myers Squibb Company, Raises PT to \$60.00

Financial news for BMY dated on 2013-12-19: Bristol-Myers, Pfizer Announces FDA Acceptance for Review Eliquis sNDA to Treat DVT

Financial news for BMY dated on 2013-12-19: Market Wrap For December 18: Markets Flat During Day One Post Fed Taper

Financial news for BMY dated on 2013-12-19: From Bristol-Myers Call: CEO Says Will Look for Deals in Core Therapy Area, Won't Do Deals in Primary Care

Financial news for BMY dated on 2013-12-19: Bristol-Myers, AstraZeneca Shares Higher Following Confirmation AstraZeneca Will Buy JV Diabetes Stake for Up to \$4.3B

Financial news for BMY dated on 2013-12-18: WSJ Reporting Bristol Myers Could Be Near a Deal to Sell Diabetes JV Stake to AstraZeneca in \$3B Deal

Financial news for BMY dated on 2013-12-12: FDA Panel Votes 10-4 Dapagliflozin's Heart Risk Acceptable;

Financial news for BMY dated on 2013-12-11: Bloomberg First Word Reporting Bristol Myers, AstraZeneca Have Won FDA Panel Support for Metreleptin in Lipodystrophy

Financial news for BMY dated on 2013-12-10: Bloomberg Reporting Express Scripts' Miller in Phone Interview Said Aiming to Cut Costs for Hep C Drugs, Planning to Pit Gilead Against Other Drugmakers

Financial news for BMY dated on 2013-12-09: Option Alert: Bristol-Myers Squibb January \$52.5 Call; 20,098 Contracts Traded Monday vs 6,067 Open Interest; Currently \$51.56

Financial news for BMY dated on 2013-12-09: FDA Posts Staff Review of AstraZeneca/Bristol's Metreleptin on Website

Financial news for BMY dated on 2013-11-18: Investing in Companies Developing Promising Immunotherapy Drugs for Melanoma

Financial news for BMY dated on 2013-11-13: Bristol-Myers Squibb Says CFO Bancroft Will Take on Expanded Role in Biz Dev, Strategy Groups, Names Caforio Exec VP, Chief Commercial Officer, Murdo Gordon Named Pres of US

Financial news for BMY dated on 2013-11-07: UPDATE: '\$BMY BRISTOL-MYERS SAYS TO CONTINUE FOCUS ON HIV, HEPATITIS B, HEART FAILURE, ONCOLOGY, IMMUNOSCIENCE AND FIBROTIC DISEASES'

Financial news for BMY dated on 2013-11-07: Colfax Tweet: '\$BMY BRISTOL-MYERS

Financial news for BMY dated on 2013-11-07: Colfax Tweet: 'BMY BRISTOL-MYERS SAYS TO CONTINUE FOCUS ON HIV, HEPATITIS B, HEART FAILURE, ONCOLOGY, IMMUNOSCIENCE AND FIBROTIC DISEASES'

Financial news for BMY dated on 2013-10-28: Market Wrap for October 28: Investors Push Apple Shares Lower

Financial news for BMY dated on 2013-10-28: Mid-Afternoon Market Update: Markets Mixed as JC Penney Rises

Financial news for BMY dated on 2013-10-28: Mid-Day Market Update: Burger King Surges On Upbeat Earnings; Sohu Shares Dip

Financial news for BMY dated on 2013-10-28: Mid-Morning Market Update: Markets Mixed; Merck Profit Beats Estimates

Financial news for BMY dated on 2013-10-28: UPDATE: Morgan Stanley Upgrades Bristol-Myers Squibb Co. on Potential of New Cancer Drugs

Financial news for BMY dated on 2013-10-28: Benzinga's Top Upgrades

Financial news for BMY dated on 2013-10-28: Credit Suisse Added Bristol-Myers Squibb, Vantiv to 'US Focus List,' ADP, Rowan Companies Removed

Financial news for BMY dated on 2013-10-28: Promising Phase IIb Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis To Be Presented At The 2013 Annual Meeting Of The American College Of Rheumatology

Financial news for BMY dated on 2013-10-28: Morgan Stanley Upgrades Bristol-Myers Squibb Company to Overweight, Raises PT to \$60.00

Financial news for BMY dated on 2013-10-26: Bristol-Myers Presents Data on Nivolumab from Lung Cancer Cohort of Phase 1 Study at 15th World Conference on Lung Cancer

Financial news for BMY dated on 2013-10-24: Market Primer: Thursday, October 24: Investors Switch Focus To Earnings

Financial news for BMY dated on 2013-10-23: UPDATE: Bristol-Myers Posts Q3 Profit

Financial news for BMY dated on 2013-10-23: Bristol-Myers Squibb Company Reports Q3 EPS of \$0.46 vs \$0.44 Est; Revenue of \$4.07B vs \$4.02B Est

Financial news for BMY dated on 2013-10-23: Market Primer: Wednesday, October 23: Fed Taper Outlook Looking Cloudy

Financial news for BMY dated on 2013-10-23: Earnings Scheduled For October 23, 2013

Financial news for BMY dated on 2013-10-20: Earnings Expectations For The Week Of October 21: The Crunch Is On

Financial news for BMY dated on 2013-10-18: Benzinga Weekly Preview: Earnings Season Continues, Delayed US Data To Hit Markets

Financial news for BMY dated on 2013-10-11: Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

Financial news for BMY dated on 2013-10-08: Credit Suisse Starts Pfizer, Bristol-Myers, AbbVie, Allergan at Outperform, Merck, Eli Lilly, Forest Labs at Neutral

Financial news for BMY dated on 2013-09-27: Bristol-Myers Says Expecting Three-Year Survival Rate of 22% for Yervoy Study

Financial news for BMY dated on 2013-09-24: AstraZeneca, Bristol-Myers Squibb Announce Positive Phase III Dapagliflozin Data

Financial news for BMY dated on 2013-09-23: Moody's Affirms Ratings on Bristol-Myers; Outlook Lowered from Stable to Negative

Financial news for BMY dated on 2013-09-17: Innate Pharma Announces First DSMB Review of Ongoing EffiKIR Phase II Trial with lirilumab

Financial news for BMY dated on 2013-09-16: UPDATE: J.P. Morgan Upgrades Bristol-Myers Squibb Ahead of Multiple Important Catalysts

Financial news for BMY dated on 2013-09-12: US Stock Futures Mostly Flat; Jobless Claims Data In Focus

Financial news for BMY dated on 2013-09-12: Bristol-Myers Squibb Announces Results of Phase 3 Trial of Yervoy

Financial news for BMY dated on 2013-08-31: Bristol-Myers, Pfizer Report Stroke, Systemic Embolism, Major Bleeding Uncommon in Eliquis Phase 3 ARISTOTLE Trial

Financial news for BMY dated on 2013-08-27: Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)

Financial news for BMY dated on 2013-08-18: Benzinga's Weekend M&A Chatter

Financial news for BMY dated on 2013-08-14: How Much Does It Cost To Develop A New Drug?

Financial news for BMY dated on 2013-08-12: UPDATE: Albany Molecular Research Shares Down Roughly 20% At \$10.27, Fell As Much As 23.3% At Low On Disclosure That Bristol-Myers Squibb Has Canceled Development of Drug With Company

Financial news for BMY dated on 2013-08-12: Albany Molecular Files Form 8-K Disclosing Termination Of Development Of BMS-820836 With Bristol-Myers Squibb

Financial news for BMY dated on 2013-08-02: Three Soaring, But Overlooked Health Care ETFs

Financial news for BMY dated on 2013-07-29: Bristol-Myers Squibb and Samsung BioLogics Announce Biopharmaceutical Manufacturing Relationship

Financial news for BMY dated on 2013-07-26: BMO Capital Maintains Market Perform on Bristol-Myers Squibb Company, Lowers PT to \$48.00

Financial news for BMY dated on 2013-07-26: Benzinga Market Primer: Friday, July 26: Futures Flat On Mixed Global Stocks Overnight

Financial news for BMY dated on 2013-07-25: U.S. FDA Acknowledges Receipt of Resubmission of the New Drug Application From AstraZeneca

Financial news for BMY dated on 2013-07-25: Bristol-Myers Call Concludes, Exec Said Working with Pfizer In Order to Improve Sales of Eliquis

Financial news for BMY dated on 2013-07-25: From Bristol-Myers Call: CEO Says M&A Strategy Has Not Changed, Continues to Look at Outside Deals

Financial news for BMY dated on 2013-07-25: Bristol-Myers Squibb Company Reports Q2 EPS of \$0.44, Inline; Revenue of \$4.05B vs \$4.05B Est

Financial news for BMY dated on 2013-07-25: Benzinga Market Primer: Thursday, July 25: Futures Lower After Technical Breakdown

Financial news for BMY dated on 2013-07-25: US Stock Futures Down; GM Earnings, Economic Data In Focus

Financial news for BMY dated on 2013-07-25: Earnings Scheduled For July 25, 2013

Financial news for BMY dated on 2013-07-22: Earnings Expectations for the Week of July 22 (AAPL, GM, MCD, NFLX)

Financial news for BMY dated on 2013-07-16: Benzinga's M&A Chatter for Tuesday July 16, 2013

Financial news for BMY dated on 2013-07-16: UPDATE: Amgen, Pfizer, Bristol-Myers Squibb, Gilead Among Companies that May Submit Bids for Onyx, According to Sources

Financial news for BMY dated on 2013-07-12: UPDATE: Jefferies Downgrades Bristol-Myers Squibb on Challenges Ahead

Financial news for BMY dated on 2013-07-12: Benzinga's Top Downgrades

Financial news for BMY dated on 2013-07-12: Jefferies Downgrades Bristol-Myers Squibb Company to Hold, Lowers PT to \$49.00

Financial news for BMY dated on 2013-07-11: FDA Accepts Eliquis(r) (apixaban) Supplemental New Drug Application for Review for Prophylaxis of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery

Financial news for BMY dated on 2013-07-01: Bristol-Myers Squibb IDR Cut to A- from A, Outlook to Stable from Negative - Fitch

Financial news for BMY dated on 2013-07-01: Spectrum Pharmaceuticals Elects Two New Healthcare Industry Veterans to the Board of Directors

Financial news for BMY dated on 2013-06-30: Bristol-Myers Squibb, Pfizer Announce Eliquis Meets Primary Efficacy Endpoint

Financial news for BMY dated on 2013-06-26: Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)

Financial news for BMY dated on 2013-06-22: AstraZeneca, Bristol-Myers Squibb, Announce Results from Phase IIa Study Assessing Safety and Tolerability of Dapagliflozin

Financial news for BMY dated on 2013-06-20: Bristol-Myers, Otsuka America Announce FDA Approves US Product Labeling Update for Sprycel to Include Three--Year First-Line, Five-Year Second-Line Efficacy, Safety Data in Chronic Myeloid Leukemia in Chronic Phase

Financial news for BMY dated on 2013-06-17: Bristol's Amylin Named in Suit Related to Januvia

Financial news for BMY dated on 2013-06-15: Bristol-Myers Squibb, AbbVie Announce Progression-Free Survival Data from Phase 2 Multiple Myeloma Study

Financial news for BMY dated on 2013-06-14: Bristol-Myers, Simcere Announce Partnership to Co-Develop, Co-Commercialize Orenia in China

Financial news for BMY dated on 2013-06-12: Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)

Financial news for BMY dated on 2013-06-12: AstraZeneca, Bristol-Myers Squibb Release Statement to American Diabetes Association

Financial news for BMY dated on 2013-06-12: FDA Says Considering New Study of Incretin Mimetic Diabetes Drug, Says May Need to Look for Cancer-Link Patterns

Financial news for BMY dated on 2013-06-12: A Peek Into The Market Before The Trading Starts

Financial news for BMY dated on 2013-06-12: Bristol-Meyers Squibb Announces ORENCIA Shows Comparable Efficacy to Humira in Year Two Ample Study

Financial news for BMY dated on 2013-06-08: Top-Performing Dividend Payers in Health Care with the Most Upside Potential (AET, ENSG, QCOR)

Financial news for BMY dated on 2013-06-07: UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb Following Global Pharma Review

Financial news for BMY dated on 2013-06-07: Jefferies Maintains Buy on Bristol-Myers Squibb Company, Lowers PT to \$53.00

Financial news for BMY dated on 2013-06-06: Bloomberg Reporting Bristol-Myers Health Canada Expands Indications of Abilify, Now Will Treat MDD

Financial news for BMY dated on 2013-06-04: U.S. FDA Grants Priority Review to Bristol-Myers Squibb and AstraZeneca's Metreleptin, an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of Lipodystrophy

Financial news for BMY dated on 2013-06-02: Bristol-Myers Squibb Reports Phase 1 Results from Advanced Melanoma Trial

Financial news for BMY dated on 2013-05-29: SunTrust Robinson Humphrey Initiates Coverage on Bristol-Myers Squibb Company at Buy, Announces \$55.00 PT

Financial news for BMY dated on 2013-05-29: Short Interest in Vertex Rises, in Biogen Idec Falls

Financial news for BMY dated on 2013-05-28: UPDATE: Jefferies Raises PT on Bristol Myers Squibb Following SOTP Analysis

Financial news for BMY dated on 2013-05-28: Jefferies Maintains Buy on Bristol-Myers Squibb Company, Raises PT to \$53.50

Financial news for BMY dated on 2013-05-22: Market Wrap for Wednesday, May 22: Stocks Pullback As Bernanke Says Bond Buying Could Slow

Financial news for BMY dated on 2013-05-22: Benzinga's Top Upgrades

Financial news for BMY dated on 2013-05-22: Citigroup Upgrades Bristol-Myers Squibb Company to Buy, Raises PT to \$55.00

Financial news for BMY dated on 2013-05-21: Bristol-Myers CFO Speaking at UBS Global Healthcare Conference Says Committed to 3% Boost in 2013 Dividend

Financial news for BMY dated on 2013-05-16: Leerink Swann Upgrades Bristol-Myers Squibb Company to Outperform

Financial news for BMY dated on 2013-05-16: Bristol Meyers Moving off Lows on Volume; May be Attributed to Leerink Upgrade to Outperform

Financial news for BMY dated on 2013-05-15: Market Wrap for Wednesday, May 15: Bull Market Continues as Dow and S&P Hit New Highs

Financial news for BMY dated on 2013-05-15: Bristol Myers Exec to Speak at BofA Merrill's Health Care Conference at 1PM EDT; Shares Up Nearly 8%, Continuing Higher Following 3% Move Higher on Tuesday, 1% Gain on Monday

Financial news for BMY dated on 2013-05-11: Short Interest in Vertex Rises, in Celgene Falls

Financial news for BMY dated on 2013-05-06: TD Ameritrade's IMX Survey Declines to 5.31 in April

Financial news for BMY dated on 2013-05-03: Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates

Financial news for BMY dated on 2013-05-03: Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA (efavirenz) in HIV-1 Infected Pediatric Patients

Financial news for BMY dated on 2013-04-29: Form 8-K Shows Vanda Reported Bristol-Myers Waived Options on Tasimelteon

Financial news for BMY dated on 2013-04-28: A Look Ahead: This Week's ETFs to Watch

Financial news for BMY dated on 2013-04-26: Short Sellers Move into Celgene, Regeneron

Financial news for BMY dated on 2013-04-25: Bristol-Myers Squibb Company Reports Q1 EPS of \$0.41, Inline; Revenue of \$3.83B vs \$3.88B Est

Financial news for BMY dated on 2013-04-23: Gilead, Bristol Hepatitis-C Drug Combination Suppresses Virus in Study, Helps Those Who Fail Other Drugs

Financial news for BMY dated on 2013-04-22: Bristol-Myers Trying to Break Through Triple-Top Resistance at \$41.50

Financial news for BMY dated on 2013-04-11: ETF Showdown: A Pharma Fight

Financial news for BMY dated on 2013-04-11: Bristol-Myers to Expand Massachusetts Biologics Facility, to Invest \$250M, Increase Workforce

Financial news for BMY dated on 2013-04-10: UPDATE: Jefferies Raises PT on Bristol-Myers Squibb on Positive Outlook

Financial news for BMY dated on 2013-04-10: UBS Maintains Neutral on Bristol-Myers Squibb Company, Raises PT to \$40.00

Financial news for BMY dated on 2013-04-10: Jefferies Maintains Buy on Bristol-Myers Squibb Company, Raises PT to \$45.00

Financial news for BMY dated on 2013-04-08: These Are the 100 Highest-Paid CEOs in Business Today

Financial news for BMY dated on 2013-04-08: UPDATE: BMO Capital Raises PT on Bristol Myers Squibb Co. on 1Q13 Caution

Financial news for BMY dated on 2013-04-08: BMO Capital Maintains Market Perform on Bristol-Myers Squibb Company, Raises PT to \$43.00

Financial news for BMY dated on 2013-04-08: Stocks To Watch For April 8, 2013

Financial news for BMY dated on 2013-04-07: Bristol-Myers Squibb Names Francis Cuss as New CSO

Financial news for BMY dated on 2013-04-05: Vertex, Bristol-Myers Enter Deal for Phase 2 All-Oral Studies of VX-135

Financial news for BMY dated on 2013-04-02: German Drug Panel Sees Pfizer, Bristol-Myers Eliquis Benefits in Patients 65+

Financial news for BMY dated on 2013-04-01: A Peek Into The Market Before The Trading Starts

Financial news for BMY dated on 2013-04-01: LabCorp Clinical Trials Enters 5-Year Agreement with Bristol-Myers Squibb

Financial news for BMY dated on 2013-03-26: The Supreme Court is About to Stick it to Big Pharma

Financial news for BMY dated on 2013-03-26: EMA Investigating Pancreatic Risks with GLP-1 Diabetes Drugs

Financial news for BMY dated on 2013-03-20: FDA Approves Zymodenetics Request Regarding Thrombin Topical -Bloomberg

Financial news for BMY dated on 2013-03-20: FDA Approves Bristol Myers' Unit Request to Supplement BLA -Bloomberg

Financial news for BMY dated on 2013-03-20: NIRI Appoints Charles Triano to Board of Directors

Financial news for BMY dated on 2013-03-19: S&P Likes a Pair of Low Vol ETFs

Financial news for BMY dated on 2013-03-12: A Look at a New Super Dividend ETF

Financial news for BMY dated on 2013-03-08: NICE Recommending Bristol-Myers' Abatacept, Shares Unaffected

Financial news for BMY dated on 2013-03-08: Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield

Financial news for BMY dated on 2013-03-06: William Blair Initiates Coverage on

Bristol-Myers Squibb Company at Outperform

Financial news for BMY dated on 2013-03-05: William Blair Initiates Coverage on Bristol-Myers Squibb Company at Outperform

Financial news for BMY dated on 2013-03-04: An HIV Cure Is Great News For These Drug Manufacturers

Financial news for BMY dated on 2013-03-04: UPDATE: Bank of America Downgrades Bristol-Myers Squibb to Neutral on Limited Upside

Financial news for BMY dated on 2013-03-04: Bank of America Downgrades Bristol-Myers Squibb Company to Neutral, Raises PO to \$39.00

Financial news for BMY dated on 2013-03-02: Benzinga's M&A Chatter for Friday March 1, 2013

Financial news for BMY dated on 2013-03-01: Bristol Meyers Squibb Reportedly Considered Large Acquisitions of Biogen and Shire

Financial news for BMY dated on 2013-02-12: UPDATE: Jefferies Raises PT to \$41 on Bristol-Myers Squibb on Long-Term Growth Prospects

Financial news for BMY dated on 2013-02-12: Jefferies Maintains Buy on Bristol-Myers Squibb Company, Raises PT to \$41.00

Financial news for BMY dated on 2013-02-12: A Peek Into The Market Before The Trading Starts

Financial news for BMY dated on 2013-02-12: Bristol-Myers Squibb Enters 3-Year Agreement with Reckitt Benckiser Group for Over-the-Counter Medicines

Financial news for BMY dated on 2013-02-08: The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

Financial news for BMY dated on 2013-01-29: Novo Spokesperson Says Will Introduce Tresiba in Some EU Countries in First Half - Bloomberg

Financial news for BMY dated on 2013-01-25: UBS Maintains Neutral on Bristol-Myers Squibb Company, Raises PT to \$36.00

Financial news for BMY dated on 2013-01-24: Bristol-Myers Squibb Company Reports Q4 EPS of \$0.47 vs \$0.44 Est; Revenue of \$4.20B vs \$4.14B Est

Financial news for BMY dated on 2013-01-24: US Stock Futures Mixed After Disappointing Apple Results

Financial news for BMY dated on 2013-01-24: Earnings Scheduled For January 24, 2013

Financial news for BMY dated on 2013-01-20: Earnings Expectations for the Week of January 21

Financial news for BMY dated on 2013-01-18: EMA Says Bristol-Myers Wins Backing for Extended Komboglyze Use

Financial news for BMY dated on 2013-01-16: UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Bristol Myers Squibb Co.

Financial news for BMY dated on 2013-01-16: Jefferies Maintains Buy on Bristol-Myers Squibb Company, Raises PT to \$39.00

Financial news for BMY dated on 2013-01-15: WSJ Reporting Bristol-Myers Said to Be Holding Talks Related to Hepatits Claims

Financial news for BMY dated on 2013-01-08: From Slides Ahead of JPMorgan Healthcare Conference: Bristol-Myers Sees Raising Dividend by 3% for 2013

Financial news for BMY dated on 2013-01-07: Bristol-Myers Said to Plan Experimental Migraine Drug, Awaiting Study Results on BMS-927711

Financial news for BMY dated on 2013-01-04: A Peek Into The Market Before The Trading Starts

Financial news for BMY dated on 2013-01-04: Tranzyme Completes Drug Discovery Collaboration With Bristol-Myers Squibb

Financial news for BMY dated on 2012-12-31: J.P. Morgan Reiterates Neutral Rating on Bristol Myers Squibb Co.

Financial news for BMY dated on 2012-12-31: Benzinga's Top Upgrades

Financial news for BMY dated on 2012-12-31: Benzinga's Top Upgrades

Financial news for BMY dated on 2012-12-28: Bristol, Pfizer Win FDA Approval for Eliquis -Bloomberg

Financial news for BMY dated on 2012-12-26: ELIQUIS Receives Approval In Japan for Prevention of Stroke, Systemic Embolism In Patients with Nonvalvular Atrial Fibrillation

Financial news for BMY dated on 2012-12-24: Aegerion Pharmaceuticals Wins Approval for Cholesterol Drug

Financial news for BMY dated on 2012-12-19: UPDATE: Goldman Sachs Reiterates Buy Rating, Lowers PT on Bristol-Myers Squibb Co.

Financial news for BMY dated on 2012-12-19: Goldman Sachs Maintains CL-Buy on Bristol-Myers Squibb Company, Lowers PT to \$39.00

Financial news for BMY dated on 2012-12-12: The Medicines Company, Bristol-Myers Squibb Announce Global Alliance for Recothrom

Financial news for BMY dated on 2012-12-09: Bristol-Myers, Abbott Announce Results from Phase 2 Multiple Myeloma Study

Financial news for BMY dated on 2012-12-08: Bristol-Myers, Pfizer Announce Positive Phase 3 Trial Results for ELIQUIS

Financial news for BMY dated on 2012-12-07: Citigroup Reiterates Neutral Rating, \$33 PT on Bristol Myers Squibb

Financial news for BMY dated on 2012-12-04: Bristol-Myers Raises Qtr. Dividend from \$0.34 to \$0.35/Share

Financial news for BMY dated on 2012-12-03: Bristol Myers to Terminate Avagacestat Clinical Development - Bloomberg

Financial news for BMY dated on 2012-12-03: UPDATE: Bristol Myers Says Study Data Didn't Warrant Phase 3 Study

Financial news for BMY dated on 2012-11-29: CORRECTION: Citi Initiates Coverage on Bristol-Myers Squibb Company at Neutral, Announces \$33.00 PT

Financial news for BMY dated on 2012-11-20: Bristol-Myers, Pfizer's Eliquis Approved in Europe for Prevention of Stroke

Financial news for BMY dated on 2012-11-14: Bristol-Myers, AstraZeneca's Forxiga Wins EU Approval for Treatment of Type 2 Diabetes

Financial news for BMY dated on 2012-11-12: Bristol-Myers Squibb's Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study

Financial news for BMY dated on 2012-11-12: Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

Financial news for BMY dated on 2012-11-12: UPDATE: BMO Capital Markets Downgrades Bristol-Myers Squibb to Market Perform, Lowers PT

Financial news for BMY dated on 2012-11-12: New Head-to-Head Patient Reported Outcomes Data for Orenicia

Financial news for BMY dated on 2012-11-12: BMO Capital Markets Downgrades Bristol-Myers Squibb from Outperform to Market Perform, Lowers PT from \$38 to \$37

Financial news for BMY dated on 2012-11-12: A Peek Into The Market Before The Trading Starts

Financial news for BMY dated on 2012-11-12: Bristol-Myers Squibb Presents Phase II Hepatitis C Data

Financial news for BMY dated on 2012-11-03: Moves in Smaller Health Care Stocks (GMED, SEM, UAM, VRTX)

Financial news for BMY dated on 2012-11-01: Bristol-Myers Squibb Receives Positive Decision from NIH for YERVOY

Financial news for BMY dated on 2012-10-24: UPDATE: Bristol-Myers Says FDA Willing to

Reconsider Benefit/Risk for Dapagliflozin

Financial news for BMY dated on 2012-10-24: UPDATE: Bristol-Myers Says Ready to Launch Eliquis on Approval; May Take Hep C Treatment to Phase 3 in 2014

Financial news for BMY dated on 2012-10-24: Bristol-Myers Says Strategy Has Not Changed; Sanofi Restructure Minimal in 2013; Abilify Performance Was Table in Line with View

Financial news for BMY dated on 2012-10-24: Bristol-Myers Guides FY Adj. EPS Upper End of \$1.90-2.00 vs \$1.93 Est.

Financial news for BMY dated on 2012-10-24: Bristol-Myers Squibb Reports Q3 EPS \$0.41 vs \$0.42 Est; Revenues \$3.74B vs \$3.98B Est

Financial news for BMY dated on 2012-10-24: US Stock Futures Up Ahead Of Boeing Earnings

Financial news for BMY dated on 2012-10-24: Earnings Scheduled For October 24, 2012

Financial news for BMY dated on 2012-10-22: Earnings Expectations for the Week of October 22

Financial news for BMY dated on 2012-10-15: Bristol-Myers Says FDA Approves Labeling Update for Baraclude; Includes Data on African Americans, Liver Transplant Recipients

Financial news for BMY dated on 2012-10-15: Bristol-Myers Says 88% of Patients Who Took Drugs for 12 Weeks Cleared Hep C Virus

Financial news for BMY dated on 2012-10-15: From Earlier: Fate Therapeutics Names Weyer President, CEO

Financial news for BMY dated on 2012-10-08: Eli Lilly Says Ending Partnership with Amylin Wasn't Easy; Broad Diabetes Pipeline is Advantage; End of Amylin Deal Was Bet on Dulaglutide

Financial news for BMY dated on 2012-10-05: Bristol-Myers Squibb Says Orencia Approved by EU

Financial news for BMY dated on 2012-10-04: From Earlier: Sanofi Says Lyxumia Dose Isn't Issue for Regulators; Lyxumia Isn't At All Like Byetta

Financial news for BMY dated on 2012-10-04: Morgan Stanley Maintains Bristol-Myers Squibb at Equal-weight, Lowers PT from \$36 to \$35

Financial news for BMY dated on 2012-10-03: From Earlier: Bristol-Myers Squibb, Sanofi Will Restructure Alliance; Sanofi Will Get Rights to Plavix and Avapro

Financial news for BMY dated on 2012-10-01: ELIQUIS Reduces Stroke and Systemic Embolism Compared to Warfarin in ARISTOTLE trial

Financial news for BMY dated on 2012-10-01: Deutsche Bank Transfers Coverage of Bristol-Myers Squibb

Financial news for BMY dated on 2012-09-29: Bristol-Myers Presents 4 and 5-Year Survival Data for YERVOY in Treatment-Naive and Previously-Treated Metastatic Melanoma

Financial news for BMY dated on 2012-09-26: FDA Acknowledges Receipt of Resubmission of the ELIQUIS

Financial news for BMY dated on 2012-09-21: Vanderbilt University and Bristol-Myers Squibb Sign Collaboration Agreement to Develop Novel Treatments for Parkinson's Disease

Financial news for BMY dated on 2012-09-17: Life Technologies Will Partner with Bristol-Myers Squibb

Financial news for BMY dated on 2012-09-13: UPDATE: Vical Rises 10% Pre-Market on Licensing Pact with Bristol-Myers Squibb

Financial news for BMY dated on 2012-09-13: Benzinga's Top Pre-Market Gainers

Financial news for BMY dated on 2012-09-13: A Peek Into The Market Before The Trading Starts

Financial news for BMY dated on 2012-09-13: Vical Signs Licensing Pact with Bristol-Myers Squibb for DNA Immunization Technology

Financial news for BMY dated on 2012-09-11: Bristol-Myers Squibb Foundation Announces Five New Grants to Advance Cancer Nursing Skills in Central and Eastern Europe

Financial news for BMY dated on 2012-09-11: UPDATE: Goldman Sachs Upgrades Bristol-Myers Squibb to CL-Buy on Catalysts

Financial news for BMY dated on 2012-09-11: Goldman Sachs Upgrades Bristol-Myers Squibb from Buy to CL-Buy, Raises PT from \$38 to \$40

Financial news for BMY dated on 2012-09-11: Credit Suisse Reinstates Coverage on Bristol-Myers Squibb at Neutral, Announces PT of \$36

Financial news for BMY dated on 2012-08-27: Alder Biopharmaceuticals Receives \$3.5 Million Milestone Payment from Bristol-Myers Squibb

Financial news for BMY dated on 2012-08-24: UPDATE: Bank of America Merrill Lynch Upgrades Bristol-Myers Squibb to Buy, Reiterates \$36 PT

Financial news for BMY dated on 2012-08-24: Bristol-Myers' Trash is Gilead Sciences' Treasure

Financial news for BMY dated on 2012-08-24: Bristol-Myers Slapped With \$1.8B Charge on Failed Hepatitis C Drug

Financial news for BMY dated on 2012-08-24: Bank of America Upgrades Bristol-Myers Squibb from Neutral to Buy, Announces PO of \$36

Financial news for BMY dated on 2012-08-23: Bristol-Myers Squibb Discontinues Development of BMS-986094, an Investigational NS5B Nucleotide for the Treatment of Hepatitis C

Financial news for BMY dated on 2012-08-23: Synergy Pharma Buys FV-100 Drug from Bristol-Myers

Financial news for BMY dated on 2012-08-23: Hearing Unconfirmed Takeover Chatter in Regeneron

Financial news for BMY dated on 2012-08-17: Idenix Shares Plunge After Hepatitis Drug Study Put on Hold

Financial news for BMY dated on 2012-08-15: Bristol-Myers Squibb Announces Specialty Pharmacy Patient Management Programs For Sprycel

Financial news for BMY dated on 2012-08-13: Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield

Financial news for BMY dated on 2012-08-09: Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through Bristol-Myers Squibb's Acquisition of Amylin

Financial news for BMY dated on 2012-08-09: Bristol-Myers Squibb Completes Acquisition of Amylin Pharmaceuticals, Inc.

Financial news for BMY dated on 2012-08-08: Bristol-Myers Squibb Announces Successful Completion of Cash Tender Offer for Shares of Amylin Pharmaceuticals, Inc.

Financial news for BMY dated on 2012-08-06: Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb

Financial news for BMY dated on 2012-08-06: UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb from \$39 to \$38

Financial news for BMY dated on 2012-08-06: Jefferies & Company Maintains Bristol-Myers Squibb at Buy, Lowers PT from \$39 to \$38

Financial news for BMY dated on 2012-08-02: Bristol-Myers Executive Charged with Insider Trading

Financial news for BMY dated on 2012-08-02: Call Activity in Bristol-Myers

Financial news for BMY dated on 2012-08-02: UBS Maintains Bristol-Myers Squibb at Neutral, Lowers PT from \$36 to \$34

Financial news for BMY dated on 2012-08-02: UPDATE: SEC Charges Bristol-Myers Squibb Executive With Insider Trading in Stock Options of Potential Acquisition Targets

Financial news for BMY dated on 2012-08-02: Barclays Downgrades Bristol-Myers Squibb from Overweight to Equal-weight

Financial news for BMY dated on 2012-08-02: Leerink Swann Downgrades Bristol-Myers Squibb from Outperform to Market Perform

Financial news for BMY dated on 2012-07-31: Prosetta Antiviral Inc Enters into Multi-year Antiviral Drug Development Collaboration with Bristol-Myers Squibb

Financial news for BMY dated on 2012-07-26: Bristol-Myers Said to Sell Bonds at Record-Low Coupons -Bloomberg

Financial news for BMY dated on 2012-07-25: Bristol-Meyers in Call Says It Forecasts \$2.7B in Sales for Plavix

Financial news for BMY dated on 2012-07-25: Bristol-Myers Squibb Reports Q2 EPS \$0.48 vs \$0.48 Est; Revenues \$4.44B vs \$4.45B Est

Financial news for BMY dated on 2012-07-25: US Stock Futures Mixed; Apple Shares Drop In Pre-Market Trading

Financial news for BMY dated on 2012-07-25: Earnings Scheduled For July 25

Financial news for BMY dated on 2012-07-23: Earnings Expectations for the Week of July 23

Financial news for BMY dated on 2012-07-19: Bristol Considering Options for Brivanib Development Program; Says Study Doesn't Meet Primary Objective

Financial news for BMY dated on 2012-07-19: BRISK-FL Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Does Not Meet Overall Survival Primary Endpoint

Financial news for BMY dated on 2012-07-18: Morgan Stanley Maintains Bristol-Myers Squibb at Equal-weight, Raises PT from \$34 to \$36

Financial news for BMY dated on 2012-07-17: Popular Drug Manufacturing Stocks Among Hedge Funds

Financial news for BMY dated on 2012-07-13: Jefferies & Company Maintains Bristol-Myers Squibb at Buy, Raises PT from \$38 to \$39

Financial news for BMY dated on 2012-07-11: Best & Worst Sector ETFs & Mutual Funds

Financial news for BMY dated on 2012-07-10: Dendreon, Pharmacyclics and Other Biotech Takeover Targets

Financial news for BMY dated on 2012-07-05: These Are Four of the Hottest Biotechs in the Market Right Now

Financial news for BMY dated on 2012-07-02: Bristol-Myers to Acquire Amylin

Financial news for BMY dated on 2012-07-02: Trading the Trend: Regeneron, Alexion, TripAdvisor, Expedia All Pushing Higher

Financial news for BMY dated on 2012-07-02: Benzinga's Top Pre-Market Gainers

Financial news for BMY dated on 2012-07-02: Amylin Pharmaceuticals Rises 9% Pre-Market on Bristol-Myers Acquisition

Financial news for BMY dated on 2012-07-02: Financial Breakfast: Morning News Summary for July 2, 2012

Financial news for BMY dated on 2012-07-02: US Stock Futures Mixed; Dollar Rises Against Euro

Financial news for BMY dated on 2012-07-02: Deutsche Bank Maintains Bristol-Myers Squibb at Buy, Raises PT from \$37.50 to \$39

Financial news for BMY dated on 2012-07-02: Stocks To Watch For July 2

Financial news for BMY dated on 2012-06-30: Benzinga's M&A Chatter for Friday June 29, 2012

Financial news for BMY dated on 2012-06-30: Bristol-Myers Squibb to Acquire Amylin Pharmaceuticals for \$31/Share

Financial news for BMY dated on 2012-06-26: Benzinga's M&A Chatter for Tuesday June 26, 2012

Financial news for BMY dated on 2012-06-26: Bristol-Myers Squibb Announces the Authorization of an Additional \$3 billion for Share Repurchase Program

Financial news for BMY dated on 2012-06-26: Spokesperson for Amylin Pharmaceuticals Won't Comment on Rumor of Bids from Pharma Companies

Financial news for BMY dated on 2012-06-26: Amylin Pharmaceuticals Spiking to Highs on Earlier Bid Reports

Financial news for BMY dated on 2012-06-26: Novartis, Sanofi, Merck, Bristol, AstraZeneca Weigh Amylin Final Bids; Amylin Expects Final Bids Starting End of the Week -Reuters

Financial news for BMY dated on 2012-06-25: Ahead of Obamacare Ruling, S&P Likes Health Care SPDR

Financial news for BMY dated on 2012-06-25: Social Media Outlook for Monday June 25 (TEVA, MNTA, BMY, XOM)

Financial news for BMY dated on 2012-06-25: Benzinga's Top Pre-Market Losers

Financial news for BMY dated on 2012-06-25: Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. Food and Drug Administration for ELIQUIS

Financial news for BMY dated on 2012-06-22: UPDATE: Citigroup Reiterates Buy on Bristol-Myers Squibb

Financial news for BMY dated on 2012-06-21: UPDATE: Bank of America Merrill Lynch Raises PT to \$36 for Bristol-Myers Squibb

Financial news for BMY dated on 2012-06-21: UPDATE: Citi Reiterates Buy on Bristol-Myers Squibb

Financial news for BMY dated on 2012-06-21: Bank of America Maintains Bristol-Myers Squibb at Neutral, Raises PO from \$34 to \$36

Financial news for BMY dated on 2012-06-15: Six-Year Follow-Up Data for SPRYCEL 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib

Financial news for BMY dated on 2012-06-04: Bristol-Myers Comments on Nulojix Trials

Financial news for BMY dated on 2012-06-04: The US Economy and the United Nations: Bold Strategies Needed - Tax Reform and Benefits Reform

Financial news for BMY dated on 2012-06-04: UPDATE: JP Morgan Raises PT to \$35 on Bristol-Myers Squibb on ASCO Update

Financial news for BMY dated on 2012-06-03: Benzinga's M&A Chatter for Friday June 1, 2012

Financial news for BMY dated on 2012-06-02: Teva Spikes Higher as Chairman Purchases One Million Shares

Financial news for BMY dated on 2012-05-30: Financial Astrology: The Key to Future Investing

Financial news for BMY dated on 2012-05-25: Amylin Shares Jump as Sanofi, Merck Submit Bids

Financial news for BMY dated on 2012-05-25: Amylin Said to Get First-Round Bids from Sanofi, Merck -Bloomberg

Financial news for BMY dated on 2012-05-18: BMO Capital Markets Initiates Coverage on Bristol-Myers Squibb at Outperform, Announces PT of \$39

Financial news for BMY dated on 2012-05-15: U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility

Financial news for BMY dated on 2012-05-02: German Panel: Bristol-Myers Drug Helped Melanoma Patients

Financial news for BMY dated on 2012-04-30: FDA Considering Letting Patients Purchase Drugs Without Prescriptions

Financial news for BMY dated on 2012-04-26: Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

Financial news for BMY dated on 2012-04-26: Earnings Recap for April 26, 2012

Financial news for BMY dated on 2012-04-26: UPDATE: Bristol-Myers Posts Rise In Q1

Profit

Financial news for BMY dated on 2012-04-26: Bristol-Myers Squibb Reports Q1 EPS \$0.64 vs \$0.63 Est; Revenues \$5.3B vs \$5.26B Est

Financial news for BMY dated on 2012-04-26: US Stock Futures Down Ahead Of Earnings, Jobless Claims

Financial news for BMY dated on 2012-04-26: Earnings Scheduled For April 26

Financial news for BMY dated on 2012-04-23: Benzinga's M&A Chatter for Monday April 23, 2012

Financial news for BMY dated on 2012-04-22: Hearing Amylin Considering Sale -Reuters

Financial news for BMY dated on 2012-04-19: Bristol-Meyers Reports 77% of Patients Cured 24 Weeks After Treatment

Financial news for BMY dated on 2012-04-18: Why our portfolio is John Deere green

Financial news for BMY dated on 2012-04-05: Bristol-Myers Still Eyeing Amylin; Amylin Rejected Bristol's \$22/Share Offer; Amylin Not Running A Sale Process; Carl Icahn Urged Amylin To Pursue Sale -WSJ, Sources

Financial news for BMY dated on 2012-04-03: Carl Ichan: 'Everyone Said Bristol Meyers Offered \$22 for Amylin and They Didn't Deny It'

Financial news for BMY dated on 2012-04-03: Convatec Said to be Among Potential Bidders for Montagu's BSN -Bloomberg

Financial news for BMY dated on 2012-04-02: Amylin Shares Active on Monday; Stock Down 4%

Financial news for BMY dated on 2012-04-02: Biographical Profiles in Investing: Dr. Phillip Frost

Financial news for BMY dated on 2012-03-28: Benzinga's M&A Chatter for Wednesday March 28, 2012

Financial news for BMY dated on 2012-03-28: Trading Ideas: Stocks to Watch for Thursday (AMLN, SABA, ANGI, RHT, LGF, AE)

Financial news for BMY dated on 2012-03-28: Amylin Rejected \$3.5 Billion Offer; Stock Soars

Financial news for BMY dated on 2012-03-28: Amylin Spokesperson Won't Comment on Rejection of Bristol Meyers Offer

Financial news for BMY dated on 2012-03-28: Amylin Pharmaceuticals Spikes 42% Higher on Rejection of Bristol-Meyers Squib Offer

Financial news for BMY dated on 2012-03-28: Bristol-Myers Squibb and Meso Scale Discovery Enter Agreement to Develop Diagnostic Assays for Alzheimer's Disease

Financial news for BMY dated on 2012-03-28: Bristol-Myers Squibb and Meso Scale Discovery Enter Agreement to Develop Diagnostic Assays for Alzheimer's Disease

Financial news for BMY dated on 2012-03-15: A Look At The New Russell High Yield ETF (HDIV, ABT, KFT)

Financial news for BMY dated on 2012-03-08: Fresh Del Monte, BlackRock and Other Stocks Insiders Are Buying

Financial news for BMY dated on 2012-03-07: Radiation Blast Could Turbocharge Bristol-Myers Melanoma Drug -Bloomberg

Financial news for BMY dated on 2012-03-07: Deutsche Bank: Bristol-Myers Squibb's Cardiorenal Meeting Removed from FDA Website

Financial news for BMY dated on 2012-03-01: Pfizer Analyst: Delay in Eliquis Approval Would Not be Terribly Material to Bristol-Myers or Pfizer in Our View. However, This Could Cut into Sales Forecasts Slightly.

Financial news for BMY dated on 2012-03-01: From Earlier: Bristol-Myers Squibb and Pfizer Announce FDA Extends Action Date for ELIQUIS(r) (apixaban) by Three Months

Financial news for BMY dated on 2012-02-28: FDA Approves Important Safety Label Changes For The Class Of Cholesterol-Lowering Drugs Known As Statins -Reuters

Financial news for BMY dated on 2012-02-27: Benzinga's M&A Chatter for Monday February 27, 2012

Financial news for BMY dated on 2012-02-27: Positive Rumors Circulate About Vertex Pharmaceuticals

Financial news for BMY dated on 2012-02-17: Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish

Financial news for BMY dated on 2012-02-17: Bristol Myers Squibb Says Gob Sunpoena in January for Ambilify Info

Financial news for BMY dated on 2012-02-14: Benzinga's M&A Chatter for Tuesday February 14, 2012

Financial news for BMY dated on 2012-02-14: Hearing Renewed Takeover Chatter in Vertex Pharmaceuticals

Financial news for BMY dated on 2012-02-09: Trovogene: Built on Experience and Ready to Move Higher

Financial news for BMY dated on 2012-02-08: Benzinga's M&A Chatter for Wednesday February 8, 2012

Financial news for BMY dated on 2012-02-08: Positive Rumors Circulate About Vertex Pharmaceuticals

Financial news for BMY dated on 2012-02-08: From Earlier: Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex

Financial news for BMY dated on 2012-02-03: Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc.

Financial news for BMY dated on 2012-02-03: Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex

Financial news for BMY dated on 2012-02-01: Two Biotechs That Continue to Attract Positive Attention From Investors

Financial news for BMY dated on 2012-01-30: Bristol-Myers CEO Andreotti Says Not Making Decisions on Diabetes Salesforce Cuts; Planning to Talk to FDA on Forward Path for Drug -Bloomberg

Financial news for BMY dated on 2012-01-26: UPDATE: Bristol-Myers Squibb Reports Rise In Q4 Earnings

Financial news for BMY dated on 2012-01-26: Bristol-Myers Squibb Reports Q4 EPS \$0.53 vs \$0.55 Est; Revenues \$5.45B vs \$5.51B Est

Financial news for BMY dated on 2012-01-26: Earnings Scheduled For January 26

Financial news for BMY dated on 2012-01-24: Bristol-Meyers, Pfizer Receive Positive Mad Money/Jim Cramer Mention -CNBC

Financial news for BMY dated on 2012-01-24: BioLineRx Surges after Hep C License Agreement

Financial news for BMY dated on 2012-01-22: Earnings Expectations for the Week of January 23

Financial news for BMY dated on 2012-01-19: Morgan Stanley Downgrades Bristol Myers-Squibb to Equal-weight

Financial news for BMY dated on 2012-01-19: Achillion's Hep C Pipeline Likely Can't Compete

Financial news for BMY dated on 2012-01-19: From Earlier: Bristol-Myers Squibb and AstraZeneca Receive Complete Response Letter from U.S. Food and Drug Administration for Dapagliflozin

Financial news for BMY dated on 2012-01-17: Hearing 6 Potential Buyers Bid on Inhibitex, 2 at \$26.00/Share

Financial news for BMY dated on 2012-01-17: S&P Lukewarm On New Low Volatility ETFs

Financial news for BMY dated on 2012-01-13: UPDATE: McNicoll Lewis & Vlask Downgrades Inhibitex to Hold

Financial news for BMY dated on 2012-01-13: Bristol-Myers Squibb Begins Tender Offer

to Acquire Inhibitex

Financial news for BMY dated on 2012-01-13: San Francisco Health Care Conferences Provide Plenty of Buzz and Chatter

Financial news for BMY dated on 2012-01-10: Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target?

Financial news for BMY dated on 2012-01-09: Benzinga's M&A Chatter for Monday January 9, 2012

Financial news for BMY dated on 2012-01-09: Just What The Doctor Ordered: 4 ETFs For Biotech M&A

Financial news for BMY dated on 2012-01-09: Forget Dendreon, Inhibitex is the New Biotech Success Story

Financial news for BMY dated on 2012-01-09: Bank of America Raises PO on Idenix Pharmaceuticals to \$18

Financial news for BMY dated on 2012-01-09: Morning Market Movers

Financial news for BMY dated on 2012-01-09: Option Alert: Inhibitex January 15.00 Call Gains 5900% on Takeover

Financial news for BMY dated on 2012-01-09: Benzinga's Top Pre-Market Gainers

Financial news for BMY dated on 2012-01-09: Financial Breakfast: Morning News Summary for January 9, 2012

Financial news for BMY dated on 2012-01-09: Bristol-Myers Squibb to Acquire Inhibitex for \$26/Share in Cash

Financial news for BMY dated on 2012-01-09: Brean Murray Raises PT on Inhibitex to \$26

Financial news for BMY dated on 2012-01-09: Bristol-Myers To Acquire Inhibitex For \$2.5B

Financial news for BMY dated on 2012-01-09: Stocks To Watch For January 9

Financial news for BMY dated on 2012-01-09: US Stock Futures Flat; Alcoa Earnings In Focus

Financial news for BMY dated on 2012-01-09: Inhibitex Rises 156% Pre-Market on Bristol-Myers Squibb Acquisition

Financial news for BMY dated on 2012-01-09: Bristol-Myers To Acquire Inhibitex For \$2.5B

Financial news for BMY dated on 2012-01-09: Stocks To Watch For January 9

Financial news for BMY dated on 2012-01-07: Bristol-Myers Squibb to Acquire Inhibitex for \$26/Share

Financial news for BMY dated on 2012-01-04: 8 High-Yielding Stocks That Are Showing Strong Momentum

Financial news for BMY dated on 2012-01-04: Bank of America Merrill Lynch Provides Update on Bristol-Myers Squibb

Financial news for BMY dated on 2012-01-03: From Earlier: Teva Pharmaceutical CEO to Retire in May; Dr. Jeremy Levin To Succeed Shlomo Yanai as CEO

Financial news for BMY dated on 2011-12-30: Bristol-Myers Squibb Hits 52-Week High of \$35.35

Financial news for BMY dated on 2011-12-23: Goldman Sachs Positive on Onyx Pharmaceuticals After Brivanib Failure

Financial news for BMY dated on 2011-12-22: BRISK-PS Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Completed

Financial news for BMY dated on 2011-12-22: Bristol-Myers Squibb and the Gladstone Institutes Enter Three-Year Discovery Partnership in Alzheimer's Disease

Financial news for BMY dated on 2011-12-22: Bristol-Myers Squibb Hits 52-Week High of \$35.30

Financial news for BMJ dated on 2011-12-21: Merck Hands Exelixis \$12 Million Up Front For a Preclinical Compound Program

Financial news for BMJ dated on 2011-12-21: Bristol-Myers Squibb Hits 52-Week High of \$35.22

Financial news for BMJ dated on 2011-12-20: Bristol-Myers Squibb Hits 52-Week High of \$34.69

Financial news for BMJ dated on 2011-12-19: Benzinga's M&A Chatter for Monday December 19, 2011

Financial news for BMJ dated on 2011-12-19: Hearing Unconfirmed Takeover Chatter in Elan with Bristol Meyers Squibb Rumored Buyer at \$16/Share

Financial news for BMJ dated on 2011-12-19: Bristol-Myers Squibb Hits 52-Week High of \$34.51

Financial news for BMJ dated on 2011-12-16: Bristol-Myers Squibb Hits 52-Week High of \$34.44

Financial news for BMJ dated on 2011-12-15: Bristol-Myers Squibb Hits 52-Week High of \$33.97

Financial news for BMJ dated on 2011-12-14: Bristol-Myers Squibb Hits 52-Week High of \$33.73

Financial news for BMJ dated on 2011-12-14: NeurOp Announces Extension to Drug Discovery Collaboration with Bristol-Myers Squibb

Financial news for BMJ dated on 2011-12-09: Five Biotech Stocks to Watch Going into Big Doctors' Meeting

Financial news for BMJ dated on 2011-12-08: BofA Reiterates Neutral, \$34 PT On Bristol-Myers

Financial news for BMJ dated on 2011-12-08: A Peek Into The Market Before The Trading Start

Financial news for BMJ dated on 2011-12-08: Astra, Bristol-Myers Report Phase 3 Dapagliflozin Results

Financial news for BMJ dated on 2011-12-07: Bristol-Myers Squibb Hits 52-Week High of \$33.36

Financial news for BMJ dated on 2011-12-06: Bristol-Myers Squibb Announces Increase in Dividend; Boosts Dividend to \$0.34/Share from \$0.33/Share

Financial news for BMJ dated on 2011-12-06: Bristol-Myers Squibb Hits 52-Week High of \$33.28

Financial news for BMJ dated on 2011-12-02: Bristol-Myers Squibb Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals for Phase II Combination Study in Patients Chronically Infected with Hepatitis C

Financial news for BMJ dated on 2011-12-01: Mad Money Lightning Round: Cramer Dislikes Microsoft, Radioshack

Financial news for BMJ dated on 2011-11-29: Bank of America Reiterates Neutral on Bristol-Myers Squibb

Financial news for BMJ dated on 2011-11-29: Deutsche Bank Reiterates Buy on Bristol-Myers Squibb

Financial news for BMJ dated on 2011-11-29: FDA Accepts ELIQUIS New Drug Application for Review

Financial news for BMJ dated on 2011-11-28: ONGLYZA Approved for Use in Europe as Combination Therapy With Insulin in Adults

Financial news for BMJ dated on 2011-11-22: Mad Money Lightning Round: Cramer Likes Waste Management

Financial news for BMJ dated on 2011-11-21: Hep-C Stocks Soar On M&A News

Financial news for BMJ dated on 2011-11-18: FDA Approves Erwinaze To Treat A Form Of Leukemia

Financial news for BMJ dated on 2011-11-16: End-of-Day Market Summary for November

16, 2011

Financial news for BMJ dated on 2011-11-16: Bristol-Myers Squibb and AstraZeneca Announce Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients with Type 2 Diabetes

Financial news for BMJ dated on 2011-11-16: Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients

Financial news for BMJ dated on 2011-11-14: Morgan Stanley Maintains Overweight Rating on Bristol-Myers Squibb

Financial news for BMJ dated on 2011-11-14: ISI Group Publishes Report on Bristol-Myers Squibb

Financial news for BMJ dated on 2011-11-14: Financial Breakfast: Morning News Summary for November 14, 2011

Financial news for BMJ dated on 2011-11-14: Bank of America Merrill Lynch Neutral on Bristol-Myers Squibb

Financial news for BMJ dated on 2011-11-13: New Data Presented on Phase 3 Trial of ELIQUIS in Prevention of Venous Thromboembolism in Patients with Acute Medical Illness

Financial news for BMJ dated on 2011-11-11: Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz in Brazil

Financial news for BMJ dated on 2011-11-09: Dako Enters New Collaboration With Bristol-Myers Squibb on Pharmacodiagnosics

Financial news for BMJ dated on 2011-11-08: Bristol-Myers Squibb Company Phase IIIB Comparison of BARACLUDE Monotherapy Versus BARACLUDE Plus Tenofovir Combination Shows No Statistical Difference Between Study Arms

Financial news for BMJ dated on 2011-11-08: A Peek Into The Market Before The Trading Starts

Financial news for BMJ dated on 2011-11-08: Tranzyme Pharma Announces the Extension of Its Chemistry-Based Drug Discovery Collaboration With Bristol-Myers Squibb

Financial news for BMJ dated on 2011-11-07: FDA Approves Erbitux to Treat Late-Stage Head And Neck Cancer; Erbitux Marketed by Bristol-Myers Squibb

Financial news for BMJ dated on 2011-11-04: A Peek Into The Market Before The Trading Starts

Financial news for BMJ dated on 2011-11-04: Pharmasset and Bristol-Myers Squibb Announce New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir for HCV Genotype 1

Financial news for BMJ dated on 2011-11-02: Are Upcoming Study Results Spurring Insider Buying at Ligand Pharmaceuticals?

Financial news for BMJ dated on 2011-10-31: A Look at The New DRGS ETN

Financial news for BMJ dated on 2011-10-27: Higher Profit for Bristol-Myers Squibb Company

Financial news for BMJ dated on 2011-10-27: Pfizer Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for BMJ dated on 2011-10-27: Financial Breakfast: Morning News Summary for October 27, 2011

Financial news for BMJ dated on 2011-10-27: Bristol-Myers Squibb Reports Q3 EPS \$0.61 vs \$0.58 Est; Revenues \$5.35B vs \$5.30B Est

Financial news for BMJ dated on 2011-10-26: Bristol-Myers Squibb and AstraZeneca Announce U.S. Food and Drug Administration Extends Action Date for Dapagliflozin by Three Months

Financial news for BMJ dated on 2011-10-26: Bristol-Myers Squibb and Gilead Sciences Announce Licensing Agreement for Development and Commercialization of New Fixed-Dose Combination Pill for People Living with HIV

Financial news for BMJ dated on 2011-10-25: Earnings Preview: Vertex Pharmaceuticals' EPS, Revenue Expected to Rise

Financial news for BMY dated on 2011-10-25: Merck Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for BMY dated on 2011-10-25: Celgene Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for BMY dated on 2011-10-25: Biogen Idec Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for BMY dated on 2011-10-24: Bristol-Myers Squibb Earnings Preview: Analysts Expect Rising Revenue, Falling EPS

Financial news for BMY dated on 2011-10-24: Gilead Sciences Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for BMY dated on 2011-10-23: Earnings Expectations for the Week of October 24

Financial news for BMY dated on 2011-10-18: Court Cuts Apotex Payment To Sanofi, Bristol In Plavix Case

Financial news for BMY dated on 2011-10-17: Eli Lilly Earnings Preview: Analysts Expect Rising Revenue, Falling EPS

Financial news for BMY dated on 2011-10-14: Abbott Laboratories Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for BMY dated on 2011-10-11: Bristol-Myers Squibb Foundation Announces Collaboration with World Health Organization

Financial news for BMY dated on 2011-10-06: Bristol-Myers and Quidel to Open Near 52-Week Highs

Financial news for BMY dated on 2011-10-05: Bank of America Raises PO on Bristol-Myers Squibb to \$34

Financial news for BMY dated on 2011-10-04: Bristol Myers Squibb Entered \$1.5B Credit Pact

Financial news for BMY dated on 2011-10-04: Bristol-Meyers CEO Says Plans to Continue Growing Company, Deals Have to be Strategic

Financial news for BMY dated on 2011-09-26: UPDATE: Deutsche Bank Raises PT on Bristol-Myers Squibb to \$37.50

Financial news for BMY dated on 2011-09-22: Bears at Work 09-22-2011

Financial news for BMY dated on 2011-09-22: UPDATE: Goldman Sachs Upgrades Bristol-Myers Squibb to Buy

Financial news for BMY dated on 2011-09-22: Bristol-Myers Squibb and Ambrx Announce Collaboration for Novel Biologics Programs in Diabetes and Heart Failure

Financial news for BMY dated on 2011-09-22: Goldman Sachs Upgrades Bristol-Myers Squibb to Buy, PT Raised to \$37

Financial news for BMY dated on 2011-09-20: Bristol-Myers Squibb and Saladax Biomedical Expand Collaboration for Diagnostic Assays for Alzheimer's Disease

Financial news for BMY dated on 2011-09-19: VIX Pops 10%

Financial news for BMY dated on 2011-09-19: Stocks Hitting 52-Week Highs

Financial news for BMY dated on 2011-09-19: UPDATE: Jefferies Upgrades Bristol-Myers Squibb to Buy

Financial news for BMY dated on 2011-09-19: Benzinga's Top Upgrades

Financial news for BMY dated on 2011-09-19: A Peek Into The Market Before The Trading Starts

Financial news for BMY dated on 2011-09-19: Jefferies Upgrades Bristol-Myers Squibb to Buy, PT Raised to \$35

Financial news for BMY dated on 2011-09-16: Bristol-Myers Squibb and AstraZeneca Announce ONGLYZA When Added to Insulin in Adults with Type 2 Diabetes Maintained Reductions in Blood Sugar Levels Over 52 Weeks in Investigational Study Extension

Financial news for BMY dated on 2011-09-07: Goldman Sachs Suggests Searching for Yield Through Options

Financial news for BMY dated on 2011-08-30: A Peek Into The Market Before The Trading Starts

Financial news for BMY dated on 2011-08-30: ICON Selected as a Preferred Provider for Early Phase Clinical Development by Bristol-Myers Squibb

Financial news for BMY dated on 2011-08-29: J.P. Morgan Maintains Neutral on Bristol-Myers Squibb

Financial news for BMY dated on 2011-08-29: Bank of America Raises PO On Bristol-Myers Squibb To \$32

Financial news for BMY dated on 2011-08-15: Friday's Biotech/Pharma Stocks Trading

Financial news for BMY dated on 2011-08-10: GNS Healthcare Announces Collaboration With Bristol-Myers Squibb

Financial news for BMY dated on 2011-08-02: Citi Reiterates Buy on Bristol Myers Squibb, Raises PT to \$39

Financial news for BMY dated on 2011-08-02: Citigroup Raises PT On Bristol-Myers Squibb To \$39

Financial news for BMY dated on 2011-07-28: Thursday's S&P Sector Recap

Financial news for BMY dated on 2011-07-28: Pfizer Earnings Preview: Analysts Expect Falling EPS

Financial news for BMY dated on 2011-07-28: Earnings Roundup

Financial news for BMY dated on 2011-07-28: Bristol-Myers Squibb's Profit Falls, Still Tops Estimates

Financial news for BMY dated on 2011-07-28: UPDATE: Bristol-Myers Reports Upbeat Q2 Earnings, Raises 2011 Forecast

Financial news for BMY dated on 2011-07-28: Bristol-Myers Guides Year EPS Higher to \$2.20-2.30; Guides FY 2013 EPS \$1.95

Financial news for BMY dated on 2011-07-28: Bristol-Myers Squibb Reports Q2 EPS \$0.56 vs \$0.55 Est; Revenues \$5.43B vs \$5.04B Est

Financial news for BMY dated on 2011-07-28: US Stock Futures Slightly Up Ahead Of Earnings, Jobless Claims Data

Financial news for BMY dated on 2011-07-28: Earnings Scheduled For July 28

Financial news for BMY dated on 2011-07-26: Earnings Preview: Merck EPS, Revenue Expected to Rise from Previous Quarter

Financial news for BMY dated on 2011-07-25: Celgene Earnings Preview: Analysts Expect Falling Revenue, Rising EPS Over Last Quarter

Financial news for BMY dated on 2011-07-25: Vertex Pharmaceuticals Earnings Preview: Analysts Expect Falling Revenue, Rising EPS Over Last Quarter

Financial news for BMY dated on 2011-07-25: Bristol-Myers Squibb Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter

Financial news for BMY dated on 2011-07-24: Earnings Expectations for the Week of July 25

Financial news for BMY dated on 2011-07-21: Biogen IDEC Earnings Preview: Analysts Expect Falling Revenue Over Last Quarter

Financial news for BMY dated on 2011-07-21: Earnings Preview: Gilead Sciences EPS, Revenue Expected to Rise from Previous Quarter

Financial news for BMY dated on 2011-07-20: Jefferies Reports FDA Votes Against BMY Dapagliflozin Approval

Financial news for BMY dated on 2011-07-18: Jefferies Lowers PT On Bristol-Myers Squibb To \$27

Financial news for BMY dated on 2011-07-15: FDA Says Bristol-Astrazeneca Diabetes Drug is Effective

Financial news for BMY dated on 2011-07-15: FDA Posts Staff Review of Bristol-Astrazeneca Drug for Diabetes

Financial news for BMY dated on 2011-07-12: 10 High Yield, High Momentum Stocks

Financial news for BMY dated on 2011-07-11: Citi Maintains Buy on Bristol-Myers Squibb

Financial news for BMY dated on 2011-07-06: Bristol-Myers Squibb and Innate Pharma Announce Global License Agreement for an Investigational Immuno-Oncology Biologic

Financial news for BMY dated on 2011-06-30: Morgan Stanley Provides Color on Bristol Myers Squibb

Financial news for BMY dated on 2011-06-28: Q&A with Aethlon Medical CEO, Jim Joyce; The Potential for the Hemopurifier(r) Medical Device in Cancer Immunotherapy

Financial news for BMY dated on 2011-06-28: Tuesday's Mid-Day Options Volume Leaders

Financial news for BMY dated on 2011-06-28: Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz(r) (atazanavir sulfate) in sub-Saharan Africa and India

Financial news for BMY dated on 2011-06-27: Goldman Sachs Reiterates Neutral on Bristol Myers Squibb and AstraZeneca

Financial news for BMY dated on 2011-06-27: Morgan Stanley Provides Color on Bristol Myers Squibb

Financial news for BMY dated on 2011-06-24: Stocks to Watch for 6/24/11: Fresh 52 Week Highs and Lows

Financial news for BMY dated on 2011-06-23: Market Battles Back 06-23-2011

Financial news for BMY dated on 2011-06-23: Thursday's S&P Sector Recap 6/23/11

Financial news for BMY dated on 2011-06-23: Critical Levels Broken 06-23-2011

Financial news for BMY dated on 2011-06-23: Thursday's Mid-Day Options Volume Leaders

Financial news for BMY dated on 2011-06-23: J.P. Morgan Maintains Neutral on Bristol Myers Squibb

Financial news for BMY dated on 2011-06-23: UPDATE: Bristol Myers Squibb Trading Over 6% Higher on Positive Phase 3 Results

Financial news for BMY dated on 2011-06-23: UPDATE: Bristol Myers Squibb Trading Over 6% Higher on Positive Phase 3 Results

Financial news for BMY dated on 2011-06-23: Deutsche Bank Discusses Apixaban From Bristol-Myers Squibb

Financial news for BMY dated on 2011-06-23: Benzinga's Top Upgrades

Financial news for BMY dated on 2011-06-23: Morgan Stanley Upgrades Bristol Myers Squibb to Overweight, Raises PT to \$34

Financial news for BMY dated on 2011-06-23: Jefferies Anticipates Next Key Event in the Oral Anticoagulant Space

Financial news for BMY dated on 2011-06-23: ELIQUIS Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study

Financial news for BMY dated on 2011-06-23: Morgan Stanley Upgrades Bristol-Myers Squibb To Overweight, Raises PT To \$34

Financial news for BMY dated on 2011-06-22: Bristol-Myers Squibb

Financial news for BMY dated on 2011-06-20: Biotech/Pharma Stocks; Take A New Approach to Cancer

Financial news for BMY dated on 2011-06-16: Bristol-Myers Squibb Announces FDA Approves NULOJIX

Financial news for BMY dated on 2011-06-16: Citi Reports On FDA Approval For BMY

Financial news for BMY dated on 2011-06-08: Goldman Sachs Suggests Buying Puts on Bristol-Myers Squibb

Financial news for BMY dated on 2011-06-07: Technical Trading Summary 6/7/2011

Financial news for BMY dated on 2011-06-07: J.P. Morgan Provides Color on Bristol Myers Squibb and Pfizer

Financial news for BMY dated on 2011-06-06: J.P. Morgan Maintains Neutral on Bristol-Myers Squibb

Financial news for BMY dated on 2011-06-02: Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement to Conduct Combination Studies with YERVOY and Vemurafenib

Financial news for BMY dated on 2011-06-01: Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer

Financial news for BMY dated on 2011-06-01: Hapoalim Cutting Ocverage On Multitude Of Names

Financial news for BMY dated on 2011-06-01: Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest ROE

Financial news for BMY dated on 2011-05-26: Pharmasset Announces All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated

Financial news for BMY dated on 2011-05-25: AMRI to Receive Milestone Payment from Bristol-Myers Squibb for the Initiation of a Phase II Study

Financial news for BMY dated on 2011-05-24: Diabetes Device Market to Reach \$24 Billion by 2017

Financial news for BMY dated on 2011-05-22: Top Healthcare and Major Drugs stocks to watch- Sector Performance

Financial news for BMY dated on 2011-05-20: Pfizer's and Bristol-Myers Squibb's ELIQUIS Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement

Financial news for BMY dated on 2011-05-18: GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term

Financial news for BMY dated on 2011-05-16: Bank Of America Ups PT To \$29 On BMY

Financial news for BMY dated on 2011-05-11: Benzinga's Top Downgrades (NSM, SNHY, BMY, RIMM)

Financial news for BMY dated on 2011-05-11: Goldman Sachs Switches Top New Product Story From BMY To JNJ

Financial news for BMY dated on 2011-05-11: Goldman Sachs Downgrades Bristol-Myers Squibb To Neutral, \$32 PT

Financial news for BMY dated on 2011-05-02: TOP 15 Stocks To Watch this week- AAPL, BRK-A, BRK-B, BJ, C, F, GM, GPRO, IP, KND, N, NRTLQ, ONTY, SPPI, YRCW

Financial news for BMY dated on 2011-04-28: Earnings Roundup For April 28 (XOM, AZN, HST, PEP, POT, PG, IP, DOW, S, AET, BMY, VIA, CL, EQT, CCE, OXY)

Financial news for BMY dated on 2011-04-28: UPDATE: Bristol-Myers Squibb Reports Better-Than-Expected Q1 Results

Financial news for BMY dated on 2011-04-28: Bristol-Myers Squibb Reports EPS of \$0.58 vs. \$0.53 Estimate; Revenues \$5.01B vs. \$4.95B Estimate (BMY)

Financial news for BMY dated on 2011-04-28: US Stock Futures Mixed As Investors Await GDP Data, Earnings Reports

Financial news for BMY dated on 2011-04-28: Earnings Scheduled For April 28 (MSFT, AET, VIA, XOM, CL, PEP, BMY, MMI, TWC, PG, DOW, S, TYC, CCE, SWY, HOT, EK, EXPE, D, VRSN, EMN)

Financial news for BMY dated on 2011-04-27: Earnings Preview for Bristol Myers Squibb Company (BMY, CTIC)

Financial news for BMY dated on 2011-04-26: Jefferies Comments On Bristol-Myers Squibb

Financial news for BMY dated on 2011-04-18: Don't Fall For The 'Defensive Portfolio' Hype

Financial news for BMY dated on 2011-03-31: Investigational Direct-Acting Antiviral BMS-790052 Plus PEG-Interferon Alfa and Ribavirin Achieved Up to 92% Sustained Virologic Response in Phase II Dose-Ranging Study

Financial news for BMY dated on 2011-03-31: Jefferies Downgrades BMY To Hold

Financial news for BMY dated on 2011-03-31: Benzinga's Top Upgrades (CAVM, EMR, ARMH, BMY)

Financial news for BMY dated on 2011-03-31: Jefferies Downgrades Bristol-Myers Squibb To Hold

Financial news for BMY dated on 2011-03-31: Jefferies Ups BMY To Hold

Financial news for BMY dated on 2011-03-29: Biotech/Pharma Snapshot; Advances in Cancer Immunotherapy, Dendreon Corporation

Financial news for BMY dated on 2011-03-28: Is Approval of Bristol-Myers Squibb's Yervoy Start of New Chapter at FDA?

Financial news for BMY dated on 2011-03-28: Pharma/Biotech Stock News: FDA Approves YERVOY (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer

Financial news for BMY dated on 2011-03-28: Pharma/Biotech Stock News: FDA Approves YERVOY (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer

Financial news for BMY dated on 2011-03-28: Deutsche Bank Updates On BMY Yervoy Approval

Financial news for BMY dated on 2011-03-28: UPDATE: Goldman Sachs Raises PT on Bristol-Myers Squibb to \$32 (BMY)

Financial news for BMY dated on 2011-03-25: Did Bristol-Myers Just Find A Cure For Melanoma? (BMY)

Financial news for BMY dated on 2011-03-25: FDA Approves Bristol-Myers Squibb Drug Yervoy To Treat Melanoma

Financial news for BMY dated on 2011-03-25: FDA Approves Bristol Myers Squibb's Drug Yermoy To Treat Melanoma (BMY)

Financial news for BMY dated on 2011-03-25: Bristol Myers Squibb Receives Positive FDA News (BMY)

Financial news for BMY dated on 2011-03-25: Goldman Sachs Says Buy Bristol-Myers Squibb Company (BMY)

Financial news for BMY dated on 2011-03-25: Goldman Sachs Anticipates BMY Melanoma Drug Approval

Financial news for BMY dated on 2011-03-22: Goldman Sachs Maintains Buy on Bristol-Myers Squibb (BMY)

Financial news for BMY dated on 2011-03-18: Biotech Sector Snapshot HIV Drug Development

Financial news for BMY dated on 2011-03-17: Biotech/Pharma Sector Close-Up; Drug Resistance Potential for HIV Drugs; Can Medical Devices take over when drugs fail?

Financial news for BMY dated on 2011-03-09: Bristol-Myers Squibb to Present at Barclays Capital Global Healthcare Conference

Financial news for BMY dated on 2011-03-09: KineMed Extends Collaboration With Bristol-Myers Squibb

Financial news for BMY dated on 2011-03-08: FDA Accepts New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes

Financial news for BMY dated on 2011-03-07: Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing Facility

Financial news for BMY dated on 2011-03-04: Fast Money Picks For March 7th (BMY, PGH, GM, STJ)

Financial news for BMY dated on 2011-03-03: Slow Grind Squeezes Shorts 03-03-2011

Financial news for BMY dated on 2011-03-03: Goldman Sachs Suggests Buying Calls on

Bristol-Myers Squibb (BMY)

Financial news for BMY dated on 2011-03-01: Bristol-Myers Squibb Names Elliott Sigal to Board of Directors

Financial news for BMY dated on 2011-03-01: Bristol-Myers Squibb's BARACLUDE Approved by the European Commission for the Treatment of Chronic Hepatitis B

Financial news for BMY dated on 2011-02-23: Mad Money Lightning Round: Cramer Advises Investors To Buy Apache (BMY, AAPL, APA, IBN, FCX, BHP)

Financial news for BMY dated on 2011-02-22: Citi On BMY Product Trends For The Week Ending 2/11

Financial news for BMY dated on 2011-02-11: Two ETFs for the Recovery in Big Pharma

Financial news for BMY dated on 2011-02-08: Jefferies Comments On BMY Financials

Financial news for BMY dated on 2011-02-07: FDA Approves Labeling Update for REYATAZ Capsules to Include Data Supporting the Recommended Adult Dose for HIV-1 Infected Pregnant Women

Financial news for BMY dated on 2011-02-07: Cowen Ups BMY To Outperform

Financial news for BMY dated on 2011-02-03: Roche Misses on Tamiflu Decline - Analyst Blog

Financial news for BMY dated on 2011-02-03: Roche Misses on Tamiflu Decline - Analyst Blog

Financial news for BMY dated on 2011-02-02: Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab

Financial news for BMY dated on 2011-01-28: Company News for January 28, 2011 - Corporate Summary

Financial news for BMY dated on 2011-01-28: Hapoalim Securities Reiterates Sell Rating on Bristol-Myers Squibb (BMY)

Financial news for BMY dated on 2011-01-28: Company News for January 28, 2011 - Corporate Summary

Financial news for BMY dated on 2011-01-27: BMY Misses by a Penny in Q4 - Analyst Blog

Financial news for BMY dated on 2011-01-27: BMY Misses by a Penny in Q4 - Analyst Blog

Financial news for BMY dated on 2011-01-27: Bristol-Myers Squibb Reports 47 Cent EPS (BMY)

Financial news for BMY dated on 2011-01-27: A Peek Into The Market Before The Trading Starts

Financial news for BMY dated on 2011-01-27: Bristol-Myers Squibb Reports Q4 EPS of \$.47 vs. \$.48

Financial news for BMY dated on 2011-01-27: Earnings Scheduled For January 27 (CAT, MSFT, PG, T, BMY, LLY, AMZN, AZN, TWC, SNDK, NOK, CB, JBLU, VRSN, PMCS, CL, MSI, KLAC)

Financial news for BMY dated on 2011-01-26: Earnings Preview: Bristol-Myers - Analyst Blog

Financial news for BMY dated on 2011-01-26: Earnings Preview: Bristol-Myers - Analyst Blog

Financial news for BMY dated on 2011-01-26: Abbott Labs Tops 4Q Estimates - Analyst Blog

Financial news for BMY dated on 2011-01-26: Abbott Labs Tops 4Q Estimates - Analyst Blog

Financial news for BMY dated on 2011-01-25: Bristol-Myers Squibb and sanofi-aventis Announce FDA Decision to Grant Pediatric Exclusivity For PLAVIX

Financial news for BMY dated on 2011-01-25: Earnings Preview: Abbott Labs - Analyst Blog

Financial news for BMY dated on 2011-01-25: Earnings Preview: Abbott Labs - Analyst Blog

Financial news for BMY dated on 2011-01-24: AstraZeneca Responds to FDA Letter - Analyst Blog

Financial news for BMY dated on 2011-01-24: AstraZeneca Responds to FDA Letter - Analyst Blog

Financial news for BMY dated on 2011-01-21: Jefferies Previews Q4 and FY2010 Earnings for Bristol-Myers Squibb (BMY)

Financial news for BMY dated on 2011-01-20: Bleeding Risk with MRK's Candidate - Analyst Blog

Financial news for BMY dated on 2011-01-20: Pfizer Inks Deal With Theraclone - Analyst Blog

Financial news for BMY dated on 2011-01-20: Pfizer Inks Deal With Theraclone - Analyst Blog

Financial news for BMY dated on 2011-01-20: Bleeding Risk with MRK's Candidate - Analyst Blog

Financial news for BMY dated on 2011-01-14: Merck's Blood Thinner in Trouble - Analyst Blog

Financial news for BMY dated on 2011-01-14: Merck's Blood Thinner in Trouble - Analyst Blog

Financial news for BMY dated on 2011-01-13: Morgan Stanley Lowers BMY 2011e EPS To \$2.23 From \$2.30

Financial news for BMY dated on 2011-01-11: Bristol-Myers Inks Deal - Analyst Blog

Financial news for BMY dated on 2011-01-11: Bristol-Myers Inks Deal - Analyst Blog

Financial news for BMY dated on 2011-01-10: Bristol-Myers Squibb and Pharmasset Enter into a Clinical Collaboration Agreement

Financial news for BMY dated on 2011-01-06: Label Expansion for Roche's Actemra - Analyst Blog

Financial news for BMY dated on 2011-01-06: Label Expansion for Roche's Actemra - Analyst Blog

Financial news for BMY dated on 2011-01-06: Goldman Sachs Healthcare CEO's Conference (BMY, MRK, CELG)

Financial news for BMY dated on 2011-01-06: Bayer Seeks Approval for Xarelto - Analyst Blog

Financial news for BMY dated on 2011-01-06: Bayer Seeks Approval for Xarelto - Analyst Blog

Financial news for BMY dated on 2011-01-04: Bristol-Myers Outlook Mixed - Analyst Blog

Financial news for BMY dated on 2011-01-04: Bristol-Myers Outlook Mixed - Analyst Blog

Financial news for BMY dated on 2011-01-03: 10 Companies 'Less Valuable' Than Facebook

Financial news for BMY dated on 2011-01-03: J&J to Bring Cancer Test to Market

Financial news for BMY dated on 2010-12-27: Stocks Going Ex Dividend the First Week of January

Financial news for BMY dated on 2010-12-22: Another Setback for AstraZeneca - Analyst Blog

Financial news for BMY dated on 2010-12-22: Another Setback for AstraZeneca - Analyst Blog

Financial news for BMY dated on 2010-12-21: Big Pharma in Frenzy of Drug Deals

Financial news for BMY dated on 2010-12-20: Bristol-Myers Squibb Co. Officer Sells 10,000 Shares of BMY

Financial news for BMY dated on 2010-12-20: S&P 500 Buybacks: Top Q4 Earnings-Boost Stocks

Financial news for BMY dated on 2010-12-20: Bristol-Myers Squibb and Oncolys BioPharma Announce Global Licensing Agreement for Investigational HIV Compound

Financial news for BMY dated on 2010-12-17: Regulatory Setback for AstraZeneca - Analyst Blog

Financial news for BMY dated on 2010-12-17: Regulatory Setback for AstraZeneca - Analyst Blog

Financial news for BMY dated on 2010-12-15: Stocks To Watch For December 15 (BRCM, BMY, JOYG, YHOO, ADSK)

Financial news for BMY dated on 2010-12-14: Bristol Myers-Squibb Lifts Dividend

Financial news for BMY dated on 2010-12-14: Bristol-Myers Squibb Increases Dividend by 3.1% to \$.33

Financial news for BMY dated on 2010-12-14: Bob Doll's Picks

Financial news for BMY dated on 2010-12-09: Best Stocks For Creating A Passive Income Stream

Financial news for BMY dated on 2010-12-08: Phase III Data on PFE's Bosutinib - Analyst Blog

Financial news for BMY dated on 2010-12-08: Phase III Data on PFE's Bosutinib - Analyst Blog

Financial news for BMY dated on 2010-12-07: Good News for Bristol-Myers - Analyst Blog

Financial news for BMY dated on 2010-12-07: Good News for Bristol-Myers - Analyst Blog

Financial news for BMY dated on 2010-12-07: Citigroup On BMY's Sprycel

Financial news for BMY dated on 2010-12-06: FDA Accepts Bristol-Myers Squibb's Application for Subcutaneous Formulation of ORENCIA(r)

Financial news for BMY dated on 2010-11-30: Bristol-Myers Squibb Set to Present Sprycel Data (BMY)

Financial news for BMY dated on 2010-11-24: Gilead Files NDA for Combo HIV Drug - Analyst Blog

Financial news for BMY dated on 2010-11-24: Gilead Files NDA for Combo HIV Drug - Analyst Blog

Financial news for BMY dated on 2010-11-24: Gilead Files NDA for Combo HIV Drug - Analyst Blog

Financial news for BMY dated on 2010-11-24: Gilead Files NDA for Combo HIV Drug - Analyst Blog

Financial news for BMY dated on 2010-11-22: Zacks Analyst Blog Highlights: Gap Inc., Pfizer, Bristol-Myers Squibb, Johnson and Johnson and Bayer - Press Releases

Financial news for BMY dated on 2010-11-22: Zacks Analyst Blog Highlights: Gap Inc., Pfizer, Bristol-Myers Squibb, Johnson and Johnson and Bayer - Press Releases

Financial news for BMY dated on 2010-11-19: Another Pipeline Setback for Pfizer - Analyst Blog

Financial news for BMY dated on 2010-11-19: Deutsche Bank Has Buy Rating On Bristol Myers Squibb (BMY)

Financial news for BMY dated on 2010-11-19: Another Pipeline Setback for Pfizer - Analyst Blog

Financial news for BMY dated on 2010-11-18: Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Up to \$750 Million

Financial news for BMY dated on 2010-11-18: Simcere Beats on Top & Bottom Line - Analyst Blog

Financial news for BMY dated on 2010-11-18: Bristol-Myers Squibb Sued for Denying Overtime Pay

Financial news for BMY dated on 2010-11-18: Simcere Beats on Top & Bottom Line - Analyst Blog

Financial news for BMY dated on 2010-11-16: Boost for Bayer - Analyst Blog

Financial news for BMY dated on 2010-11-16: Zacks Analyst Blog Highlights: Isis Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Johnson & Johnson and Genzyme - Press Releases

Financial news for BMY dated on 2010-11-12: Unconfirmed Rumors that Delcath Systems Inc. (DCTH) is in talks with Bristol-Myers Squibb Company (BMY) on possible takeover in low \$20s.

Financial news for BMY dated on 2010-11-11: Zacks Analyst Blog Highlights: DuPont, Bristol Meyers, Wal-Mart, Chesapeake and EnCana - Press Releases

Financial news for BMY dated on 2010-11-10: Trade Deficit Improves a Bit - Analyst Blog

Financial news for BMY dated on 2010-11-09: Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews

Financial news for BMY dated on 2010-11-09: Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook

Financial news for BMY dated on 2010-11-09: Pharma and Biotech Industry Outlook - Nov. 2010 - Industry Outlook

Financial news for BMY dated on 2010-11-09: Zacks Analyst Blog Highlights: Toyota Motor Corp., King Pharmaceuticals Inc., Bristol-Myers Squibbs', Johnson & Johnson and Pfizer - Press Releases

Financial news for BMY dated on 2010-11-08: Jefferies Likes Bristol Myers' Pipeline (BMY)

Financial news for BMY dated on 2010-11-03: Deutsche Bank Has Note On Bristol-Myers Squibb (BMY)

Financial news for BMY dated on 2010-11-03: Bristol-Myers Waiting On Ipilimumab Approval From FDA

Financial news for BMY dated on 2010-11-02: Bristol-Myers Squibb Announces that FDA Has Extended the Review Timeline for the Ipilimumab Biologics

Financial news for BMY dated on 2010-10-29: Friday's Put/Call Ratio Leaders (NWL, RYL, NVS, QSII, BMY)

Financial news for BMY dated on 2010-10-27: Zacks Analyst Blog Highlights: United States Steel, Bristol-Myers Squibb, AstraZeneca plc, BHP Billiton and Wyndham Worldwide - Press Releases

Financial news for BMY dated on 2010-10-27: Citi Raises Estimates On Bristol-Myers Squibb (BMY)

Financial news for BMY dated on 2010-10-26: Earnings Were Solid 10-26-2010

Financial news for BMY dated on 2010-10-26: Current OX Put/Call Ratio 10-26-2010

Financial news for BMY dated on 2010-10-26: Hapoalim Securities Reiterates Sell On Bristol Myers (BMY)

Financial news for BMY dated on 2010-10-26: Bristol-Myers Squibb Warned by FDA

Financial news for BMY dated on 2010-10-26: Bristol-Myers Squibb Third Quarter Featured Solid Operating Performance, EPS of \$.59

Financial news for BMY dated on 2010-10-26: Earnings Scheduled For October 26 (DD, DV, BMY, COH, MCK, AFL, DWA, FIS, X, F, NBR, VLO, MHP, SHW, LXK, BRCM, KMB, WU, UA)

Financial news for BMY dated on 2010-10-26: Stocks To Watch For October 26 (F, TXN, DD, AMGN, BMY)

Financial news for BMY dated on 2010-10-22: Earnings Preview: Bristol-Myers - Analyst Blog

Financial news for BMY dated on 2010-10-19: Label Expansion at Bristol-Myers -

Analyst Blog

Financial news for BMY dated on 2010-10-18: U.S. Food and Drug Administration Approves Bristol-Myers Squibb's BARACLUDE as a Treatment for Chronic Hepatitis B

Financial news for BMY dated on 2010-10-14: Coverage Discontinued On ZymoGenetics

Financial news for BMY dated on 2010-10-12: Bristol-Myers Squibb Completes Acquisition of ZymoGenetics, Inc. at \$9.75 per Share

Financial news for BMY dated on 2010-10-12: Top 4 NYSE Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)

Financial news for BMY dated on 2010-10-11: Benzinga's Top Pre-Market NASDAQ Gainers (HRBN, RVSN, EXEL, SMTX)

Financial news for BMY dated on 2010-10-07: Jon Najarian Is Watching Delcath Systems (DCTH) And Savient Pharmaceuticals (SVNT)

Financial news for BMY dated on 2010-10-07: Unconfirmed Chatter that Bristol-Myers Squibb Company (BMY) will Acquire Delcath Systems Inc. (DCTH) at \$15.00 a share

Financial news for BMY dated on 2010-10-05: Citi Has Buy Rating On Bristol-Myers Squibb (BMY)

Financial news for BMY dated on 2010-10-04: Bristol Myers at Neutral - Analyst Blog

Financial news for BMY dated on 2010-10-04: Morgan Stanley Downgrades Bristol-Myers Squibb

Financial news for BMY dated on 2010-09-28: BMY ZGEN Deal; HSR Period Expires

Financial news for BMY dated on 2010-09-28: A Peek Into The Market Before The Trading Starts

Financial news for BMY dated on 2010-09-28: Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics

Financial news for BMY dated on 2010-09-24: The Rapid Growth Of Layoffs In Pharma, As Industry Despairs Of Its Future (BMY, ABT, PFE, MRK)

Financial news for BMY dated on 2010-09-24: Benzinga's Top Downgrades (NOA, SHAW, NSC, BMY)

Financial news for BMY dated on 2010-09-24: Bristol-Myers Downgraded To Sell

Financial news for BMY dated on 2010-09-22: PT Raised For BMY By Deutsche Bank

Financial news for BMY dated on 2010-09-21: BMY's Diabetes Candidate Encourages - Analyst Blog

Financial news for BMY dated on 2010-09-17: Mad Money Lightning Round: Cramer Loves HJ Heinz, Considers Eastman Kodak As Mere Speculations (HNZ, BMY, NANO, EK, BAC, NAT)

Financial news for BMY dated on 2010-09-15: Pharmaceutical Stocks Worth Owning For The Dividend Alone

Financial news for BMY dated on 2010-09-15: Pharmaceutical Stocks Worth Owning For The Dividend Alone

Financial news for BMY dated on 2010-09-10: Bristol-Myers Squibb Begins Tender Offer to Acquire ZymoGenetics, Inc. (BMY, ZGEN)

Financial news for BMY dated on 2010-09-09: Zacks Analyst Blog Highlights: Bristol-Myers Squibb, ZymoGenetics, Family Dollar Stores, Wal-Mart Stores and Dollar General Corporation - Press Releases

Financial news for BMY dated on 2010-09-09: BMY to Acquire ZymoGenetics - Analyst Blog

Financial news for BMY dated on 2010-09-08: Most Active NASDAQ Stocks Today (ZGEN, INTC, SIRI, JASO, AMAT)

Financial news for BMY dated on 2010-09-08: Vincent Wong Announces an Investigation into the Possible Breaches of Fiduciary Duty by the Board of ZymoGenetics, Inc

Financial news for BMY dated on 2010-09-08: Bristol-Myers Squibb to Present at Global Healthcare Unplugged Conference

Financial news for BMY dated on 2010-09-08: BMY to Acquire ZGEN for \$9.75/Share

Financial news for BMY dated on 2010-09-08: Mid-Day Market Movers (ZGEN, EDAP, QXM, HDY)

Financial news for BMY dated on 2010-09-08: ZymoGenetics Advances On Acquisition News

Financial news for BMY dated on 2010-09-08: Piper Jaffray Reiterates Neutral Rating on ZymoGenetics (ZGEN)

Financial news for BMY dated on 2010-09-08: Company News for September 8, 2010 - Corporate Summary

Financial news for BMY dated on 2010-09-08: Benzinga's Top Pre-Market NASDAQ Gainers (ZGEN, TUNE, ARMH, JASO)

Financial news for BMY dated on 2010-09-08: Protalix BioTherapeutics And PROLOR Biotech May Rise On "Protein Acquisition" (PBTH, PLX)

Financial news for BMY dated on 2010-09-08: Citi Likes Bristol-Myers Acquisition Of Zymogenetics (BMY, ZGEN)

Financial news for BMY dated on 2010-09-07: Bristol-Myers Squibb to Acquire ZymoGenetics

Financial news for BMY dated on 2010-09-07: Bristol-Myers Squibb To Acquire ZymoGenetics For \$9.75 Per Share (BMY, ZGEN)

Financial news for BMY dated on 2010-09-07: Bristol-Myers Squibb to Acquire ZymoGenetics (BMY, ZGEN)

Financial news for BMY dated on 2010-09-07: Gilead Files MAA for HIV Drug - Analyst Blog

Financial news for BMY dated on 2010-09-07: Bristol-Myers Squibb Announces Dividend of \$.32

Financial news for BMY dated on 2010-09-01: Wells Fargo Securities Reiterates Outperform Rating on Bristol-Myers (BMY)

Financial news for BMY dated on 2010-08-31: Bristol-Myers Squibb Boosted by Blood Thinner Study

Financial news for BMY dated on 2010-08-30: Goldman Sachs Introduces And Adjusts Estimates For Major Pharmaceuticals

Financial news for BMY dated on 2010-08-27: ZGEN's HCV Candidate Progresses - Analyst Blog

Financial news for BMY dated on 2010-08-26: GDP Next Big Number to Watch 08-26-2010

Financial news for BMY dated on 2010-08-26: Reverse Head & Shoulders Pattern 08-26-2010

Financial news for BMY dated on 2010-08-25: Hapoalim Securities Has Positive Thoughts On Bristol Myers (BMY)

Financial news for BMY dated on 2010-08-23: Generic Risk For Gilead's Hepsera - Analyst Blog

Financial news for BMY dated on 2010-08-19: Good News for BMY Pipeline - Analyst Blog

Financial news for BMY dated on 2010-08-17: Top 4 Large-Cap Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)

Financial news for BMY dated on 2010-08-13: All Is Not Well In The Pharmaceutical Industry

Financial news for BMY dated on 2010-08-13: U.S. Probing Pharmaceutical Corruption (GSK, PFE, BMY, LLY)

Financial news for BMY dated on 2010-08-12: Amgen's Vectibix Disappoints - Analyst Blog

Financial news for BMY dated on 2010-08-12: Bristol-Myers Has PT Raised By Jefferies Int'l

Financial news for BMY dated on 2010-08-11: Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (LLY, GSK, BMY, PFE)

Financial news for BMY dated on 2010-08-05: Fast Money Picks For August 6th (JPM, RTP, KO, BMY, BMY)

Financial news for BMY dated on 2010-07-26: Corporate Catalysts For The Week Starting July 26

Financial news for BMY dated on 2010-07-22: Bristol-Myers Squibb Misses Revenue Estimates (BMY)

Financial news for BMY dated on 2010-07-22: Bristol-Myers Squibb Posts In-Line Q2 Net Income, Revenue Falls Short

Financial news for BMY dated on 2010-07-14: Ryan Recommends Bristol-Myers and Merck (BMY, MRK, PFE)

Financial news for BMY dated on 2010-07-14: Zacks Analyst Blog Highlights: Intel, Kraft Foods, Bristol Myers, Wal-Mart and Target - Press Releases

Financial news for BMY dated on 2010-07-13: Miller Tabak Likes Bristol Myers Squibb (BMY), Novartis (NVS) And Merck (MRK)

Financial news for BMY dated on 2010-07-08: Jefferies Raises Estimates and Price Target for Bristol-Myers Squibb (BMY)

Financial news for BMY dated on 2010-07-08: Top Yielding Big Pharmaceutical Stocks

Financial news for BMY dated on 2010-06-30: Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (AZN, LLY, GSK, BMY)

Financial news for BMY dated on 2010-06-29: "Mad Money Lightning Round:" Jim Says BMY Better Than PFE At The Moment

Financial news for BMY dated on 2010-06-28: Citi (C) Has A Price Target Of \$30 For Bristol Myers Squibb (BMY)

Financial news for BMY dated on 2010-06-22: Fast Money Picks For June 23rd (STD, JEF, KR, BMY)

Financial news for BMY dated on 2010-06-22: Fast Money's Trades For Wednesday

Financial news for BMY dated on 2010-06-21: Citi's Outlook For U.S. Pharmaceuticals (TEVA, BMY, ABT, MCK)

Financial news for BMY dated on 2010-06-21: Benzinga's Top Pre-Market Gainers (AIPC, EXEL, CRUS, GXDX)

Financial news for BMY dated on 2010-06-11: Calls Bought on Bristol Myers Squibb (BMY)

Financial news for BMY dated on 2010-06-10: Benzinga's After Hours Gainers (WEN, BMY, PFE)

Financial news for BMY dated on 2010-06-08: Analyst Buys Bristol-Myers, Shorts Apple (AAPL, CMG, TOL, BMY, CAG)

Financial news for BMY dated on 2010-06-07: Using the Euro as a Barometer 06-07-2010

Financial news for BMY dated on 2010-06-07: Monday Morning's Options Volume Leaders (C, BAC, AAPL, BP, BMY, SPY, GS)

Financial news for BMY dated on 2010-06-07: BMY's Sprycel and ipilimumab Have Blockbuster Sales Potential

Financial news for BMY dated on 2010-06-07: Company News for June 7, 2010 - Corporate Summary

Financial news for BMY dated on 2010-06-07: Benzinga's Top Upgrades (SYMC, NILE, AMB, BMY, CSCO)

Financial news for BMY dated on 2010-06-07: BMY Upgraded To Buy At Goldman

Financial news for BMY dated on 2010-06-04: Jefferies Gives Bristol-Myers Squibb A Hold Rating (BMY)

Financial news for BMY dated on 2010-06-04: Calls Bought on Bristol Myers (BMY)

Financial news for BMY dated on 2010-06-01: Bristol-Myers Squibb Shows Healthy Trends (BMY)

Financial news for BMY dated on 2010-05-27: Citigroup Outlook For U.S. Major Pharmaceuticals (MRK, PFE, BMY)

Financial news for BMY dated on 2010-05-26: Daniel Peris Feels Investors Are Turning To Dividend Stocks

Financial news for BMY dated on 2010-05-25: Bristol-Myers Squibb Gets "Hold" Rating (BMY, C)

Financial news for BMY dated on 2010-05-24: Bristol-Myers Expects Positive Results On Drug-Trials (BMY)

Financial news for BMY dated on 2010-05-24: Citi Says DMARDs "Not Immune to Tough Economy" (JNJ, MRK, BMY, AMGN, ABT)

Financial news for BMY dated on 2010-05-19: Stocks Under Pressure 05-19-2010

Financial news for BMY dated on 2010-05-19: Market Jittery 05-19-2010

Financial news for BMY dated on 2010-05-19: Traders Sell Out of BMY Calls (BMY)

Financial news for BMY dated on 2010-04-29: Bristol (BMY) Unfazed By Healthcare Reform

Financial news for BMY dated on 2010-04-29: Bristol Myers Squibb Co. (BMY) Up After Reporting First-Quarter Results

Financial news for BMY dated on 2010-04-29: News Summary (PALM, HPQ, BMY, ORLY)

Financial news for BMY dated on 2010-04-29: Stock Market News for April 29, 2010 - Market News

Financial news for BMY dated on 2010-04-29: Company News for April 29, 2010 - Corporate Summary

Financial news for BMY dated on 2010-04-16: Mad Money Lightning Round: Jim Thinks SD, NVDA, ORA, CVE Are Great Investments

Financial news for BMY dated on 2010-04-14: Top Stocks of New York

Financial news for BMY dated on 2010-03-24: Stock Market News for March 24, 2010 - Market News

Financial news for BMY dated on 2010-03-23: Before Jumping Into A Single Health Care Stock Consider This ETF

Financial news for BMY dated on 2010-03-22: Investors Flock To Healthcare ETFs On Historic Reform

Financial news for BMY dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for BMY dated on 2010-03-17: This Healthcare ETF (XLV) Is Seeing Above Average Call Buying

Financial news for BMY dated on 2010-03-03: New CEO Appointed For Bristol-Myers (BMY) To Deal With \$11 Billion Loss

Financial news for BMY dated on 2010-03-03: Bristol-Myers Signs A Pact With Allergan Inc. (BMY, AGN)

Financial news for BMY dated on 2010-03-03: Bristol Myers Squibb And Allergan Enters Into Global Agreement

Financial news for BMY dated on 2010-03-02: COO Andreotti Is New Bristol-Myers CEO (BMY, SNY)

Financial news for BMY dated on 2010-03-02: Unusual Movements Expected In These Shares (BAC, BMY, DBRN, MDR, PCG)

Financial news for BMY dated on 2010-02-15: A Portfolio That Delivers

Financial news for BMY dated on 2010-02-05: Market Round-up (UBS, GOOG, AAPL, MOT, PG, PFE, MRK, LLY, CVS, WAG)

Financial news for BMY dated on 2010-02-04: Merck (MRK) Is A Frontrunner Among Pharma Stocks

Financial news for BMY dated on 2010-01-29: Eli Lilly (LLY) Has A Healthy Pipeline : CEO Tells CNBC

Financial news for BMY dated on 2010-01-28: Bristol (BMY), Lilly (LLY) Up Sales And Settle Dispute

Financial news for BMY dated on 2010-01-28: Company News for January 28, 2010 - Corporate Summary

Financial news for BMY dated on 2010-01-28: Stock Market News for January 28, 2010 - Market News

Financial news for BMY dated on 2010-01-28: Earnings Round-up For Companies Reporting Before The Markets Open (MOT, T, AMZN, MMM, MSFT, MO, BDX, AEP, AZN, BMY, CAH, CEL, C, D, EL)

Financial news for BMY dated on 2010-01-23: Jim Cramer Thinks It Is Time To Sell UNH, HUM, RHB

Financial news for BMY dated on 2010-01-22: Big Pharma Will Trade On the Following Fundamentals: Morningstar Says Big Pharma Well Positioned

Financial news for BMY dated on 2010-01-13: Short Selling Bets Increased Against Citigroup (C), Apple (AAPL)

Financial news for BMY dated on 2010-01-05: Mead Johnson's Split From BMY Makes It An Attractive Buy (MJN, BMY, GS)

Financial news for BMY dated on 2010-01-05: BMY Has Cash To Buy Growth

Financial news for BMY dated on 2009-12-28: Bristol-Myers Squibb Co. (BMY) Gets A Hold Rating

Financial news for BMY dated on 2009-12-23: Stock Futures Point To A Higher Open After Spending Data (MU, RHT, BMY)

Financial news for BMY dated on 2009-12-23: Bristol Myers Squibb Co. (NYSE: BMY) Lowers FY09 Guidance

Financial news for BMY dated on 2009-12-23: Company News for December 23, 2009 - Corporate Summary

Financial news for BMY dated on 2009-12-22: Walmart (WMT) And Comcast (CMCSA) For 2010

Financial news for BMY dated on 2009-12-14: Bristol-Myers (BMY) Replaces CFO Huet

Financial news for BMY dated on 2009-12-14: Benzinga's News Roundup (C, JAVA, BMY, V, TRA)

Financial news for BMY dated on 2009-12-10: Jim Cramer Is Bullish On UBSI, TRA, NITE, PFE, THS, JPM, BMY

Financial news for BMY dated on 2009-11-18: Most Active Stock Options November 18, 2009 & Trading Activity

Financial news for BMY dated on 2009-11-17: \$ Keystone Morning Quickie

Financial news for BMY dated on 2009-11-16: Company News for November 16, 2009 - Corporate Summary

Financial news for BMY dated on 2009-11-11: Cramer Talks About HLF, BMY, PFE, CELG

Financial news for BMY dated on 2009-11-09: Jim Cramer Names His Best Picks for Cancer Cures (BMY, IMGN, PFE, DNDN, EXEL)

Financial news for BMY dated on 2009-10-01: BRISTOL MYERS SQUIBB CO (BMY) calls for profit booking around \$22-23

Financial news for BMY dated on 2009-08-14: WallStSense.com Fundamental & Technical Coverage of CRM, TRH, ADP, CNQ, BMY and VLO